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Abstract
Cancer is a leading cause of death all over the world. Retinoic acid and vitamin 
D3 play an important role in cellular proliferation and differentiation and as such have 
potential therapeutic value as differentiating agents in the treatment of cancer and 
hyperkeratinising diseases.
The use of differentiating agents to suppress prostate and breast cancer 
proliferation is now one of the new therapeutic strategies. However, the use of all trans 
retinoic acid (ATRA) and vitamin D3 as differentiating agents is limited by their rapid 
metabolism through the self induction of the cytochrome P450 enzymes that are 
involved in their catabolism. The P450 enzymes responsible for the metabolism of 
ATRA and la,25-(OH)2-D3 (calcitriol) are cytochrome P450 26 (CYP26A1) and 
cytochrome P450 24 (CYP24A1) respectively. Therefore the use of potent and selective 
inhibitors of CYP26A1 and CYP24A1 with ATRA and la,25-(OH)2-D3 respectively 
may represent a new strategy for the treatment of cancer.
The pharmacophore model of CYP26A1 inhibitors was constructed using MOE 
software. A database of 71 inhibitors with different conformations have been built and 
arranged according to activity. The resulting pharmacophore model has 8 features of 
which 5 features are essential to get the CYP26A1 inhibitory activity. The designed 
model was used to build new inhibitors, which have reasonable activity.
Two series were synthesised for CYP26A1 inhibition. The first series was 
designed to investigate the effect of changing the structure of the lead compound on the 
inhibitory activity against CYP26A1 and was depending mainly on presence of 
imidazole moiety, and the second series was a result of the pharmacophore search and 
was mainly oxadiazole derivatives. These two series were biologically evaluated using a 
MCF-7 breast cancer cell assay previously described by our group and also some of the 
compounds were tested in the biochemical assay. Changing of the structure could be 
tolerated to a certain limit as long as the imidazole ring is included which is the main 
part responsible for the binding with the haem in CYP26A1 enzyme. Some of the 
resulting compounds has good activity, specially methyl anti-3-( 1H-1 -imidazolyl)-3-[4- 
(phenylamino)phenyl]-2-methylpropanoate which should IC50 of 26 nM in the 
biochemical CYP26A1 assay. The oxadiazole derivatives did not show very good 
activity against CYP26A1 cell based assay, may be owing to the decrease in the
flexibility of the molecules. Further investigation in the first series, i.e. the imidazole 
containing compounds, is being continued in our group.
As for CYP24A1 inhibition, two series; the azoles and the tetralones, were 
synthesised and biologically evaluated. The tetralones do not seem to have a very good 
activity against CYP24A1, as the most active compound, which is 2-[l-(2- 
ethylphenyl)methylidene]-6-methoxy-1,2,3,4-tetrahydro-1 -naphthalenone showed IC50 
of 1.92 pM which about 4 folds less potent than ketoconazole (IC50 = 0.52 pM). As for 
the azoles, it seems that the azoles would be much more active than the tetralone 
derivatives as N-[2-( 1H-1 -imidazolyl)-2-phenylethyl]-4-[(£)-2-phenyl-1 -ethenyl]
benzamide displayed greater inhibitory activity (IC50 = 0.3 pM) than the standard 
ketoconazole (IC50 = 0.52 pM). As a result of this work, it seems that the azole type of 
these compounds could be of interest for future development.
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Appendix I Pharmacophore search resulting fragments
. In t r o d u c t io n
Introduction 2
1.1. Cytochrome P450:
Each day we are barraged by a bestiary of exotic chemicals. Our food is filled 
with unpleasant compounds: the plants we eat contain complex poisons and cooking 
forms a variety of reactive scorched molecules. Living in an industrial society, we are 
subject to all manner of pollutants. Our vices dose us with depressants and stimulants. 
Fortunately, we effectively recognise, transform, and eliminate these dangerous 
molecules, rendering them harmless. The human body is designed to absorb carbon- 
rich molecules, so that we can use the fats and vitamins in our diet. Unfortunately, 
many unwanted molecules, such as poisons and drugs, are also swept along with these 
nutrients into the body. To make matters worse, we are not designed for excreting 
these foreign carbon-rich molecules. The urinary system and digestive system are best 
at removing soluble compounds, such as urea. So, to ensure that carbon-rich toxins do 
not accumulate and poison us, we have a special system to take these molecules and 
make them more soluble, and thus more suitable for elimination. Cytochrome P450 
(Figure 1.1) is at the heart of this transformation system(1\
Camphor
Oxygen
Hemer-
Figure 1.1. Cytochrome P450. The molecule shown here is from a bacterial cell that 
can grow using camphor as its sole source of carbon. This bacterial cytochrome P450 
is free-floating in the cell, whereas our own enzymes are typically tethered to the 
surface of the endoplasmic reticulum. Coordinates were taken from entry ldz8 at the 
Protein Data Bank (www.pdb.org).
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1.1.1. Historical introduction:
Perhaps the beginning of the cytochrome P450 monooxygenase story (2) 
should acknowledge the early compilation of knowledge of the metabolism of 
xenobiotics (compounds foreign to the body) by R.T. Williams in 1947 and the 
subsequent, much larger volume (3). From such studies, as well as work from the 
laboratories of Brodie (4) and Miller (5), it became clear that liver microsomes were the 
source of NADPH-dependent, oxidative enzymes capable of metabolising a number 
of xenobiotics. While an extremely large number of compounds are known substrates 
of the liver microsomal enzymes, the types of the reactions that are catalysed are finite 
and the manner of oxygen activation appears to be common for all of the mechanisms. 
It is clear that the active catalyst in the process is the haemoprotein cytochrome P450.
The name cytochrome P450 is derived from the spectral properties of this 
haemoprotein. In its reduced (ferrous form), it binds carbon monoxide to give a 
complex that absorbs light maximally at 450 nm.
1.1.2. Distribution and types of cytochrome P450:
In mammals, all P450s are membrane bound, a fact that hindered early studies
(6). Most are found in the endoplasmic reticulum, but five are localised primarily in 
mitochondria. However, work by Avadhani’s group has revealed that significant 
fractions of several of the P450s that are usually considered to be microsomal can also 
localise to mitochondria (7). The P450s in the endoplasmic reticulum all interact with 
and receive electrons from a single flavoprotein, NADPH-P450 reductase. The 
mitochondrial P450s use an electron transport chain with the iron-sulphur protein 
adrenodoxin and the flavoprotein adrenodoxin reductase.
The human genome encodes fifty-seven P450 proteins (8). A recent survey (9) 
classified fifteen P450s, such as CYP1, CYP2, and CYP3, involved in the metabolism 
of xenobiotic chemicals (i.e., chemicals, such as drugs, not normally found in the 
body); fourteen primarily involved in the metabolism of sterols (including bile acids); 
four that oxidise fat-soluble vitamins, such as CYP26A1; and nine involved in the 
metabolism of fatty acids and eicosanoids, such as CYP11, CYP17 and CYP19. 
Substrates (either xenobiotic or endobiotic) are essentially unknown for the remaining 
fifteen of the fifty-seven.
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1.1.3. P450s as therapeutic targets:
Some P450s are well-established targets for rational drug design (6). Chief 
among these is CYP19A1, the aromatase enzyme. This P450 catalyses the three-step 
oxidation of androgens to oestrogens; decreased expression of CYP19 is desirable in 
oestrogen-dependent tumours (10). Another long-standing target is CYP5A1, usually 
known as thromboxane synthase (11).
Other P450s are less well developed as targets. One possibility for further 
study is CYP3A4, the main human P450 in liver and small intestine. Research has 
been undertaken to find safe and effective inhibitors of CYP3A4 in order to enhance 
the bioavailability of expensive drugs such as HIV protease inhibitors. However, most 
of these studies are still in their infancy(6).
1.1.4. P450s and their endogenous substrates:
The majority of the P450s with known functions are those that oxidise steroids 
and vitamins (6). Historically, less attention has been given to these P450s by 
pharmacologists working in drug metabolism, probably because of the relatively 
narrow range of substrate selectivity among these P450s. Most of the available 
information at the molecular level has developed in the last five to ten years. 
Associated with defects in at least thirteen different human P450s are several diseases, 
including glaucoma (CYP1B1), adrenal hyperplasia (CYP11A1, CYP21A2), 
mineralocorticoid excess (CYP17A1), and rickets (CYP27B1) (12). The endogenous 
P450 substrates may be divided into several major classes (Table 1.1): cholesterol 
and bile acids; steroids; prostaglandins; vitamins A and D; and other eicosanoids. 
P450s in these five categories generally do not contribute to the metabolism of drugs.
Substrates P450
Cholesterol and 
bile acids CYP7A1, CYP7B1, CYP8B1, CYP27A1, CYP39A1, CYP46A1, CYP51
Steroids CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2
Prostaglandins CYP5A1, CYP8A1
Vitamins A and D CYP24A1, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP2R1
Other eicosanoids CYP2C8, CYP2C9, CYP2J2, CYP4A11, CYP4B1, CYP4F2, CYP4F3, and CYP4F8
Table 1.1. Endogenous substrates of P450s.
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1.2. Retinoids:
The retinoids are a class of chemical compounds that are related chemically to 
vitamin A. They are either natural analogues such as: retinoic acid and retinol, or 
synthetic analogues such as: etretinate and acitretin.
Retinoids, either natural or synthetic derivatives, are known to play a crucial 
role in cellular and tissue differentiation (13) and that is why retinoids are used in
According to the basic structure, retinoids can be classified into four main 
generations:
1) First generation retinoids:
These retinoids contain a P-ionine ring and include retinol, retinal, tretinoin 
(Retin-A), isotretinoin and alitretinoin (Figure 1.2).
medicine.
1.2.1. Types
o
Retinol Retinal
O
Tretinoin Isotretinoin
OH
Alitretinoin
Figure 1.2. First generation retinoids.
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2) Second generation retinoids:
The second generation retinoids (Figure 1.3) have an aromatic ring in place of 
the P-ionine ring and include etretinate and its metabolite acitretin .
Figure 1.3. Second generation retinoids.
3) Third generation retinoids:
They have two aromatic rings and so they are less flexible. They include 
tazarotene and bexarotene (Figure 1.4).
Figure 1.4. Third generation retinoids.
4) Acyclic retinoid (14):
This is a novel synthetic retinoid, with a 20 carbon acyclic structure (Figure 
1.5) that binds to the cellular retinoic acid-binding protein (CRABP) and has 
relatively low toxicity.
0
Etretinate Acitretin
Tazarotene bexarotene
‘COOH
Figure 1.5. Chemical structure of acyclic retinoid (polyprenoic Acid).
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1.2.2. Mechanism of action of retinoids:
The actions of retinoids are mediated through the nuclear retinoid receptors, 
which are members of the steroid/thyroid/retinoid hormone receptor family 
Retinoid receptors act as ligand-inducible transcription factors that enhance the 
transcription of target genes by binding to retinoic acid response elements (RAREs) in 
the promoter region of retinoid-responsive genes. The retinoid receptors can be 
divided into six regions, designated A through E (16,17) (Figure 1.6). The C domain is 
a cysteine-rich DNA-binding domain which contains two zinc finger structures. The E 
domain contains the ligand (retinoid)-binding site and also has a region required for 
dimerisation with other receptors. The amino acid sequences of the C and E domains 
are highly conserved across the classes of retinoid receptors, whereas the A, B, and F 
domains are less conserved across receptors but remain highly conserved for the same 
receptors across different species.
m
RXR RAR
AF-2
IB D ^ T
AF-2
■ ■ " ► L B D ,
AF-1
DNA
Figure 1.6. Retinoid receptors (modular structure)(17).
Two families of retinoid nuclear receptors have been described, the retinoic 
acid receptors (RARs)(19,20) and the retinoid X receptors (RXRs)(21,22). The RARs (a, 
P, and y) bind the naturally occurring retinoid all trans retinoic acid (ATRA) with high 
affinity, whereas the RXRs (a, P, and y) do not bind ATRA (23). 9-cw-retinoic acid 
(9cRA) is a naturally occurring, biologically active isomer of ATRA (24) that is 
capable of binding and transactivating both the RXRs as well as the RARs. This 
multiplicity of receptors and gene pathways may in part explain the diverse effects of 
retinoids on a wide range of cellular processes.
Under normal physiologic conditions, the concentration of ATRA and other 
naturally occurring retinoids is under tight metabolic control. The physiological
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plasma concentration of ATRA is approximately 5 nM (25). Although circulating 
ATRA enters cells via passive diffusion, its contribution to intracellular ATRA levels 
is likely to be inconsequential under normal conditions because cells derive retinoic 
acid from intracellular oxidation of retinaldehyde, a metabolite of retinol (26). 
Intracellular ATRA is bound to specific binding proteins, the cellular retinoic acid 
binding proteins (CRABPs) (27) (Figure 1.7). CRABP I and CRABP II are highly 
conserved throughout evolution and appear to regulate the amount of retinoic acid 
capable of binding to their nuclear receptors (28). Binding of ATRA to CRABP 
appears to facilitate intracellular oxidative catabolism of ATRA to the inactive 
metabolite, 4-hydroxy-retinoic acid (29).
CRA RP-II.ATR A C R A W J I  ATRA
C m p ln
C ytop lasm
N ucleus
Figure 1.7. Binding of retinoids to the CRABP (30).
1.2.3. Clinical uses and trials of retinoids:
1.2.3.1. Retinoids and cancer:
The relationship between retinoids and cancer has been known for many years 
(31) and has been reviewed by several investigators (32,33). Retinoids have been 
demonstrated to inhibit development of a number of different types of tumours such 
as: epithelial tumours associated with the skin (34’35), respiratory trac t(36), colon (37), 
mammary glands (38) and prostate cancer (39). They also have been found to be 
effective in treatment of cancers occurring secondary to immune deficiency such 
Kaposi sarcoma (40,41) and to inhibit the growth of a variety of neoplastically 
transformed cells, such as HL-60 promyelocytic leukaemia cells (42) by differentiating 
these cells(43), suggesting their potential role as a cancer chemotherapeutic agent.
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Also retinoids have been evaluated as chemopreventive agents, and found to 
be effective in suppressing tumour development in several carcinogenesis models, 
including those of the skin, breast, oral cavity, lung, prostate, bladder, liver and 
pancreas (44, 45 \  Administered either topically or systemically, in the diet or 
intragastrically, and before, concurrently or after a carcinogen or a tumour-promoting 
agent, certain retinoids were found to possess differentiating activity.
1.2.3.2. Retinoids and dermatology:
The use of natural retinoids preceded the use of synthetic retinoids in 
dermatological condition. However the development of synthetic retinoids, such as 
isotretinoin and etretinate, with less toxicity than the natural retinoids resulted in the 
study of different dermatological effects of retinoids.
The retinoids are used mainly for the treatment of acne vulgaris and related 
acne form diseases (46). They have been found very useful in the treatment of psoriasis 
vulgaris and its pustular and erythrodermic variants (47). The profound first use of 
retinoids in disorders of keratinisation like ichthyosis (48) often ends at the mention of 
potential side effects (49).
1.2.3.3. Retinoids and the immune system:
Retinoids have been reported to potentiate natural killer cell activity, T-cell- 
mediated cytotoxicity, antibody responses, and macrophage functions (50). 
Mononuclear phagocytes (monocytes/macrophages) play a key role in host immune 
responses and may also be involved in mediating the immunopotentiating effects of 
retinoids (50). Retinoids have been shown to modulate several mononuclear phagocyte 
functions, such as IL-1 production, tumoricidal activity, phagocytosis, Fc receptor 
expression, and synthesis of macrophage tissue transglutaminase (51). Both retinoic 
acid and retinyl palmitate have been reported to stimulate production of IL-1 from 
murine peritoneal macrophages, human peripheral blood mononuclear cells, and a 
murine macrophage cell line (52). Retinoids may be causing an increased production of 
IL-1 through inducing increased gene expression. It has been assumed that retinoids 
regulate cellular functions through alteration of gene expression (53). Thus, retinoids 
may be altering macrophage functions at the transcriptional level.
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1.2.3.4. Miscellaneous Uses:
The retinoids also show promising results in many other fields, which include 
suppressing growth of vascular smooth muscle cells (SMCs) from the systemic and 
pulmonary circulation in asthmatic patients (54), decreasing the hypertrophic process 
after myocardial infarction (55) and accelerating wound healing through reversing the 
inhibitory effects of glucocorticoids and enhancing the formation of healthy 
granulation tissue (56).
1.2.4. Resistance to Retinoids:
Resistance almost invariably develops when ATRA is administered as a 
maintenance agent on a daily basis (13). The precise mechanisms of resistance have not 
been determined, but there are several potential mechanisms, based on the 
assumptions that a threshold concentration of free retinoic acid must be achieved at 
the site of nuclear receptors and that receptor-bound ligands are required to activate 
target genes. Thus drug resistance could develop as a result of:
A) alteration to the retinoic acid receptor, RARa;
B) alterations in the mechanisms regulating intracellular retinoic-acid binding 
and metabolism; or
C) insufficient concentrations of ATRA, which result from rapid upregulation 
of its catabolism through a specific type of cytochrome endogenous P450 which is 
CYP26A1.
The following section will focus on the specific endogenous P450, CYP26A1.
1.3. CYP26A1:
1.3.1. Definition and History:
CYP26A1 (P450RAI) is a cytochrome P450 enzyme that specifically 
metabolises retinoic acid (RA) (Figure 1.8). It was first cloned and characterised from 
zebrafish (57).
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Figure 1.8. Metabolism of R A .(58)
CYP26A1 metabolises RA to more polar derivatives including 4-hydroxy 
retinoic acid (4-OH RA), 18-hydroxy retinoic acid (18-OH RA) and 4-oxo retinoic 
acid (4-oxo R A )(59).
1.3.2. Distribution and role of CYP26A1:
CYP26A1 is expressed in the liver, heart, pituitary gland, adrenal gland, testis, 
duodenum, colon, and in specific regions of the brain and the placenta (60'62). Based on 
recent studies (6I), it is suggested that the major role of CYP26A1 is a protective one, 
that is, the regulation of intracellular ATRA steady-state levels, exhibiting a similar 
negative feedback as has been demonstrated for CYP24, which is involved in 
cholecalciferol catabolism (30’63).
Although the major retinoid products (4-hydroxy- and 4-oxo-ATRA) of 
CYP26A1 were originally considered to be inactive retinoids, there is compelling 
evidence to suggest that they are highly active modulators of positional specification 
in amphibian embryonic development and they bind and activate RAR subtypes as 
efficiently as ATRA (64, 65). Thus, in development CYP26A1 may fulfil functions 
distinct from metabolic inactivation of ATRA.
CYP26A1 is readily induced by ATRA in a variety of normal and some cancer 
cells (MCF7, T47D, NB4, HepG2, HPK1A, and LNCaP) and the enzyme efficiently
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converts ATRA into its oxygenated derivatives. Although the therapeutic potential of 
ATRA has been demonstrated, a major drawback to its clinical application is the 
prompt emergence of resistance, attributed to the induction of oxidative catabolism 
through CYPs (66'69), and CYP26A1 could be a major contributor. Because ATRA 
deficiency is associated with the progression of some cancers (70'72), it is possible that 
ATRA-induced CYP26A1 is involved in rapid metabolism of ATRA in cancer 
patients. In addition, it is firmly established that inappropriate metabolism of ATRA 
by CYPs can generate a condition of retinoid deficiency, which is characterised by 
hyperkeratinisation and desquamation as seen in dermatological diseases such as acne, 
psoriasis, and ichthyosis (73).
The cloning and characterisation of CYP26A1 represents an important 
development in ATRA (retinoid) biochemistry and molecular biology. The enzyme’s 
inducibility by ATRA and its ATRA metabolic/catabolic activity define a feedback 
loop, which may be critical in regulating both normal and therapeutic levels of ATRA. 
This emphasises the importance of maintaining stable physiological levels of ATRA. 
Thus, compounds designed to inhibit CYP26A1 activity may be useful in elevating 
normal tissue ATRA levels or maintaining high therapeutic levels of ATRA. As stated 
earlier, since ATRA has proven useful in the treatment and/or chemoprevention of 
some cancers and skin disorders, it is now possible to investigate the contributions of 
the expression/activity of CYP26A1 (or lack thereof) in various diseases(30).
CYP26A1 has recently been mapped to human chromosome 10q23-q24 (74), a 
region where several suppressor gene loci have been described (75) as well as the split- 
hand-split foot syndrome (SHSF-3) (76). Thus, it is possible that mutations in 
CYP26A1 may play a role in these diseases. On the other hand, CYP26B1 is localised 
on chromosome 2P12 with 6 exons and codes 512 amino acid proteins (77). CYP26C1 
is not widely expressed in the adult but is inducible by ATRA in HPKla, transformed 
keratinocyte cell lines, and it is suggested that it may play a specific role in 
catabolising both ATRA and 9-cw-retinoic acid (9cRA)(78).
1.3.3. CYP26A1 Inhibitors:
A number of ATRA-metabolism inhibitors have been developed over the past 
20 years. Early studies focused on the antimycotics (Figure 1.9), ketoconazole, 
miconazole and clotrimazole (7980), which showed moderate inhibition of RA
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metabolism, but in the following years, many compounds have been investigated.
NCOCH,
Ketoconazole Clotrimazole Miconazole
Figure 1.9. Chemical structures of antimycotics.
1) Liarozole and related compounds:
Liarozole (Figure 1.10) is the only retinoic acid metabolism blocking agent 
(RAMBA) that has been evaluated clinically in patients with cancer. Liarozole is an 
imidazole-containing compound that inhibits the cytochrome P450-dependent 
metabolism of ATRA. In vitro, Liarozole (IC50, 2.2 fiM) suppressed the P450- 
mediated conversion of RA to more polar metabolites by hamster liver microsomes. 
In vivo, it enhanced the plasma level of RA from mostly undetectable values (less than 
0.5 ng/mL) in control rats to 1.4 ± 0.1 and 2.9 ± 0.1 ng/mL in animals treated orally 
with 5 and 20 mg/kg of liarozole, respectively (81). Although Liarozole displays good 
activity, its use is limited due to the adverse side effects and lack of specificity toward 
CYP enzymes (82).
Two other Liarozole analogues have been investigated; R115866 (talarozole 
(83)) and R116010 (Figure 1.10) that showed potent activity. With regard to potency, 
R115866 is a nanomolar (IC50 = 4 nM) inhibitor of the CYP26A1 -dependent RA 
conversion and about three orders of magnitude more powerful than liarozole (IC50 =
2.2 pM). As for its selectivity, R115866 shows trivial inhibitory effects on the CYP- 
dependent formation of testosterone and oestradiol, whereas liarozole suppressed the 
biosynthesis of these gonadal hormones more potently (IC50 = 0.2-0.3 pM) than the 
RA conversion by CYP26A1 (84).
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Figure 1.10. Structures of liarozole, R115866 and R116010.
In intact T47D cells, R116010 potently inhibits RA metabolism with an IC50 
value of 8.7 nM. As such, R116010 is more than 100-fold more potent than liarozole- 
fumarate, R116010 is also more selective compared with liarozole-fumarate (85).
Another series of benzofuran triazoles (a) (Figure 1.11) was synthesised in an 
effort to enhance the activity of liarozole, but these compounds showed only 
comparable activity with liarozole (58).
R
R = alkyl, aryl
X = N, Y = CH; X = CH, Y =
Figure 1.11. Benzofuran triazoles derivatives (a).
2) Azolyl retinoids and related compounds:
These compounds (Figure 1.12) have been developed through introduction of 
an azole group at C-4 of ATRA to yield potent inhibitors of RA metabolism (86'88).
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Figure 1.12. Examples of Azolyl retinoids.
In these compounds, the nature of the C-4 substituent is important in 
determining affinity for the enzyme and also the corresponding methyl esters and 
imidazole amide are significantly (24- to 48-fold) more potent than the corresponding 
free acids (86). Compounds with 4-imidazole substitutions were the most potent 
inhibitors. Thus, it would appear that the imidazolyl nitrogen lone pair makes the 
strongest coordination to the iron atom of the haem in the active site of the enzyme.
3) 2,6-Disubstituted naphthyl derivatives:
The design of these compounds (Figure 1.13) depends on fusing the haem- 
binding imidazolylpropylamino moiety of R116010 with a naphthalene core carrying 
a CYP26A1 selectivity handle at the 6-position (89'91). The 2,6-disubstituted 
naphthalene core, from a 2-D perspective, overlays in a complementary fashion with 
the conjugated olefinic moiety of the tetraenoic acid side chain of ATRA. 
Additionally, a suitable tether at the 6-position of the naphthyl core was proposed to 
mimic that of the ATRA side chain. The presence of a terminal carboxylate increases 
the selectivity in these compounds.
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Figure 1.13. Examples of 2,6-disubstituted naphthyl derivatives.
4) Benzeneacetic acid derivatives:
The design of these compounds is not clear, but they show potent activity against 
CYP26A1. The most potent inhibitor of these compounds with an IC50 of 14 nM (92) is 
shown in (Figure 1.14).
CHXO OH
Figurel.14. Most potent derivative of benzeneacetic acid series.
5) Miscellaneous Compounds:
These compounds are of diverse structures (Figure 1.15), which include: 
pyrrolidine derivatives (93), indole derivatives (94), diphenylethane derivatives (95) or 
tetralone derivatives (96). These compounds showed moderate activities.
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1.4. Vitamin D:
Vitamin D is a group of fat-soluble prohormones. Several forms of vitamin D 
have been discovered which chemically are secosteroids, i.e. broken-open steroids. 
They are classified into five forms (97) (Figure 1.16):
• D2 : ergosterol.
• D3 : cholecalciferol.
• D4 :22,23-dihydroergocalciferol.
• D5 : sitosterol (24-ethylcholecalciferol).
• D6 : stigmasterol.
The two major forms of vitamin D, are vitamin D2 or ergocalciferol, and vitamin D3 
or cholecalciferol.
R =
JW
'V
JW'
Figure 1.16. Structural differences of vitamin D.
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Vitamin D2 is derived from fungal and plant sources but not produced in the 
human body. Vitamin D3 is in the skin when 7-dehydrocholesterol reacts with 
ultraviolet light with peak synthesis occurring at wavelengths between 295-297 nm
(97)
In the next section the focus will be on the most important form of vitamin D, 
vitamin D3 .
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1.4.1. Biosynthesis and Metabolism of Vitamin D3:
Upon UV irradiation, 7-dehydrocholesterol is converted to previtamin D3 in 
the human skin. This precursor is transformed by a rearrangement of double bonds to 
form vitamin D3 (Figure 1.17).
The next step that occurs in the liver, involves hydroxylation of vitamin D3 at 
carbon 25 to give 25-hydroxyvitamin D3 (25-(OH)-D3) by vitamin D3-25-hydroxylase 
(CYP27A1). Further processing occurs in the kidney which involves the enzyme 25- 
hydroxyvitamin D3-la-hydroxylase (CYPla) that introduces a hydroxyl group at the 
a-position of carbon 1 of the A ring to produce la,25-dihydroxyvitamin D3 ( la ,25- 
(OH)2-D3) also known as calcitriol which is the hormonally active metabolite. The 
enzyme 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1) in the kidney, is involved 
in the catabolism of 25-(OH)-D3 and calcitirol to 24,25-dihydroxyvitamin D3 (24,25- 
(OH)2-D3) and la,24,25-trihydroxyvitamin D3 (la,24,25-(OH)2-D3) respectively 
(Figure 1.17).
The degradation of calcitriol to form calcitrioic acid, involves several steps 
catalysed by the CYP24A1 enzyme via the C-24 oxidation pathway (Figure 1.17).
The three vitamin D3 hydroxylases mentioned above have been isolated and 
cloned. Based on their sequence-alignment (98'100), they were found to contain haem-
binding and functional domains typical of cytochrome P450 haem protein enzyme
( 1 0 1 )
1.4.2. Biological actions of Vitamin D3:
Vitamin D3 and its active metabolites play an important role in the 
maintenance of organ systems:
• Regulation of Ca2+ homeostasis: Vitamin D3 regulates the calcium and 
phosphorus levels in the blood by promoting their absorption from food in the 
intestines, and by promoting re-absorption of calcium in the kidneys (102).
• Mobilisation of bone mineral: it promotes bone formation and mineralisation 
and is essential in the development of an intact and strong skeleton. However, 
at very high levels it will promote the resorption of bone (102).
• Vitamin D3 affects the immune system through its influences on cytokine 
production (103).
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Figure 1.17. Biosynthesis and metabolism of vitamin D3 (102, l04),
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1.4.3. Mechanism of action:
As with vitamin A, most of the effects of vitamin D involve a nuclear receptor. 
The vitamin D receptor (VDR) is a member of the steroid/thyroid hormone 
superfamily of receptors. When la,25-OH D3 binds to its receptor, the complex forms 
a heterodimer with an unoccupied RXR. This heterodimer subsequently binds to the 
regulatory regions on specific genes in target tissue (105). These regions are called 
vitamin D response elements (VDREs). The binding to VDREs can increase or 
decrease expression of genes. The proteins thus made carry out the functions of 
vitamin D.
1.4.4. Therapeutic uses of vitamin D:
1) Nutritional Rickets:
Nutritional rickets results from inadequate exposure to sunlight or deficiency 
of dietary vitamin D (102). The usual practice is to administer vitamin A in 
combination with vitamin D. A number of balanced vitamin A and D preparations are 
available for this purpose. Vitamin D2 or Vitamin D3 is used in this condition.
2) Hypoparathyroidism:
Vitamin D3 and its analogues are a basic therapy of hypoparathyroidism. 
Dihydrotachysterol (DHT) (Figure 1.18) has a faster onset, shorter duration of action, 
and a greater effect on bone mobilisation than does vitamin D3 and traditionally has 
been a preferred agent (102). Calcitriol (Figure 1.18) is also effective in the 
management of hypoparathyroidism and certain forms of pseudohypoparathyroidism 
in which endogenous levels of calcitriol are abnormally low (102).
Figure 1.18. Structures of Dihydrotachysterol and Calcitriol analogues of Vitamin D.
Dihydrotachysterol Calcitriol
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3) Hyperparathyroidism secondary to chronic renal failure:
Hyperparathyroidism is a frequent complication of chronic renal failure and 
requires close monitoring and treatment to prevent the complications of renal 
osteodystrophy (I02). Therapy includes prevention of hyperphosphatemia by the 
administration of phosphate binders (calcium carbonate or acetate) and the use of 
vitamin D3 compounds such as calcitriol. For patients on haemodialysis intravenous 
calcitriol achieves effective suppression of elevated parathyroid hormone (PTH) 
levels. However, hypercalcemia and/or hyperphosphatemia are frequent complications 
that limit the calcitriol therapy (102). Synthetic vitamin D3 analogues (102), such as: 
paricalcitol, Calcifediol, Doxercalciferol and Oxacalcitriol (Figure 1.19) appear to 
represent more effective agents to control secondary hyperparathyroidism associated 
with end stage renal disease since it suppresses intact PTH (IPTH) levels with less 
impact on calcium and phosphorus metabolism.
OH
OH
Paricalcitol (Zemplar)
OH
.CH.
Calcifediol
OH
.CH.
OH
Doxercalciferol (Hectorol)
OH
.CH
OH
Oxacalcitriol (Oxarol)
Figure 1.19. Structures of analogues of Vitamin D used in hyperparathyroidism.
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4) Psoriasis:
Calcipotriene (Figure 1.20) is a synthetic vitamin D3 analogue indicated for 
topical application in the treatment of moderate plaque psoriasis (103). It has the same 
affinity for the vitamin D receptor as calcitriol, but its effect on calcium metabolism is 
100 to 200 times less (103). Calcipotriene inhibits epidermal cell proliferation and 
enhances cell differentiation. It reduces cell numbers and total DNA content(102).
OH
.CH
OH
Calcipotriene
Figure 1.20. Structure of Calcipotriene.
1.4.5. Vitamin D and cancer:
There are many studies, which are mostly based on observational or case 
controlled studies (106), that correlate vitamin D and cancer prevention. The findings 
by Abe et al. (107) in 1981 that la,25-(OH)2D3 inhibited the proliferation of variety of 
human leukemic cell lines, led to a considerable interest in the design and synthesis of 
1 a,25-(OH)2D3 mimics by the pharmaceutical industry (108).
The major drawback of la,25-(OH)2D3, however, is its effect on calcium 
metabolism, which results in hypocalcaemia and hypercalciuria (108). Newly developed 
vitamin D analogues with lower calcemic activity have been shown to retain many 
therapeutic properties of la,25-(OH)2D3 (109). More than 2000 synthetic analogues of 
the biologic form of vitamin D (la,25-(OH)2D3) are presently known (109). Studies 
using the human osteosarcoma cell line MG-63 demonstrated that 3 of these 
analogues (KH1060, EB1089, and CB1093 (Figure 1. 21)), have a greater 
antiproliferative effect than la,25-(OH)2D3 (,09). Several other analogues are currently
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being tested in preclinical and clinical trials for the treatment of various types of 
cancer(109).
OH
.OH.OH
HO OHHO OH
EB1089KH1060
CB1093
Figure 1.21. Vitamin D (la,25-(OH)2D3) analogues.
Although the exact mechanism underlying the growth inhibitory actions of 
vitamin D and its analogues in cancer cells is not fully understood, the volume o f data 
supports a multipronged effect involving(109):
1) Cell cycle regulators:
The la,25-(OH)2D3-VDR system arrests the cancerous cell cycle at the Go-Gi 
transition through multiple mechanisms (109).
2) Growth factors and growth factor receptors:
The growth inhibition of cancer cells by la,25-(OH)2D3 is also associated with 
growth factor signalling. Transforming growth factor-h (TGF-h) is a potent
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inhibitor of the proliferation of many cell types and is involved in cell cycle 
control and apoptosis. Vitamin D analogues induce autocrine TGF-h activity 
through increasing expression of TGF-h isoforms and/or TGF-h receptors in 
nonmalignant and malignant breast cells (109).
3) Apoptosis:
la,25-(OH)2D3-induced apoptosis is an important contributor to the growth- 
suppressing properties of the sterol in cancer. In cancer cells, la,25-(OH)2D3 
analogues induce apoptosis through reciprocal modulation in the antiapoptotic 
protein Bcl-2 and the proapoptotic protein Bax content(109).
4) Differentiation:
la,25-(OH)2D3 regulates proliferation and differentiation of different kinds of 
cells, including keratinocytes, osteoblasts, and hematopoietic cells(109).
5) Invasion and metastasis:
For tumour suppressive activity, besides growth inhibition, vitamin D and its 
analogues decrease the invasiveness of several cell types in vitro, and they inhibit 
angiogenesis and metastasis in xenograft and transgenic mouse models in vivo
(109)
1.5. Vitamin D hydroxylase (CYP24A1):
The hydroxylase enzymes that are involved in the metabolism of 25- 
hydroxyvitamin D3 (CYPla and CYP24A1) are members of the cytochrome P450 
superfamily(110).
The important role of vitamin D in many physiological and pathological 
processes (104, m '112) has attracted many researchers in developing new drugs for 
targeting the key enzymes in the synthesis or metabolism of the active vitamin D3 
hormone, la,25(OH)2-D3i-
♦ 25-Hydroxyvitamin D-la-hydroxylase (CYP27B1 or CYPla): the key 
enzymes in the synthesis of the biological active metabolite, calcitriol.
♦ la,25-Dihydroxyvitamin D 24-hydroxylase (CYP24A1): a multi catalytic 
enzyme, that causes side-chain oxidative cleavage of 25(OH)2-D3 resulting in 
calcitroic acid formation (llj). This multicatalytic sequence is also known as 
the C-24 oxidation pathway (Figure 1.17).
Although there have been successes in cloning the rat 24-hydroxylase enzyme
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and in determining the enzyme’s derived sequence (114), structural information from 
X-ray crystallography or NMR analysis is still missing.
1.5.1 CYP24A1 inhibitors:
Various azole compounds have been shown to inhibit CYP24A1. The azole 
compounds bind directly to the prosthetic haem iron via a lone pair of electrons from 
the heterocyclic nitrogen and through interaction with other sites in the binding
shown to inhibit CYP24A1, e.g. ketoconazole and liarozole (Figure 1.9 and 1.10). 
The use of CYP24A1 inhibitors could potentially slow down the metabolism and 
depletion of the active vitamin D hormone, calcitriol.
However, selectivity is a crucial demand in designing CYP24A1 inhibitors in 
order to avoid impairment of la,25(OH)2 -D3 synthesis by 1 a-hydroxylase, a distinct, 
but related mitochondrial CYP.
Figure 1.22. Azole and calcitriol analogues which show inhibition of
pockets (115). A few standard azole compounds from other companies have been
ci
S D Z 89-443 V ID 4 0 0
(#)-enantiomer
O 0
H(
Sulfone analogue (K R C -2 4 S 0 2P h -l) Sulfoxim ine analogue
HO
Genistein Tetralone derivative
CYP24A1.
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SDZ 89-443 and VID400 (Figure 1.22) have been identified as potent 
CYP24A1 inhibitors and also very selective for CYP24A1 compared with CYP27B 
(116). These selective inhibitors of CYP24A1 were used by the Schuster group to study 
vitamin D metabolism in human keratinocytes.
Other compounds that have been described as potent, selective and low- 
calcemic inhibitors of CYP24A1 include some 24-sulfone (117) and 24-sulfoximine 
(118) analogues (Figure 1.22) of the hormone l a ,25(OH )2 -D3.
It has been postulated from in vivo studies, that CYP24A1 inhibitors can be 
useful agents for the treatment of androgen-independent prostate cancer(119).
Ly and co-workers (120) have added liarozole to calcitriol in an androgen- 
independent DU 145 cell line; this resulted in an increase in the half-life of calcitriol 
and enhanced up-regulation of the vitamin D receptor. Liarozole, a CYP24A1 
inhibitor was also used in Phase II trials for hormone-refractory prostate cancer (121). 
There are also promising results from preclinical studies carried out in prostate cancer 
cells to study the combination of ketoconazole (CYP24A1 inhibitor) with calcitriol 
(122-123) jt was jn rat osteosarcoma cells that ketoconazole can inhibit the self­
induced metabolism of calcitriol(124).
An enhancement of antiproliferative activity of calcitriol analogues by P450 
enzyme inhibitors has been demonstrated in different cell lines. For example, Zhao 
and co-workers showed that ketoconazole and liarozole (P450 enzyme inhibitors, 
including CYP24A1 inhibitor) enhanced the antiproliferation of MCF-7 and T47-D 
breast cancer cell lines, this combination therapy might synergise the anticancer 
properties (125).
More recently, tetralone derivatives (Figure 1.22) synthesised by the Welsh 
School of Pharmacy group greatly enhanced the apoptotic and the differentiation 
effect of endogenous calcitriol on prostate cancer cell lines DU-145 and PC-3 by 
reducing the metabolism of calcitriol resulting in greater inhibition of proliferation of 
the cancer cells (126). In vitro studies with genistein (Figure 1.22.), a soy isoflavone 
that is able to inhibit calcitriol metabolising enzyme (CYP24A1), have shown 
induction of apoptosis and inhibition of cell growth in androgen-sensitive (LNCaP) 
and androgen-independent (PC3 and VeCaP) prostate cancer cell lines (127).
CYP24A1 inhibitors could be a promising combination therapy together with 
calcitriol, as indirect differentiation therapy for hormone-refractory (androgen- 
independent) prostate cancer by sustaining the level of calcitriol and allowing the dose
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of calcitriol to be reduced thus reducing the side-effects of calcitriol. This 
combination has been shown to slow the growth of the prostate cancer cells and 
restore normal responses to hormonal signalling (126,128).
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a Aims and Objectives
The aim of this project was to develop new, potent and selective inhibitors of 
CYP26A1 and CYP24A1 that could be used in the differentiation therapy of different 
types of cancer, such as prostate and breast cancer.
1) CYP26A1 Inhibitors:
From previous work that has been done within our group, a lead compound 
(Figure 2.1) had been developed (129) which showed very high activity against 
CYP26A1 with IC50 of 2.8 nM in a biochemical based assay.
.c h 3
Figure 2.1. The structure of the lead compound.
The aim of this project was to:
1) Build a pharmacophore model for CYP26A1 inhibitors. Molecular 
Operating Environment (MOE) was used for this purpose.
2) Investigate the effect of changes of the lead structure on the inhibitory 
activity Figure 2.2.
removal of NH
CH, CH;
V J
monomethyl
aryl/biaryl acrylate
heteroaryl
Figure 2.2. Developments in the lead structure.
3) Beside this, we intended to use the produced pharmacophore to build new 
compounds which could show comparable activity but involved easier synthetic 
pathways.
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2) CYP24A1 Inhibitors:
As there are no available compounds which inhibit CYP24A1 on the market, 
we hoped to find an inhibitor which is potent and at the same time selective in the 
inhibition of CYP24A1.
Two series were designed to try to manage this approach. The first series of 
CYP24A1 inhibitors was chosen to resemble VTD 400, combined with calcitriol as the 
lead compound for this series (Figure 2.3).
•OH
'OH
VID400
(fl)-enantiomer
Calcitriol Designed series 1
Figure 2.3. Designing of the CYP24A1 first series.
The second series took the tetralone (124) compounds synthesised in our group 
as the lead compound with modification to increase the activity and the selectivity 
(Figure 2.4).
h 3c o
benzylidene tetralones
Fig. 2.4. The designed tetralone compounds.
h 3c o
benzyl tetralones
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3.1.1. Introduction:
The official definition of pharmacophore elaborated by the IUPAC and 
published in 1998 (130) is the ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with a specific biological 
target structure and to trigger (or to block) its biological response.
A pharmacophore could be considered as the most common features of a 
group of molecules exhibiting a similar biological activity, which are recognised by 
the same active site of the target protein.
The concept of pharmacophores as a simple representation of molecules and 
chemical groups in certain order was introduced about a century ago, there has been 
increasing interest and focus on pharmacophores in recent years following the 
advances in computational chemistry research (131).
There are many ways of constructing pharmacophores and several computer- 
based applications with the ability to build pharmacophores have been introduced 
since the 1980s (l32) such as: APOLLO <133), ALADDIN (134), DANTE (135‘138’, RAPID 
<l39>, SCREEN and its PMapper from ChemAxon <l40) and ChemX fingerprints <I4I) 
from Chemical Design (now Accelrys). Not all of these programmes are intensively 
used today.
The representation of pharmacophores varies from one package to another and 
includes the nature of the pharmacophore points (fragments, chemical features) and 
the geometric constraints connecting these points (distances, torsions, three- 
dimensional coordinate location constraints).
There are two main techniques for building pharmacophores (142), which depends 
mainly on the availability of the three-dimensional structure of the binding site of the 
target:
1) If the 3D structure of the target is known, the structure-based pharmacophore 
could be built. Several programmes are available for this task, such as: Cerius 
software package, available from Accelrys Inc (143), the unity programme 
available from Tripos Inc (144) and the molecular operating environment MOE 
software package (l45).
2) If the 3D structure of the target is unknown and only the active ligands 
structures are available, the ligand-based pharmacophore can be used. There 
are several programmes available for this technique, including Catalyst (146),
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available from Accelrys Inc, DiscoTech (147), and Gasp (148), both from Tripos 
Inc.
3.1.2. Pharmacophores in MOE:
MOE (Molecular Operating Environment) is the modeling platform developed 
by the Chemical Computing Group. All the applications in MOE have been integrated 
using the Scientific Vector Language (SVL) (149) and this was the chosen programme 
for building a CYP26A1 inhibitor pharmacophore.
3.1.3. Building a Pharmacophore model for CYP26A1 Inhibitors:
In this study, a ligand-based three-dimensional model for CYP26A1 inhibitors 
was developed in an attempt to find a new class of compounds with affinity to 
CYP26A1.
The Pharmacophore building was performed according to the following steps:
1) As there is no available database for CYP26A1 inhibitors, the first step was 
the building of the training set database of the CYP26A1 inhibitors.
2) The structures of the CYP26A1 inhibitors are very diverse, therefore the 
second step was the alignment of the most active CYP26A1 inhibitors instead 
of alignment of the whole set.
3) Running the Pharmacophore consensus which provides us with the suggested 
features of the aligned molecules.
4) Using Pharmacophore search together with the Pharmacophores query editor 
to focus the query.
5) Finally, refining the query using the output results from the Pharmacophore 
search.
(1) Building the training set:
A set of 71 compounds with biological activity ranging from 0.009 nM to 
15.17 jiM published in different papers (15(M62). Structures of these compounds are 
listed below in Table 3.1.1. with their activities. The compounds were built using the 
MOE builder in MOE software package and were minimised to the closest local 
minimum using the MMFF94s force field implemented in the programme, with 
0.00001 gradient. The compounds in the database have been sorted according to their 
activities, from the highest to the lowest activity.
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(a) 0.009 nM (159) (b) 0.05 nM(159)
\ _
HO-
2 nM'(159)
2.33 nM(l59)
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4.2 nM(l61)
OH
5 nM ( 1 6 1 ) 5.84 nM(l59)
6.3 nM(l6n
8nM "61) 9nM (,6l)
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11 nM (Rl 15866)(155)
19 nM<161)
21.4 nM<l61)
>OH
11.2 nM<161)
16 nM(16l)
20 nM<161)
21.67 nM(159)
12 nM(161)
18nM(l6l>
'OH
20 nM<162)
H
23 nM<159)
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46.67 nM(159)
•OH
46.7 nM<16,) 47 nM061'
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X J H
OH
,OH
583 nM(l6l) 4.53 hM(,60)
,N!H;
6 (tM (Liarozole)<15l) 13.56 hM<153) 19.65 hM(,57)
34 (xM (Ketoconazole)<150) 15.17 (iM(l56)
Table 3.1.1. Structures of the database training set.
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(2) Aligning active molecules:
There are two ways in MOE programme to build the pharmacophore from the 
available database, one is the pharmacophore elucidation and the other is the 
alignment followed by using the pharmacophore consensus. As the training set 
contains 71 compounds of very diverse structures, it was very difficult to depend on 
the pharmacophore elucidation method, and that is why alignment/pharmacophore 
consensus method was chosen.
For alignment, the two most active compounds (a) and (b) in the database 
have been chosen and the partial charges have been calculated for these compounds. 
Then, alignment using the flexible alignment application available in the MOE 
programme was performed with the iteration limit set to 100, the failure limit to 20 
and the energy cut-off to 10. The stochastic conformational search was enabled to 
allow a random conformation to be generated for each molecule prior to alignment. 
The resulting database was sorted according to the objective function (S) then by the 
similarity (F) to give the aligned compounds shown in Figure 3.1.1 with the best 
value.
Figure 3.1.1. The alignment of the most 2 active compounds (a) and (b).
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(3) Running the Pharmacophore consensus:
From the pharmacophore query editor in MOE the consensus on the aligned 
molecules was run, using the PCH_A11 scheme, the tolerance parameter was chosen 
to be 1 and the threshold to be 100%. This resulted in a pharmacophore with 8 
features, as shown in Figure 3.1.2.
MI
Figure 3.1.2. The suggested pharmacophore from the consensus.
The 8 features are:
1) FI: Acceptor and metal ligator.
2) F2: Aromatic ring centre.
3) F3: Acceptor and metal ligator.
4) F4: Aromatic or hydrophobic region.
5) F5-F7: Hydrophobic regions.
6) F8: Hydrophobic or aromatic regions.
(4) Focusing the query:
Running the pharmacophore search on the CYP26A1 database showed that 
only 18 compounds out of 71 have a full hit for the entire features. Therefore, a partial 
match was allowed, which resulted in 62 matches with partial hit to the 
pharmacophore out of the 71 active compounds in the database.
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(5) Refining the query:
The final pharmacophore obtained had the same features as the original one with 
the 8 features, but with different diameters.
Also the distances between different features have been found to be as shown in 
the following Figure 3.1.3:
Figure 3.1.3. Showing the distances between different pharmacophoric features.
The distances are:
1) F1-F2: 1.17
o
A.
2) F2-F4: 3.63
o
A.
3) F4-F5: 2.87 A.
4) F5-F6: 5.07
o
A.
5) F6-F7: 5.38 A.
6) F7-F3: 3.00
o
A.
7) F3-F8: 2.98
o
A.
• Conclusion:
In conclusion the CYP26A1 inhibitor pharmacophore has 8 features, of which 
only 5 features should be fulfilled to have an active inhibitor. Those five features are:
1) F I: Acceptor and metal ligator.
2) F2: Aromatic ring centre.
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3) F4: Aromatic or hydrophobic region.
4) F5: Hydrophobic regions.
5) F6: Hydrophobic regions.
Therefore, a partial match could be allowed, so long as these 5 features are 
fulfilled from the 8 features identified.
3.1.4. Uses of CYP26A1 inhibitors pharmacophore model:
The produced CYP26A1 inhibitors pharmacophore investigate if the changes of 
the lead compound would be tolerated or not and also to search for new molecules 
that could be active as CYP26A1 inhibitors (Table 3.1.2).
Structure Hits NAMEON 0
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oN 0
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Table 3.1.2. A table shows the hits of the investigated compounds and the new 
molecules.
Investigation of the match of the lead compound with the CYP26A1 inhibitors 
pharmacophore shows that the lead compound has a very good hit with the essential 
pharmacophoric features, i.e. FI, F2, F4, F5, F6 (Figure 3.1.4). As for the changes in 
the lead compound structure, some changes seem to be tolerated within the 
pharmacophore, such as replacement of the dimethyl groups with mono methyl 
(compounds (14-15) and (19-20)) or replacement of the naphthyl moiety with a
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phenyl one (compounds (14-15)). Whereas, other changes in the lead compound, such 
as removing of the imidazole ring (compound (28)) or replacing the imidazole moiety 
with imidazolyl carbonyloxy one (compound (24)) do not seem to be tolerated within 
the pharmacophore as shown from decreased number of the pharmacophoric hits to 
the essential pharmacophoric features (Table 3.1.2).
Figure 3.1.4. Alignment of the lead compound with the CYP26A1 pharmacophore 
model.
As for the search for new molecules which could have activity as inhibitors of 
CYP26A1, the National Cancer Institute (NCI) database was used to perform this 
search and using different fragments from this search (Appendix I) resulted in the 
design of some new molecules with different structures than the lead compound (as 
could be seen in Table 3.1.2 in compounds (52, 56 and 60)). These fragments were 
chosen to fulfil at least the previously mentioned five main features and at the same 
time those fragments should be linked in a manner that keeps the mentioned distances 
between these features (Figure 3.1.3). For this purpose, these fragments could be such 
as the following:
1) FI: Acceptor and metal ligator: in this region we could have something like a 
nitrogen or oxygen atom as part of a heterocyclic ring.
2) F2: Aromatic ring centre: this should be an aromatic ring either heterocyclic or 
normal aromatic, this ring should contain the previously mentioned 
heteroatom either as a part of the ring or attached directly to the ring to keep
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the distance between FI and F2.
3) F3: Acceptor and metal ligator: as previously mentioned this feature is not 
one of the main features, so it could be excluded when thinking about building 
our compounds. However, if it is fulfilled then it should have either a 
heteroatom alone not included in a ring system, or a heteroatom inside a ring.
4) F4: Aromatic or hydrophobic region:, again this is one of the main features, so 
to fulfil it requires either an aromatic ring; aryl/biaryl or heteroaryl or a 
hydrophobic aliphatic chain.
5) F5 and F6: Hydrophobic regions. These two main features should be fulfilled, 
to do so would require, for example, either an aliphatic chain or halogen.
6) F7: Hydrophobic regions: this feature is not essential, but could be dealt with 
like F5 and F6.
7) F8: Hydrophobic or aromatic regions: again this feature is not essential, but 
could be treated like F4.
The newly designed compounds shows very good alignment to the essential 
pharmacophoric features, i.e. FI, F2, F4, F5, F6. Figure 3.1.4 shows the alignment of 
compound (60), one of the new molecules with the pharmacophore model.
Figure 3.1.4. Alignment of a new molecule with the CYP26A1 pharmacophore 
model.
Results & Discussion 50
3 . 2 . C hem istry  
o f  CYP26A1
Results & Discussion 51
3.2.1. Introduction:
As a continuation of the effort made within our group to develop CYP26A1 
inhibitors with good potency and selectivity, many compounds have been designed as 
CYP26A1 inhibitors, taking R115866 (83) (Figure 3.2.1), the most potent clinically 
evaluated CYP26A1 inhibitor, as a lead compound combined with a pharmacophore 
model search and docking studies with a CYP26A1 homology model, which was 
published by our group (163).
R115866
Figure 3.2.1. R115866.
3.2.2. Docking studies:
As yet no one has published a crystal structure for CYP26A1, possibly 
because CYP26A1 is hard to crystallise, as it is a membrane bound enzyme. As a 
result of this, the published homology model of CYP26A1 (163) was used in the 
docking studies.
In general, there are two strategies for docking a ligand into a macromolecule. 
The first one is to use the whole molecule of a ligand as a starting point and then 
perform a particular search algorithm to explore the energy landscape of the ligand at 
the binding site, looking for optimal solutions (local energy minima). The search 
algorithms include molecular dynamics and genetic algorithms. The programmes 
AutoDock(164), Gold(165) and MOE Dock(166) are some examples in this group.
The second strategy, called fragment-based docking, is to start by placing one 
or several base fragments of the ligand into a binding pocket, and then to build the 
rest of the molecule in the site. DOCK4.0 (167), FlexX (168>169)? LUDI (170), Hammer­
head (171), GROWMOL (172) and HOOK (173) are programmes in this group, although 
some of these algorithms are mainly used in the area of de novo ligand design.
The fragment-based approach is faster than the whole molecule-based docking
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method. However, only the local interactions between the protein binding site and the 
ligand fragments under construction are taken into account during the docking 
procedure. Thus it is difficult to evaluate if the global energy minimum has been 
found. The results from the fragment-based approach are also sensitive to the choice 
of the base fragment and its placement. Indeed, if the binding site has a deeply buried 
pocket with hydrogen bond donors or acceptors, this approach gives good results. 
However, if the pocket is dominated by lipophilic residues or characterised by a 
shallow pocket, not only is the placement of the base fragment not definite, but also it 
is difficult for the programme to decide where to add the next fragments. 
Consequently, the resulting docking structures can deviate from the real binding mode 
significantly. While the docking results from whole-molecule-based methods are not 
dependant on the choice of the base fragment, they require much more computation to 
find an optimal solution in general. For a large flexible ligand, the whole molecule- 
based docking approach may not find a good binding mode due to the vast space to be 
searched(174).
Ligands were docked within the active site of the homology model using the 
FlexX docking programme of SYBYL, performed with the default values. The FlexX 
docking programme of SYBYL was used as it is one of the most suitable software 
programmes to perform fragment-based docking and to do the virtual screening. The 
active site was defined by all the amino acid residues within a 6.5 A distance from 
TRP112, VAL116, THR304, VAL370 and GLY373, including the haem in a 
heteroatom file. The output of FlexX docking was visualised in MOE and the 
scoring.svl script (Code, scoring.svl) was used to identify interaction types between 
ligand and protein.
The docking studies of CYP26A1 inhibitor (S)-R115866 (Figure 3.2.2) show 
that the triazole nitrogen is perpendicular to the haem iron of the CYP26A1 model at a 
distance of 2.6 A. Furthermore (S)-R115688 establishes a hydrogen bond between the 
benzothiazole nitrogen and the NH of SERI 15, as well as several hydrophobic 
interactions with the side chains of TRP112, PHE374, PHE84, PHE299, VAL116, 
PR0371 and other residues.
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Fig. 3.2.2. Interactions between (5)-Rl 15866 and the CYP26A1 active site(163).
3.2.3. Design of CYP26A1 inhibitors:
The compounds were designed by taking R115866 as a lead compound, and 
simplifying its structure to a scaffold that contains only the main part supposed to be 
crucial for enzyme inhibition. Also, the main part was chosen to coincide with the 
main features of the pharmacophore. The profile of the compounds was divided in 
three parts.
The scaffold (Figure 3.2.3) was chosen to be the imidazol-l-ylmethyl- 
phenylamine moiety. This moiety contains two essential components for the active 
binding of the molecule. The imidazole is essential for metal-ligand interaction with 
the haem part of the enzyme. The phenylamino group holds the inhibitor tightly in the 
active site with the phenyl ring forming hydrophobic bonds mainly with the haem, 
TRP112, PHE374 and the amino group forming hydrogen bonding with PRO 113. The 
phenylamino also plays a role in positioning the imidazole in an optimal position from 
the haem.
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Figure 3.2.3. The proposed scaffold.
The A substituent, designed to be heteroaryl or aryl analogues, is a very 
important substituent because it affects the dimensions, the stereochemistry and the 
hydrophobicity of the molecule, and is therefore important in placing the imidazole 
ring in the right position just above the haem portion of the enzyme. The A substituent 
is also crucial in determining the overall binding pattern of the inhibitor to the enzyme 
and holding the inhibitor tightly in the active site through hydrophobic bond 
formation mainly with PHE374, PR0113, SERI 15 and PHE84 and hydrogen bond 
formation with different hydrogen donors or acceptors at the active site such as 
SERI 15 and ALAI 14 thereby affecting the selectivity and efficacy of the molecule.
The B substituent, which was chosen to be an acid substituent, since it was 
reported that the introduction of a carboxylic group to the structure of certain 
members of a group of CYP26A1 inhibitors was found to greatly increase the 
biological activity of the synthesised compounds (89). Another reason is to mimic the 
natural substrate, retinoic acid, which contains a carboxylic group. The carboxylic 
moiety affects the binding of the molecule to the active site through hydrogen bonds it 
might form with different residues at the active site such as GLY300, GLU303 and 
THR304. The carboxylic moiety may also affect the movement and penetration of the 
molecule through biological membranes.
Also, compounds which do not contain the amino group, have been designed 
and docked to study the importance of the presence of the amino group, as the 
presence of this amino group in the para position represents synthetic difficulties in 
the synthesis of many derivatives.
3.2.3.I. Docking of the molecules and analysis of the results:
The FlexX programme was chosen as it is one of the most suitable software 
programmes to perform a virtual screening. Indeed, it can screen a large number of
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molecules on a workstation computer within a few days. Other docking programmes 
such as those using a genetic algorithm or a Monte Carlo approach can screen a 
smaller number of molecules under the same conditions or require a more powerful 
computer to be applied to a large number of molecules (175).
In the database, the formal charges of all the constructed compounds in the 
library were first computed and their conformation energy minimised using 
MMFF94X as the force field. The database was then exported in Mol2 format to 
SYBYL databases and docked as multiple ligands in the active site using the same 
parameters applied in the docking of retinoic acid and R115866 (163).
The results of the docking were only analysed visually due to the lack of 
correlation between the FlexX scoring functions and the visual compound-active site 
interaction. The position of the imidazole ring from the haem was first evaluated. In 
the well docked compounds, the distance between the imidazole N3 and the iron of 
the haem should be around 3 A thereby allowing the coordination bond to be formed. 
Secondly, the side chain A was assessed for its ability to form hydrophobic 
interactions with different residues at the active site especially TRP112 and PHE374. 
This part together with the position of side chain B is crucial in driving the imidazole 
ring in a conformation that allows good interaction with the haem. Finally, side chain 
B was evaluated for its capacity to offer the maximal hydrogen bonding and lipophilic 
interaction with the active site especially GLY300, thereby, holding the inhibitor 
tightly in the active site.
The docking study showed that the designed compounds (Table 3.2.1) can 
form a good coordinating bond with the haem centre of the CYP26A1 protein with a 
distance ranging from 1.83 A to 3.88 A. Most of the designed compounds form 
hydrophobic bonds with the forementioned amino acid residues of CYP26A1 protein. 
The absence of the amino group has not affected the docking of the designed 
compound to a high extent.
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Table 3.2.1.:
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3.2.4. Synthesis of a-unsubstituted/substituted 3-(imidazol-1- 
yl)-4-(arylamino)phenyl propanoate derivatives:
Using the data from the pharmacophore model and the docking, beside the 
lead compound synthesised within our group, this series was developed to investigate 
the effect of the changes in the structure of the lead compound on the inhibitory 
activity.
• General chemistry:
The synthesis of a-unsubstituted/substituted 3-(imidazol-l-yl)-3-(4- 
(arylamino)phenyl)propanoates was carried out according to a sequence of 4 steps 
(Scheme 3.2.1):
1) The preparation of the a-unsubstituted/substituted 3-hydroxy-3-(4- 
nitrophenyl)propanoates.
2) The reduction of the nitro to amino group.
3) The coupling of the amino group with the aryl substituents through Suzuki 
coupling reaction.
4) The preparation of the 3-(imidazol-l-yl) derivatives.
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O.N
CH I
O—S i - t -B u t  I
CH + H2C ^ J L  ,CH+ CH.COOC.H
O— CH
(3 )/(5)/(6 )
r  = c h 3, c2h 5
R' = H, CH3
At = phenyl, 2-naphthyl
(12)/(13)/(17)/(18) (14)/(15)/(19)/(20)
Scheme 3.2.1. Scheme of general chemistry: (a) Pyridine-W-oxide, LiCl, DMF, rt, 24 
h; (b) iPr2NH, n-BuLi, THF; (c) aqueous Me3N, THF, 24 h; (d) Pd-C/ H2, EtOAc, 1 
h; (e) CuOAc, pyridine, CH2C12, 72 h; (f) Imidazole, 1,l'-carbonyldiimidazole, 
CH3CN, 65 °C for lh, then rt, 24 h.
3.2.4.I. Synthesis of a-unsubstituted/substituted 3-hydroxy-3-(4- 
nitrophenyl) propanoates:
1) Synthesis of methyl 3-hydroxy-3-(4-nitrophenyl)propanoate:
The synthesis of methyl 3-hydroxy-3-(4-nitrophenyl)propanoate was carried 
out through the aldol reaction of 4-nitrobenzaldehyde (1) with 1 -(/- 
butyldimethylsilyloxy)-l-methoxyethene (2) (Scheme 3.2.2).
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(1) (2) (3)
Scheme 3.2.2. Synthesis of methyl 3-hydroxy-3-(4-nitrophenyl)propanoate (3).
The aldol reaction is an important carbon-carbon bond-forming reaction (176). 
Mukaiyama developed the aldol reaction of silyl enolate in the presence of a Lewis 
acid to solve the problem of generating an enol or enolate quantitatively(177).
The application of the aldol reaction in the synthesis of methyl 3-hydroxy-3- 
(4-nitrophenyl)propanoate, required milder conditions than that used in the 
Mukaiyama aldol reaction (178). These conditions include the use of an amine vV-oxide 
such as pyridine-TV-oxide as an alternative candidate as an organomolecular Lewis 
basic catalyst in the presence of a catalytic amount of lithium chloride.
The general conditions for this reaction involve the addition of 5.0 equivalents 
of the silyl acetal (2) to 1.0 equivalent of the aldehyde (1), using catalytic amounts of 
pyridine-iV-oxide and lithium chloride. The mixture was stirred at room temperature 
under nitrogen atmosphere for 24 h to give methyl 3-hydroxy-3-(4- 
nitrophenyl)propanoate in 34% yield.
The mechanism of the reaction (Scheme 3.2.3) (177) involves catalysis of the 
aldehyde with the Lewis acid, followed by the addition of the silyl enolate on the 
aldehydic carbonyl. The resulting intermediate undergoes rearrangement to form the 
silyl ether, which is then hydrolysed using 10% hydrochloric acid to form the desired 
compound.
N
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LA +^ SiR
L A
o o
10% HC1
OH O
A A ,
Scheme 3.2.3. Proposed mechanism of the aldol reaction between the aldehyde and 
the silyl enolate.
2) Synthesis of ethyl 3-hydroxy-3-(4-nitrophenyl)propanoate (5):
Another method for preparing the a-unsubstituted compounds is through the 
formation of the ester carbanion, which reacted with the 4-nitrobenzaldehyde to give 
the desired compound (Scheme 3.2.4).
+ c h3c o o c 2h5
(4)
Diisopropylamine
n-Butyllithium
OH
CH
0,N
(6)
Scheme 3.2.4. Synthesis of ethyl 3-hydroxy-3-(4-nitrophenyl)propanoate (5).
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The formation of ester carbanion can be afforded through the reaction of 
diisopropylamine with w-butyl lithium at -78 °C to form lithium diisopropylamide, 
which then deprotonates ethyl acetate through the known mechanism(179). The formed 
carbanion then attacks the carbonyl carbon to form ethyl 3-hydroxy-3-(4- 
nitrophenyl)propanoate (5) (Scheme 3.2.5).
n-B uLi+  HN
OR OR
H
OH
OR
OR k '
Scheme 3.2.5. Proposed mechanism for the preparation of ethyl 3-hydroxy-3-(4- 
nitrophenyl)propanoate (5).
The surprising result of this reaction was the unusual formation of the butyl 
ester (6) in addition to the required ethyl ester, which has been confirmed through 
NMR spectral data. The formation of the butyl ester indicated a possible replacement 
of the ethyl ester with a butyl species derived from the butyl lithium during the 
formation of the carbanion. The mechanism of this reaction is unknown.
3) Synthesis of methyl 3-hydroxy-2-methylene-3-(4-nitrophenyl)propanoate 
(8):
The formation of methyl 3-hydroxy-2-methylene-3-(4-nitrophenyl)propanoate 
(8) was carried out using the Baylis-Hillman reaction.
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The Baylis-Hillman reaction was first reported in 1972 (180) and has great 
synthetic utility as it converts simple starting materials into densely functionalised 
products (181). The Baylis-Hillman reaction is a reaction between an aldehyde and an 
a,p-unsaturated electron-withdrawing group. These reactions usually require Lewis 
bases as catalysts, such as tertiary phosphanes or tertiary amines, such as 1,4- 
diazabicyclo[2.2.2]octane (DABCO) (182) and diaza(l,3)bicyclo[5.4.0]undecane 
(DBU). The major problem associated with this reaction is its slow reaction rate. 
Numerous methods, including chemical (183'186) as well as physical attempts(182,187‘188) 
have been made to accelerate the reaction with some success.
The best yield for preparation o f methyl 3-hydroxy-2-methylene-3-(4- 
nitrophenyl) propanoate was found by using aqueous trimethylamine as the basic 
catalyst (189), and 4-nitrobenzaldehyde (1) and methyl acrylate (7) (Scheme 3.2.6). 
This reaction gave a very high yield (98%) o f the desired product.
H + H2C ^ A  CH
o
aqueous
trimethylamine
hT ^  ^ 3. Ha Hb
(1) (7) (8)
Scheme 3.2.6. Synthesis of methyl 3-hydroxy-2-methylene-3-(4-nitrophenyl) 
propanoate (8).
The Baylis-Hillman is initiated by the Michael type nucleophilic addition of  
tertiary amine (trimethylamine) to the activated alkene (methyl acrylate) resulting in a 
transient zwitter ionic enolate, which subsequently makes a nucleophilic attack on the 
electrophile (4-nitrobenzaldehyde) to produce the zwitter ionic adduct. The dipolar 
adduct gives the final product after proton migration followed by the elimination of  
the tertiary amine(190) (Scheme 3.2.7).
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OH
Ph'
R3N
Ph'
Scheme 3.2.7. Proposed mechanism of Baylis-Hillman reaction.
3.2.4.2. Reduction of the a-unsubstituted/substituted 3-hydroxy-3-(4- 
nitro phenyl)propanoates:
1) Reduction of the a-unsubstituted 3-hydroxy-3-(4-nitrophenyl) 
propanoates:
Unfortunately, all efforts made to reduce the a-unsubstituted 3-hydroxy-3-(4- 
nitrophenyl)propanoates (3 & 5) failed as the compounds were found to be 
completely unstable.
2) Reduction of the a-substituted 3-hydroxy-3-(4-nitrophenyI) propanoate
(8):
Reduction of methyl 3-hydroxy-2-methylene-3-(4-nitrophenyl) propanoate (8) 
to the corresponding methyl 3-(4-aminophenyl)-3-hydroxy-2-methylpropanoate (9)- 
anti and (9)-syn was achieved in one step, using 5% Pd-C and hydrogen atmosphere 
(Scheme 3.1.8).
iV
0,N
0  Pd-C/H. 5‘
H.N 4 H.N 4
(9 )-anti (9 )-syn
H,N 4
,CH,
Scheme 3.2.8. Synthesis of methyl 3-(4-aminophenyl)-3-hydroxy-2- 
methylpropanoate (9)-anti and (9)-syn.
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The reduction of the methylene to the methyl during the reduction of the nitro- 
group to the amine agreed with literature data(l91). The yield of the reduction reaction 
was not poor (48%), as a hydrogenolysis process occurred simultaneously in about 
50% of the product. This hydrogenolysis process could not be avoided even with 
varying the time of the reduction. The hydrogenolysis product (10) has the same Rp as 
the starting compound (8), but they stained differently with ninhydrin stain.
Although, the diastereoisomers of methyl 3-(4-aminophenyl)-3-hydroxy-2- 
methylpropanoate could not be separated, the NMR spectral data indicated that the 
syn and anti forms were present in a ratio of 5:8.5 respectively.
• Ninhydrin test for the amine compounds:
The ninhydrin reagent is prepared by dissolving 0.35 g of ninhydrin in 100 mL 
ethanol. The primary amine compounds give a purple stain on the TLC plate when 
immersed in ninhydrin reagent (Scheme 3.2.9).
OH
2
OH
Ninhydrin Purple complex
Scheme 3.2.9. Ninhydrin reaction with the amine compounds.
3.2.4.3. Synthesis of the substituted 4-(arylamino)phenylpropanoates 
derivatives (12)/(13)/(17)/(18):
This synthesis involves the formation of an aromatic C-N bond. Despite the 
importance of aromatic amines and their use in pharmaceutical and agrochemical 
industries, few methods have been found in the literature for C-N coupling.
The traditional methods to prepare these compounds are through copper- 
catalysed Ullmann-type reactions (192), which involve the condensation of an aromatic 
amine and an unactivated aryl halide with catalysis by copper in the presence of a 
base. Strongly aggressive conditions involving high temperature and extended 
reaction times are generally needed to secure at best moderate yields.
The most popular C-N coupling methods have utilised the palladium- or 
nickel-catalysed coupling of amines with aryl halides in the presence of a hydroxide 
base (193'194). The major drawback of this reaction is its incompatibility with base
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sensitive functional groups such as esters and ketones. As our compounds contain an 
ester group, this reaction was not suitable.
The most suitable way for the arylation of NH in our compounds is the use of 
arylboronic acids in a Suzuki coupling reaction (195). This reaction has been found to 
be successful in the synthesis of our compounds (129). This reaction is performed in the 
presence of a stoichiometric amount of copper and a tertiary amine base such as 
triethylamine or pyridine. It should be noted that the yield of the reaction is quite 
dependent on the nature of the substrate, the substitution on the boronic acid and the 
choice of the tertiary amine base. The reaction is performed in air allowing oxygen 
uptake and therefore more efficient oxidation of a reduced copper intermediate (196). 
This can be done by using vigorous stirring in flasks with a large volume relative to 
that of the solvent volume. This is more important during the first few hours of the 
reaction since it was found that the reaction proceeded smoothly to 35-45% 
conversion in the first 4-5 h, and catalytic activity rapidly diminished over the next 20 
h (197). The use of molecular sieves has been found important to obtain the best yield
(195)
The general conditions for this coupling reaction (Scheme 3.2.10) involved the 
addition of 2.0 equivalents of arylboronic acid (11) and 2.0 equivalents of base 
(pyridine) to 1.0 equivalent of amine in anhydrous dichloromethane (8 mL/0.5g of the 
substrate) followed by (1-2) equivalents of anhydrous cupric acetate and 4A 
molecular sieves. The mixture was stirred under air atmosphere at room temperature 
for 3 days and then chromatographed on silica gel to give the desired N-arylated
Cu acetate
OH
H,C. HO
B— ArCH,
amine.
(9) (1 1 )
Pyridine
OH
O
N
H3'(12)
,Ar
OH
O
Ar
(13)Ar = phenyl, 2-naphthyl
Scheme 3.2.10. Synthesis of the substituted 4-(arylamino)phenylpropanoate 
derivatives.
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Table 3.2.2. Yields and melting points of different isomers.
Ar Yield (%) m.p. (°C)
anti phenyl 44 98-101
syn phenyl 2 2 oil
anti naphthyl 40 124-126
syn naphthyl 2 0 oil
At this point separation of the diastereoisomers was achieved using the flash 
column chromatography. Although the two forms of the diastereoisomers have not 
been confirmed which is syn and which is anti, it is more likely that the syn and whioh 
-iBanti forms were obtained in a ratio of 1 : 2  respectively, as might be concluded from 
the NMR spectra comparison with very similar compounds that was mentioned in the 
literature (182). The difference between the two diastereoisomers the *H-NMR spectral 
data was mainly at the CH in position 3. The CH at position 3 appeared as a doublet 
with higher coupling constant value which -in accordance with the literature- might be 
the anti form while CH at position 3 in the proposed syn form appeared also as a 
doublet but with lower coupling constant value (table 3.2.3).
Table 3.2.2. Coupling constants of the CH at position 3:
Ar CHOH J value
anti phenyl 8 . 8  Hz
syn phenyl 5.5 Hz
anti naphthyl 8 . 8  Hz
syn naphthyl 3.8 Hz
The mechanism of the reaction (Scheme 3.2.11) is believed to be analogous to 
that of the bismuth arylation proposed by Barton, with the arylboronic acid playing a 
role similar to the triarylbismuth (198). It involves cupric acetate forming a complex 
with the amine and transmetallation with arylboronic acid. Reductive elimination of 
the resulting amine/copper/aryl complex affords the N-arylated amine. The role of the 
base in the catalytic cycle is to increase the carbanion character of the phenyl groups 
in organoboranes by their coordination with the boron atoms. This will then facilitate 
the transfer of phenyl groups from the boron to the copper complexes in the 
transmetallation step to form Ar-NH-Cu-Ar’.
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R -N H ,
N H ,-R
I
..C u ll
x ■'x
Transmetallation
R -N H -R ’
R ’-B(O H)2 
Tertiary amine base
R'
I
.C u ll
HN-R baSC H .N -R
NHR
Scheme 3.2.11. Proposed mechanism of action of the Suzuki coupling reaction o f aryl 
boronic acids with amines.
3.2.4.4. Synthesis of a-substituted 3-(imidazol-l-yI)-3-(4-(aryIamino) 
phenyl) propanoates (14)/(15)/(19)/(20):
The synthesis of the imidazole compounds was carried out through the direct 
reaction of the carbinol compounds with l,r-carbonyldiimidazole in the presence of 
excess imidazole as reported (86). The reaction was heated at reflux for one hour. An 
excess of imidazole was necessary to reduce the formation of a side product arising 
from the competitive attack of the exocyclic amino atom, instead of imidazole, on the 
intermediate imidazolide. The mechanism of the reaction involves two nucleophilic 
substitution reactions. The carbinol compounds reacted with l,r~carbonyldiimidazole 
to produce an intermediate which undergoes a second nucleophilic substitution by the 
excess imidazole to give the products (Scheme 3.2.12).
The imidazole derivatives of both the anti and syn compounds have been 
synthesised with different yields, and from the NMR spectral data (Figures 3.2.3 and 
3.2.4), we have found that the reaction of imidazole with these compounds is more 
likely to be a SnI nucleophilic substitution reaction.
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\*J P 0
(14)/(15)/(19)/(20)
Scheme 3.2.12. Proposed mechanism of formation of a-substituted 3-(imidazol-l-yl)- 
3-(4-(arylamino)phenyl)propanoates: (14) Ar = phenyl, anti; (15) Ar = phenyl, syn; 
(19) Ar = naphthyl, anti; (20) A i = naphthyl, syn.
This suggestion might be explained as there is no complete inversion of 
configuration of either of the compounds, and also, what could be seen clearly from 
Figures 3.2.3 marked area; that is for each compound, in the same reaction a 
percentage from a second product with different configuration was found which 
suggests a small degree of racemisation, a characteristic feature of a SnI nucleophilic 
substitution reaction. What also may support this assumption is the presence of the 
methyl group at position 2  which may restrict with its steric effect the formation of 
bimolecular intermediate for the reaction to be performed through Sn2  nucleophilic 
substitution reaction.
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3.2.5. Synthesis of 2,2-dimethyl-3-(1-imidazolyl)-3-aryl 
propanoate derivatives:
As the replacement of the dimethyl groups in our lead compound (IC50 = 2.8 nM) 
with a mono methyl group (highest IC50 = 26 nM) resulted in a decrease in the 
inhibitory activity (see section 3.4.2, table 3.4.2), we decided to return to the dimethyl 
groups and prepare the other compounds given by the pharmacophore and docking 
results. These compounds were simpler to prepare and also had lower lipophilicity.
The synthesis of 2,2-dimethyl-3-(l-imidazolyl)-3-arylpropanoates involved a 
sequence of 2 steps (Scheme 3.2.13):
1) The preparation of 2,2-dimethyl-3-hydroxy-3-arylpropanoate.
2) The preparation of 3-(imidazol-l -yl) derivatives.
Ar H
(21 )/(25)/(27)/(29)
CH,
CH3  O— Si—CH3
c h 3
c h 3  o — c h 3
(22)
Ar = 2-naphthyl, 
2 -pyridyl,
2 -quinazolinyl
3-nitrophenyl
(a) or (b)
OH O
Ar "yC O 
CH3 CH3
(23)/(26)/(28)/(30)
/C H 3
c h 3 c h 3
Scheme 3.2.13. Scheme of general chemistry: (a) Pyridine-A-oxide, LiCl, DMF, rt, 24 
h; (b) H2O, rt, 24 h; (c) Imidazole, l,l'-carbonyldiimidazole, CH3CN, 65 °C for lh, 
then rt, 24 h.
3.2.5.I. Preparation of 2,2-dimethyl-3-hydroxy-3-arylpropanoate:
1) Synthesis of methyl 3-hydroxy-2,2-dimethyl-3-(2-naphthyI)propanoate (23) 
and Methyl 3-hydroxy-2,2-dimethyl-3-(3-nitrophenyl) propanoate (30):
The synthesis of methyl 3-hydroxy-2,2-dimethyl-3-(2-naphthyl)propanoate
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(23) and methyl 3-hydroxy-2,2-dimethyl-3-(3-nitrophenyl) propanoate (30) was 
carried out through the aldol reaction of 2-naphthaldehyde (21) and 3- 
nitrobenzaldehyde (29) respectively with methyl trimethylsilyldimethyl ketene acetal 
(22) (Scheme 3.2.14) using the same method used before for the preparation of 
compound (3).
X ,
(21 )/(29)
c h 3 
c h 3 o
(22)
c h 3
I
O — S i— C H 3
O H  O
C H 3
■c h 3
Pyridine-W-oxide
LiCI
.CH,
A r '  Y  O
c h 3 c h 3 
(23)/(30)
Ar = (21)/(23) 2-Naphthyl, (23)/(30) 3-Nitrophenylbenzaldehyde
Scheme 3.2.14. Synthesis of methyl 3-hydroxy-2,2-dimethyl-3-(2-
naphthyl)propanoate (23) and methyl 3-hydroxy-2,2-dimethyl-3-(3-nitrophenyl) 
propanoate (30).
2) Synthesis of methyl 3-hydroxy-2,2-dimethyl-3-(2-pyridyl/quinolinyl) 
propanoate (26/28):
Aldol reaction using water at ambient temperature and without Lewis acid 
catalysis or any special activation has been used by many chemists (199'202). Although 
the true mechanism of this reaction is unknown, the yield is completely dependent on 
the reactivity of the aldehyde (202).
The method involved the reaction (Scheme 3.2.15) between methyl 
trimethylsilyldimethyl ketene acetal (22) and pyridyl-2 -carboxaldehyde (25) and 
quinazoline-2-carboxaldehyde (27) to give methyl 3-hydroxy-2,2-dimethyl-3-(2- 
pyridyl)propanoate (26) (Yield: 85%) and methyl 3-hydroxy-2,2-dimethyl-3-(2- 
quinolyl)propanoate (28) (Yield: 62%) respectively.
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.A, CH,) -  
c h 3 o — c h 3
c h 3
0 —Si—CH3
c h 3
OH
H ,0 .
Ar O
c h 3c h 3 
(26)/(28)
/ CH,
(25)/(27) (22)
Ar = (25)/(27) 2-Pyridyl, (26)/(28) 2-Quinolinyl 
Scheme 3.2.15. Synthesis of methyl 3-hydroxy-2,2-dimethyl-3-(2- 
pyridyl)propanoate and methyl 3-hydroxy-2,2-dimethyl-3-(2-quinolyl)propanoate.
3.2.5.2. Preparation of 3-(imidazol-l-yl) derivatives:
Unfortunately, all the methods that have been tried to obtain the imidazole 
derivatives from compounds (23, 26, 28 and 31) were unsuccessful, and the reaction 
stops at the point of formation of the intermediate with the l,l'-carbonyldiimidazole 
as in the case of compound (23), which formed 3-methoxy-2,2-dimethyl-l-(2- 
naphthyl)-3-oxopropyl-l//-l-imidazolecarboxylate (24) (Scheme 3.2.16).
.CH,
Imidazole
CH3 CH3 1,1 '-Carbony idiimidazoie CH3 CH3
(23) (24)
Scheme 3.2.16. Formation of the intermediate with l,l'-carbonyldiimidazole.
Also, another approach had been tried through conversion of the hydroxyl 
group to the more active bromo group, using either jV-bromosuccinimide or PBr3 in 
the presence of pyridine, but all these methods failed to replace the hydroxyl group 
with the bromide.
3.2.6. Synthesis of methyl 3-(1H-1-imidazolyl)-2-methylene-3- 
(2-naphthyl)propanoate (34):
As a result of the failure of the introduction of the imidazole in the previous 
series, we investigated the effect of the presence of a methylene group in place of the 
dimethyl groups.
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The synthesis of methyl -imidazole)-2-methylene-3-(2-
naphthyl)propanoate was carried out through two simple steps:
1) Firstly, the formation of methyl 3-hydroxy-2-methylene-3-(2- 
naphthyl)propanoate (33) through Baylis-Hillman reaction of 2-naphthaldehyde (21) 
and methyl acrylate (7 )(203) (Scheme 3.2.17) which was also used as the solvent. The 
catalyst used in this reaction is DABCO, as the aqueous trimethylamine could not be 
used as it did not form a homogenous solution. The yield of this reaction was good 
(79%).
OH
10'
8’
Pyridine-yV-oxide
LiCI T
(33)
H
+ H 2C,
(21)
Scheme 3.2.17. Synthesis of methyl 3-hydroxy-2-methylene-3-(2- 
naphthyl)prapanoate (33).
2) Secondly, the reaction of methyl 3-hydroxy-2-methylene-3-(2-nephthyl) 
prapanoate (33) with l,r-carbonyldiimidazole in the presence of excess imidazole as 
stated before (86) (Scheme 3.2.18).
10'
8'
7 ’
(34)
OH
Im idazole
1,1 '-C arbonyld iim idazole
(33)
Scheme 3.2.18. Synthesis of methyl 3-(li/-l-imidazole)-2-methylene-3-(2-naphthyl) 
propanoate (34).
Although the introduction of the methylene group retained the inhibitory 
activity (see section 3.4.1, table 3.4.1), no more derivatives were made due to the 
expected irreversible enzyme inhibition that could result from the presence of the 
exposed methylene group which makes the dimethyl substituents still favourable.
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3.2.7. Synthesis of 4-[(2-benzoxazolyl)amino]phenyl 
derivatives:
Based on previous work within our group (129) combined with our 
pharmacophore and docking results, a new series containing the benzoxazole 
heterocycle was developed.
• General chemistry:
The synthesis of the benzoxazoles series was carried out according to the 
following Scheme 3.2.18:
(35) (36) R = COOCHj (37) R » COOCH,
(36) R » COCHj (39) R « COCH,
Scheme 3.2.18. General scheme for the synthesis of the benzoxazole series: (i) 
LiAlH4 , 20 min; (ii) SCE-Py, DMSO, 0 °C, 5 min then rt, 25 min; (iii) Methyl 
acrylate, DABCO; (iv) Imidazole, 1,l'-carbonyldiimidazole, CH3CN, 65 °C for lh, 
then rt, 24 h; (v) NH2NH2 .H20 , reflux 3 h; (vi) CS2, KOH, A, 24 h; (vii) Citral, 
NaOEt.
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3.2.7.I. Coupling of the 4-aminophenyl derivatives with 2-chlorobenzoxazole:
The formation of 4-[(2-benzoxazolyl)amino]phenyl derivatives involved a 
nucleophilic substitution reaction between 4-amino phenyl derivatives and the 2- 
chlorobenzoxazole (35) in the presence of phenol (Scheme 3.2.19).
Phenol
(35) (36) R = COOCH3  (37) R = COOCH3
(38) R = COCH3  (39) R = COCH3
Scheme 3.2.19. Synthesis of 4-[(2-benzoxazolyl)amino]phenyl derivatives.
Unfortunately this reaction is not common; although it seems theoretically a 
very simple reaction. The reported method for this reaction (204) using methyl 4- 
aminobenzoate and 2-chlorobenzoxazole in benzene as a solvent did not work. The 
method using phenol is not a reported method for the preparation of benzoxazoles 
compounds, but it was reported for the preparation of benzothiazoles (205). The role of 
phenol, other than solvation, is unclear although it may act as a Lewis acid. The 
reaction of 4-aminobenzylalcohol (40) with the 2-chlorobenzoxazole (35) (Scheme 
3.2.20) led to the formation jV-(l,3-benzoxazol-2-yl)-N-[4-(phenoxymethyl)phenyl] 
amine (41) as a white solid through the protonation of the alcohol which was then 
attacked by the phenolate anion (Scheme 3.2.21).
OH
Phenol+
H2N
(41)
Scheme 3.2.20. The reaction between 4-aminobenzylalcohol (40) with the 2- 
chlorobenzoxazole (35).
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H© /
- HCI
H,
H
Scheme 3.2.21. Proposed mechanism for the reaction between 4-aminobenzylalcohol 
(40) with 2-chlorobenzoxazole (35).
3.2.7.2. Uses of the benzoxazole acetophenone (39):
The main reaction planned for the acetophenone derivative was the aldol 
condensation with citral to form a long alkyl chain that resembles vitamin A (Scheme
3.2.22).
NaOEt
(39) Citral
Scheme 3.2.22. Proposed reaction of the acetophenone derivative with citral.
However, because of the lability of the bond between the amino group and the 
benzoxazoles and the reduced reactivity of the ketone, the reaction did not work. It 
was thought that, protection of the amino group with BOC-anhydride (Scheme
3.2.23) may reduce the electron-donating ability of the amino group and possibly 
stabilise the bond between the NH and benzoxazole.
BOC-anhydride
(38) (44)
Scheme 3.2.23. Protection of 4-aminoacetophenone with BOC-anhydride
The next step was to form the methyl bromide to make the reaction with citral
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easier and to avoid drastic conditions (Scheme 3.2.24).
o
AICI3 CH,
CH, H CH, H
(44)
Scheme 3.2.24. Formation of the bromide (45).
(45)
In spite of the protection of the amino group, the NH-benzoxazole bond was 
still very labile and the formation of the branched compound failed.
3.2.7.3. Uses of the benzoxazole ester (37):
1) Synthesis of Baylis Hillman products:
The key intermediate in these reactions is the preparation of the aldehyde 
which was prepared through the following Schemes 3.2.25:
DMSO
aldehyde  (43)
Scheme 3.2.25. Preparation of the key aldehyde intermediate
The aldehyde (43) was prepared in two steps from the benzoxazole ester (37). 
As mentioned before the alcohol could not be synthesised using the phenol method 
and that is why the ester (37) has been used for this reaction. The ester was reduced 
with LiAlFL) to give the alcohol (42) in 72 % yield, after extraction, and was pure 
enough for use in the next reaction step. The alcohol was insoluble in every solvent 
except DMSO, therefore the Parikh-Doering (206) oxidation was chosen as it uses 
DMSO as the reaction solvent and reagent, using this method the aldehyde was 
obtained as a pale yellow solid in low yield (19%). The major material was baseline 
by TLC and corresponded to the pyridine-S0 3  complex. The low yield may be owing
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to either decomposition of the starting material under the reaction conditions or 
possibly N-oxidation; however isolation of either decomposition and/or by-product 
was not attempted from the DMSO/aqueous extraction layer.
The mechanism of the oxidation process using DMSO-SO3 reagent, proceeds 
via an intermediary sulphonium ion, which collapses to a carbonyl compound (the 
aldehyde in our reaction) and dimethyl sulphide by a cyclic mechanism (207) (Scheme 
3.2.26).
©
■O— S (C H 3)2
H
-r-C L  © . C H ,
[ T  £ 5 /  - > -
0  + S(CH3)2
^ ° c h 2
Scheme 3.2.26. Proposed mechanism for the oxidation of alcohol with DMSO.
Unfortunately, all the reactions that were planned using the aldehyde (e.g. 
Baylis-Hillman reaction Scheme 3.2.27) did not work, as the bond between the amino 
group and the benzoxazole is very labile under basic or acidic conditions. Also, the 
presence of the amino group in the para position reduces the reactivity of the carbonyl 
group.
+ HsC ^ i f
CDI, Im id a z o le
N
O' N
H
Scheme 3.2.27. Baylis-Hillman product.
2) Synthesis of l,3?4-oxadiazole derivatives:
With the difficulty in introducing the imidazole group in our compounds, it 
was thought that replacing the whole imidazole methyl portion with 1,3,4-oxadiazole 
(Figure 3.2.5) might result in retaining inhibitory activity; specially with the previous 
data from the pharmacophore search and the docking (Figure 3.1.3 and Table 3.2.1) 
with the CYP26A1 model, which showed very good interaction.
Results & Discussion 81
N—'
Figure 3.2.5. Replacement of the triazole by the oxadiazole.
The key intermediate of this reaction is the formation of the hydrazide which 
was prepared using the following reaction (Scheme 3.2.28).
.CH
N
H
(37)
N
H
Scheme 3.2.28. Synthesis of the hydrazide (46).
The hydrazide (46) was prepared through the reaction of the ester (37) with 
excess hydrazine hydrate. The hydrazide was obtained in a fair yield of 45% after 
recrystallisation from aqueous ethanol.
Again due to the lability of the bond between the amino group and the 
benzoxazole, the formation of the 1,3,4-oxadiazole using CS2 and KOH with reflux 
for about 2 0  h, was unsuccessful.
3.2.8. Synthesis of 2-[(4-arylamino)phenyl]-5-(aralkyl/aryl or 
alkoxycarbonylalkylsulfanyl)-1,3,4-oxadiazole:
As we previously discussed, this was a trial to replace the troubled imidazole 
ring with a more achievable oxadiazole ring, which showed good interaction with 
both the pharmacophore and the CYP26A1 homology model.
The synthesis of 2-[(4-arylamino)phenyl]-5-(aralkyl/aryl or alkoxycarbonyl 
alkylsulfanyl)-1,3,4-oxadiazole involves a sequence of 4 steps (Scheme 3.2.29):
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1) Preparation of 5-(4-nitrophenyl)-1,3,4-oxadiazoline-2-thione.
2) Coupling of 5-(4-nitrophenyl)-1,3,4-oxadiazoline-2-thione with arylalkyl/aryl 
or bromoalkyl ester chains.
3) The reduction of the nitro to an amino group.
4) The coupling of the amino group with the aryl substituents through a Suzuki 
coupling reaction.
0,N
H,N (51 )/(55)/(59) 
(d )
(50)/(54)/(58)
(52)/(56)/(60)
Scheme 3.2.29. Scheme of general chemistry: (a) CS2 , KOH, A, 24 h; (b) 
arylalkyl/alkyl bromide, K2 CO3, rt, 24h; (c) Fe, NH4CI, EtOH, 3 h; (d) naphthyl-2- 
boronic acid, CuOAc, pyridine, CH2CI2 , 72 h.
3.2.8.I. Synthesis of 5-(4-nitrophenyl)-l,3>4-oxadiazoIine-2-thione 
(48):
Different methods have been reported for the preparation of 5-aryl-2,3- 
dihydro-l,3,4-oxadiazole-2-thione where N-acylaminoiminophosphoranes were 
treated with carbon disulfide and the resulting isocyanates were cyclised without 
isolation to give 5-aryl-2,3-dihydro-l,3,4-oxadiazole-2-thiones in high yields (208).
It was also reported that 5-aryl-2,3-dihydro-1,3,4-oxadiazole-2-thiones were 
obtained by reaction of the acid hydrazides with an equivalent amount of
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thiophosgene (209'211).
Moreover, 5-aryl-2,3-dihydro-1,3,4-oxadiazole-2-thiones were obtained by 
reaction of acid hydrazides and l.l'-thiocarbonyldiimidazole in the presence of 3 
equivalents of diisopropylethylamine (DIPEA)(212).
The most common method for the preparation of 5-aryl-2,3-dihydro-l,3,4- 
oxadiazole-2 -thione is the reaction of acid hydrazides with CS2 in the presence of a 
base, such as triethylamine, imidazole, NaOH, KOH, K2CO3 or Na2CC>3, in preferably, 
alcoholic solvents such as, EtOH, MeOH, 'PrOH or THF (213'215).
For preparation of 5-(4-nitrophenyl)-l,3,4-oxadiazoline-2-thione (48) 
(Scheme 3.2.30), 4-nitrobenzoylhydrazide (37) was refluxed with CS2 in the presence 
of KOH for 24 h. The resulting residue was dissolved in H2O ant treated with IN HC1 
to give the desired compound in a yield of 75%.
(47)
O
NHNH2 i)CS2/KOH/A
 ►
2)HC1
0 2N ’
(48)
Scheme 3.2.30. Synthesis of 5-(4-nitrophenyl)-l,3,4-oxadiazoline-2-thione (48).
The mechanism of this reaction was proposed to be as follows; nucleophilic 
attack of the enolate ion (i) of the hydrazide on CS2 forming a xanthate type salt (ii). 
This salt might rearrange, through intramolecular acylation of the neighbouring amino 
function, to the potassium salt of 3-acyldithiocarbazinic acid (iv) via an intermediate 
oxadiazoline (iii). It is possible that as equilibrium exists between (v) and (viii), the 
position of which could be influenced by the relative nucleophilic character of oxygen 
versus sulphur or by steric hindrance around the carbonyl carbon. The 5-aryl-2,3- 
dihydro-l,3,4-oxadiazole-2-thione (ix) would be produced with concomitant loss of 
hydrogen sulfide, (Scheme 3.2.31)(214).
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o
II
A r — C - H N - N H 2
O H
© 01
ale. K O H
© © 
O — C — S K
A r — C = N — N H 2 +
( i ) D A r - c HN — N H 2 
( i i )
II II 0  ©
A r — C — N H N H — C — S K  -
( v i ) ( v i i ) ( v i i i )
-H2S
N NH
( i x )
Scheme 3.2.31. Proposed mechanism for the formation of 5-aryl-l,3,4-oxadiazoline- 
2 -thione (214).
3.2.8.2. Synthesis of 2-(4-nitrophenyl)-5-(alkyl/arylalkyl or 
alkoxycarbonylalkylsuIfanyI)-l,3,4-oxadiazole:
For the preparation of 2-(4-nitrophenyl)-5-(alkyl/arylalkyl or alkoxycarbonyl 
alkyl sulfanyl)-1,3,4-oxadiazole, the 5-(4-nitrophenyl)-l,3,4-oxadiazoline-2-thione 
(48) was reacted with the arylalkyl/alkyl bromides bromoalkyl ester (Scheme 3.2.32) 
in the presence of K2CO3 , at room temperature. Three representatives have been 
synthesised: 2-(4-nitrophenyl)-5-(phenethylsulfanyl)-1,3,4-oxadiazole (50) from l-(2- 
bromoethyl)benzene (49), 2-(4-nitrophenyl)-5-(pentylsulfanyl)-1,3,4-oxadiazole (54) 
from 1-bromopentane (53) in yields of 69% for both reactions and ethyl 2-{[5-(4-
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nitrophenyl)-l,3,4-oxadiazol-2-yl] sulfanyl} acetate (58) from ethyl 2-bromoacetate 
(57) in a yield of 62%.
SH
A — Br
NO' NO'
(48) (49)/(53)/(57) (50)/(54)/(58)
A = (49)/(50) Phenethyl
(53)/(54) pentyl
(57)/(58) -CH2COOCH2CH3 
Scheme 3.2.32. Synthesis of 2-(4-nitrophenyl)-5-(alkyl/aralkyl or alkoxycarbonyl 
alkyl sulfanyl)-1,3,4-oxadiazole.
3.2.8.3. Reduction of 2-(4-nitrophenyl)-5-(alkyl/arylalkylsuIfanyI)- 
l ,3 94-oxadiazole:
Reduction of 2-(4-nitrophenyl)-5-(alkyl/arylalkyl or alkoxycarbonyl alkyl 
sulfanyl)-1,3,4-oxadiazole to the corresponding 4-[5-(alkyl/arylalkyl or
alkoxycarbonyl alkyl sulfanyl)-1,3,4-oxadiazol-2-yl]aniline was tried using 5% Pd-C 
and hydrogen atmosphere. The low yield of 34% obtained in this reduction is 
probably due to poisoning of the catalyst through complexation with the sulphur atom.
Another method of reduction using iron in the presence of NH4CI (Scheme 
3.2.33.) has been used to give 4-[5-(alkyl/arylalkyl or alkoxycarbonyl alkyl sulfanyl)- 
1,3,4-oxadiazol-2-yl]anilines in much better yields of 89%, 79% and 78% 
respectively.
N hL C I
o 2n
(50)/(54)/(58) (51 )/(55)/(59)
A = (50)/(51) Phenethyl
(54)/(55) pentyl
(58)/(59) -CH 2COOCH2CH3 
Scheme 3.2.33. Reduction of 2-(4-nitrophenyl)-5-(alkyl/arylalkyl or alkoxycarbonyl 
alkyl sulfanyl)-1,3,4-oxadiazole (50)/(54)/(58).
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3.2.8.4. Synthesis of A/-(2-naphthyl)-A/-{4-[5-(alkyl/arylalkyl or 
alkoxycarbonyi alkyl sulfanyl)-1,3,4-oxadiazol-2-yl]phenyl} 
amine (52)/(56)/(60):
The Suzuki coupling reaction was used as before for the synthesis of N-(2- 
naphthyl)-jV-{4-[5-(alkyl/arylalkyl or alkoxycarbonyi alkyl sulfanyl)-l,3,4-oxadiazol- 
2-yl]phenyl} amine (52)/(56)/(60) through the reaction between naphthylboronic acid 
(16) and 4-[5-(alkyl/arylalkyl or alkoxycarbonyi alkyl sulfanyl)-l,3,4-oxadiazol-2- 
yl]aniline (51)/(55)/(59) (Scheme 3.2.34.) to give the product in a yield of 71%, 65% 
and 78% respectively.
/ ° H
r  ♦ h 2n
(16 )
A = (51)/(52) Phenethyl
(55)/(56) pentyl
(59)/(60) -CH 2COOCH2CH3 
Scheme 3.2.34. A^-(2-naphthyl)-A^-{4-[5-(alkyl/arylalkyl or alkoxycarbonyi alkyl 
sulfanyl)-! ,3,4-oxadiazol-2-yl]phenyl}amine (52)/(56)/(60).
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3 . 3 . C hem is try  
o f  CYP24A1
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(1) Azoles CYP24A1 inhibitors:
The idea behind this was to combine VID 400, a described potent CYP24A1 
inhibitor, with calcitriol as the lead compound for this series (Figure 3.3.1).
Figure 3.3.1. Design of the CYP24A1 first series.
3.3.1. Synthesis of A/-[2-(1H-1-imidazolyl)-2-phenyl/flourophenylethyl]-4- 
[(E)-2-(3,5-unsubstituted/disubstitutedphenyl)-1-ethenyl]benzam ide:
The synthesis of AL[2-(l//-l-imidazolyl)-2-phenyl/flourophenylethyl]-4-[(£)- 
2-(3,5-unsubstituted/disubstitutedphenyl)-l-ethenyl]benzamide was carried out 
according to the following steps (Scheme 3.3.1):
1) Synthesis of the l,3-unsubstituted/disubstituted-5-vinylbenzene.
2) Preparation of 4-[(£)-2-(3,5-unsubstituted/dimethoxyphenyl)-l-ethenyl] 
benzoic acid.
3) Synthesis of A-(2-hydroxy-2-phenylethyl)-4-[(£)-2-(3,5-unsubstituted/ 
dimethoxyphenyl) - 1 -ethenyljbenzamide.
4) Synthesis of 2-4-[(£)-2-(3,5-unsubstituted/dimethoxyphenyl)-l-ethenyl] 
phenyl-5-phenyl-4,5-dihydro- 1,3-oxazole.
5) Synthesis of A-[2-(liYl-imidazolyl)-2-phenylethyl]-4-[(£)-2-(3,5-unsub- 
stituted/dimethoxyphenyl) - 1 -ethenyl]benzamide.
VID400
(/?)-enantiomer
Cl
Calcitriol Designed series 1
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HO' HjCO'(61) (66 )
(iv)
CHj JHjBr
(H i) R1 “  OAc (unsuccesful), 
OCHj, 
or H
AcO' >Ac AcO' )Ac AcO' )Ac(62) (65)(63)
(71)/(74)
R2 = H or CH3,
(Vi)R = H or F
(vii)
(viii)
Scheme 3.3.1. Synthesis of the azole derivatives: (i) AC2O, rt, 17 h; (ii) N- 
bromosuccinimide, benzoyl peroxide, reflux 3 h; (iii) PPI13, reflux 6  h; (iv) 
Ph3PCH3Br, r-BuOK, rt, 2 h; (v) Pd(OAc)2, ToP, Et3N, 80 °C, 2 h; (vi) 1,1’-
carbonyldiimidazole, rt, overnight; (vii) methanesulphonic anhydride, NEt3, 0 °C in 
the fridge overnight; (viii) imidazole, 24 h, 125 °C.
3.3.1.1. Synthesis of 4-[(£)-2-(3,5-diacyl/alkyloxyphenyI)-l-ethenyl]benzoic acid:
(1) Preparation of 3-(acetyloxy)-5-methylphenyl acetate (62):
The first step in the preparation of 4-[(E)-2-(3,5-diacyl/alkyloxyphenyl)-l- 
ethenyl] benzoic acid was to obtain the vinylbenzene compound.
In this reaction (215), orcinol (61) was used as the starting material, and the two 
hydroxyl groups were protected using acetic anhydride. The reaction took a long time
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(17 h) at room temperature, however it gave the acetylated (62) product in almost 
quantitative yield (99%) (Scheme 3.3.2).
CH
CHHO' OH
(61) (62)
Scheme 3.3.2. Preparation of 3-(acetyloxy)-5-methylphenyl acetate (62).
(2) Preparation of 3-(acetyloxy)-5-(bromomethyl)phenyl acetate (63):
Bromination of 3-(acetyloxy)-5-methylphenyl acetate (62) was performed 
using Wohl-Ziegler bromination (215). In Wohl-Ziegler bromination, N- 
bromosuccinimide (NBS) was used in the presence of benzoyl peroxide as a catalyst, 
and CCI4 as the solvent (Scheme 3.3.3).
c h 3 CH2Br
W-Bromosuccinimide
Benzoyl-peroxideUH3 H3C CHH3C
(63)(62)
Scheme 3.3.3. Preparation of 3-(acetyloxy)-5-(bromomethyl)phenyl acetate (63).
The mechanism of bromination with NBS involves a free radical process (216). 
Thermal decomposition of benzoyl peroxide provides the radical initiator (Step 1). 
Reaction with molecular bromine (present as an impurity in the NBS) affords the 
bromine radical (Step 2) which abstracts a proton from the benzylic methyl (Step 3). 
An ionic reaction between NBS and the HBr formed in Step 3 affords molecular 
bromine (Step 4) which reacts with the benzylic radical to give the product and a 
bromine radical (Step 5). Propagation occurs when the bromine atom reinserts itself 
into Step 3 (Scheme 3.3.4),
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Step 1 Ph o
JL Co. .Ph „  _  „  _  - 2 C 0 2 „  .2 Ph V J  O --------=-► 2 Ph
Step 2 Ph + Br2  ►- PhBr + Br
Step 3
CH;
Br
• CH
HBr
Step 4
Step 5
N Br + HBr
• CH,
+ Br2 
'R
NH Br2
Br
Scheme 3.3.4. Proposed mechanism for NBS bromination.
(3) Preparation of 3,5-diacetoxybenzyl-(triphenyl)phosphonium bromide (65):
The preparation of this phosphonium salt was an important step for the 
preparation of the Wittig reagent to proceed to the vinyl benzene. The reaction (215) 
was performed by refluxing 3-(acetyloxy)-5-(bromomethyl)phenyl acetate (63) with 
triphenylphosphine (64) (Scheme 3.3.5) to give the phosphonium bromide salt in a 
yield of 57%.
(63) (64) (65)
Scheme 3.3.5. Preparation of 3,5-diacetoxybenzyl-(triphenyl)phosphonium bromide 
(65).
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Unfortunately, all attempts to generate the Wittig reagent from the 
phosphonium salt, using strong base, e.g. NaH, was not successful, and that is why an 
alternative pathway was taken.
(4) Preparation of l,3-dimethoxy-5-vinylbenzene (68):
The synthesis of l,3-dimethoxy-5-vinylbenzene (68)(217) was performed using 
the simple Wittig reaction. Methyl triphenylphosphonium bromide (67) and /-BuOK 
were used to generate the Wittig reagent which was then reacted with 3,5- 
dimethoxybenzaldehyde (66) to form l,3-dimethoxy-5-vinylbenzene (68) (Scheme 
3.3.6) as a colourless oil in a yield of 70%.
CHO
H,c CH
(66)
+ Ph3PCH3Br
(67)
t-BuOK
H,C
(68)
Scheme 3.3.6. Preparation of l,3-dimethoxy-5-vinylbenzene (68).
The mechanism of the Wittig reaction (218) (Scheme 3.3.7) begins with the 
generation of the Wittig reagent. This is followed by cycloaddition of the Wittig 
reagents to the aldehyde to form a heterocycle called an oxaphosphetane. The 
oxaphosphetane then decomposes to give triphenylphosphine oxide and an alkene.
/0-t—C—kYv
Scheme 3.3.7. Mechanism of the Wittig reaction
Ph"
o
IIT
Ph
‘Ph FT
(2 1 8 )
(5) Preparation of methyl 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoate 
(70):
The synthesis of methyl 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoate 
(6 8 ) involves the coupling of l,3-dimethoxy-5-vinylbenzene (6 6 ) with 4-iodo- 
methylbenzyl ester (69) via palladium-catalysed Heck reaction (Scheme 3.3.8). The
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reaction was performed in a basic medium using Et3N at 80 °C for 24 h to give the 
desired compound in a yield of 8 6 %.
£H2
, c h 3
+
HjC.
(66) (69)
Pd(OAc)2/ ToP
NEty 80 C
Scheme 3.3.8. Preparation of methyl 4-[(E)-2-(3,5-dimethoxyphenyl)-1 - 
ethenyljbenzoate (70).
The mechanism of the Heck reaction (219) (Scheme 3.3.9) involves a catalytic 
cycle with a series of transformations around the palladium catalyst. The palladium 
compound required in this cycle is generally prepared in situ from palladium(II) 
acetate as a palladium(II) precursor which was reduced by tri(o-tolyl)phosphine to 
di(tri(o-tolyl)phosphine)palladium(0 ) and tri(o-tolyl)phosphine is oxidized to tri(o- 
tolyl)phosphine oxide in step I. Step II is an oxidative addition in which palladium 
inserts itself in the aryl iodide bond. In step III, palladium forms a n complex with the 
alkene and in step IV the alkene inserts itself in the palladium - carbon bond in a syn 
addition step. Step V is a p-hydride elimination step with the formation of a new 
palladium - alkene n complex. This complex is destroyed in step VI. The palladium(O) 
compound which is regenerated by reductive elimination of the palladium(II) 
compound by a base in the final step VII.
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AcO Pd OAc
OP(o-Tolyl)3 + 2 R3N.OAc
3 P(o-Tolyl)3 + 2 R3N
base
VII
I Pd H
H I/base P(o-Tolyl)3
Pd 0
P(o-Tolyl)3
I Pd
I Pd
R '
R
I Pd
R'
I Pd P(o-Tolyl)3
Scheme 3.3.9. Mechanism of the Heck reaction
(6) Preparation of 4-[(£)-2-(3,5-unsubstituted/dimethoxyphenyl)-l- 
ethenyl] benzoic acid
a) Preparation of 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoic acid (71):
The synthesis of 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoic acid (71) 
(Scheme 3.3.10a) from methyl 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoate
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(70) was a simple alkaline hydrolysis of the ester using 2M NaOH in EtOH as a 
solvent to give the desired free acid in 100% yield.
.ch3
c h 3 ?h3 OH
2M NaOH
(70) (71)
Scheme 3.3.10a. Preparation of 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoic 
acid (71).
b) Preparation of 4-[(£)-2-Phenyl-l-ethenyl]benzoic acid (74):
The same method used for the preparation of 4-[(F)-2-(3,5-dimethoxyphenyl)-
1-ethenyl]benzoic acid (71) was tried for the preparation of 4-[(£)-2-phenyl-1 - 
ethenyl]benzoic acid (74), but unfortunately the yield was not good (28%).
Another method has been used for the preparation of 4-[(£)-2-phenyl-l- 
ethenyl]benzoic acid (74) (Scheme 3.3.10b), which has been mentioned in the 
literature (220) using 4-bromobenzoic acid (73) and styrene (72) to give 4-[(E)-2- 
phenyl-1-ethenyl]benzoic acid (74) in a yield of 85%.
OH
Pd(OAc)2/ ToP I ; ►
NEty 125 C
(74)
OHCH2
+
Br
(73)
Scheme 3.3.10b. Preparation of 4-[(£)-2-phenyl-l-ethenyl]benzoic acid (74).
3.3.I.2. Synthesis of 4-[(£)-2-(3,5-unsubstituted/dimethoxyphenyl)-l-ethenyl] 
benzamide derivatives (75)/(76)/(81):
The synthesis of 7V-(2-hydroxy-2-phenylethyl)-4-[(is)-2-(3,5- 
dimethoxy/unsubstitutedphenyl)-l-ethenyl] benzamide (75)/(76) and N-[2-(4-
fluorophenyl)-2-hydroxyethyl]-4-[(£)-2-(3,5-dimethoxy/unsubstitutedphenyl)-1 -eth- 
enyl]benzamide (81) was carried out using the reagent l,l'-carbonyldiimidazole with 
the corresponding 4-unsubstituted/fluoro-2-amino-l-phenylethanol (Scheme 3.3.11).
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l,r-Carbonyldiimidazole was used as a coupling reagent in the synthesis of the amide 
compound (75, 76 and 81). The products were isolated as pure white solids in 
different yields as shown in Table 3.3.1.
•OH
rt, overnight
Scheme 3.3.11. Synthesis of 4-[(fT)-2-(3,5-dimethoxy/unsubstitutedphenyl)-l- 
ethenyl]benzamide derivatives(75)/(76)/(81).
Table 3.3.1.
Compd.
No.
R Ri Yield (%)
(75) H o c h 3 94
(76) H H 87
(81) F o c h 3 73
3.3.I.3. Synthesis of 2-{4-[(£)-2-(3,5-unsubstituted/dimethoxyphenyl)-l- 
ethenyI]phenyl}-5-phenyl-4,5-dihydro-l,3-oxazole derivatives (82)/(83)/(84):
This synthesis involved formation of an oxazole ring structure in which the 
oxazole compounds (82-84) were prepared by the reaction of the amide-containing 
compounds (75, 76 and 81) with methanesulphonic anhydride and a base (Et3N ) (221' 
222) (Scheme 3.3.12). The yield of the oxazole compounds was very good for all of the 
compounds as shown in Table 3.3.2.
(82-64 )
NEtj,0‘c,2 4 h
Scheme 3.3.12. Synthesis of 2-{4-[(£)-2-(3,5-dimethoxy/unsubstitutedphenyl)-l- 
ethenyl]phenyl}-5-phenyl-4,5-dihydro-1,3-oxazole derivatives (82)/(83)/(84).
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Table 3.3.2.
Compd.
No.
R Ri Yield (%)
(82) H o c h 3 100
(83) H H 97
(84) F o c h 3 98
The mechanism of this reaction involved nucleophilic attack by the hydroxyl 
group at the sulphur atom of methanesulphonic anhydride to form the intermediate 
(a). The activation of the carboxyl-oxygen as a nucleophile occurs as a result of the 
abstraction of the amido proton by the base; Et3N (222) (Scheme 3.3.13).
Hr*'  - 8— 0
<•)
Scheme 3.3.13. Mechanism of formation of the oxazole ring.
3.3.I.4. Synthesis of A/-[2-(l//-l-imidazolyl)-2-phenylethyl]-4-[(£)-2-(3,5- 
dimethoxy/unsubstitutedphenyl)-l-ethenyl]benzamide derivatives (85)/(86)/(87):
In this last step, heating of the oxazole compounds (82-84) in the presence of 
imidazole opened the oxazole ring by nucleophilic displacement(223) (Scheme 3.3.14).
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125 *C, 24 h
Nucleophilic 
displacement 
and 
ring opening
(85-87)(82-84)
Scheme 3.3.14. Synthesis of the final compounds (85-87).
A reasonable yield of compounds (85)/(86) was produced 68%/47% 
respectively, while the flouro derivative (87) was not produced in a very good yield 
35% (Table 3.3.3). All compounds were recrystallised from aqueous EtOH.
Table 3.3.2.
Compd.
No.
R Ri Yield (%)
(85) H OCH3 68
(86) H H 47
(87) F OCH3 35
(2) Tetralones CYP24A1 inhibitors:
This series was designed based on previous work in our group on the 2- 
substituted-3,4-dihydro-2//-naphthalen-1 -one derivatives (tetralones) (224). The most 
potent tetralones in the previous series were the 2-methyl and 2-phenyl substituted 
benzyl tetralones (Figure 3.3.2) with IC50 values of 0.9 and 2.1 pM respectively in a 
rat mitochondrial C YP24 assay.
c h 3
H3CO ‘
Figure 3.3.2. The structure of the lead compounds.
The target compounds (Figure 3.3.3) were planned to develop the lead 
compounds to explore the effect of varying the 2-substituents on IC50. Also, a slight
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preference for a 6-methoxy rather than a 6-hydroxy substituent in the naphthalene ring 
was noted; therefore the 6-methoxy has been included.
benzyl tetralonesbenzylidene te tra lones
Figure 3.3.3. The target compounds.
The drawing of the benzylidene tetralones in the £-form at the double bond at 
the position of attachment between the tetralone and benzyl ring depends on previous 
x-ray crystallography of compound (96) that has been made and published before by 
our group(96).
3.3.2. Synthesis of the  (E)-2-(2-substitutedbenzylidene)-6- 
m ethoxytetralone derivatives (90)/(93) and their reduced 2-(benzyl)- 
te tra iones (91 )/(94):
This synthesis involved direct condensation of commercially available 6- 
methoxytetralone (tetralone) (88) with the appropriate benzaldehyde (89 and 92) in 
ethanolic KOH solution (Scheme 3.3.15)(225).
The reduced 2-(benzyl)-tetralones (91)/(94) were readily obtained by 
hydrogenation of 2-benzylidenetetralone derivatives (90)/(93) with 10% Pd/C catalyst 
for 1 h, at approximately 30 psi (Parr hydrogenator) (Scheme 3.3.15),
RO
HjCO'
(90) R = CFj 
(93) R = CH2CHj
(88 )
(89)/(92)
Scheme 3.3.15. Synthesis of the (£)-2-(2-substitutedbenzylidene)-6-methoxytetralone 
derivatives (90)/(93) and their reduced 2-(benzyl)-tetralones (91)/(94): (i) 4 % 
ethanolic KOH, rt, 1 h; (ii) Pd-C/ H2, MeOH, 1 h.
The mechanism of the formation of 2-benzylidenetetralone derivatives (90)/ 
(93) is illustrated in Scheme 3.3.16. In this base-catalysed condensation between two 
carbonyl compounds, the hydroxide ion (from KOH) abstracts a proton from the a- 
carbon of the tetralone to form the carbanion (226). The carbanion attacks the
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electrophilic carbonyl carbon atom of the benzaldehyde to gives the unstable 
alkoxide, which abstracts a hydrogen ion from water to form intermediary aldol. The 
elimination of water from the aldol forms a carbon-carbon double bond which is 
conjugated to the aromatic ring, giving stability to the molecule (227).
c l «
Alkoxide
2-benzylidene tetralone
Scheme 3.3.16. Mechanism of the formation of the 2-benzylidene tetralones.
3.3.3. Synthesis of 6-methoxy-2-(1-{2-[(E)-2-phenyl-1-
ethenyl]phenyl}methylidene)-1,2,3,4-tetra hydro-1 -naphthalenone (98) 
and its reduced  com pound (99):
The 6-methoxy-2-( 1 - {2-[(£)-2-phenyl-1 -ethenyl]phenyl} methylidene)-1,2,3,4- 
tetrahydro-1-naphthalenone (98) were prepared by Suzuki coupling of the 2-bromo- 
benzylidene tetralone (224) (96) with ZraH.s-2-phenylvinylboronic acid (97) (Scheme
3.3.17).
The 2-bromo-benzylidene tetralone (96) was prepared according to the same 
general procedure mentioned before for the synthesis 2-benzylidenetetralone 
derivatives (90)/(93) using 2-bromobenzaldehyde (95) and 6-methoxytetralone 
(tetralone) (88) in ethanolic KOH solution. This reaction was followed by Suzuki 
coupling of 2-bromo-benzylidene tetralone (224) (96) with rr<ms-2-phenylvinylboronic 
acid (97) in the presence of Pd(PPh3)4  catalyst(228) (Scheme 3.3.17).
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4% KOH/EtOH
y  rt2h H3C ^ / V
H2/Pd
(W )
Scheme 3.3.17. Synthesis of compounds (98) and (99).
Reduction of (98) by hydrogenation with 10% Pd/C catalyst for 1 h, at 
approximately 30 psi (Parr hydro genator), gave the reduced compound (99) (Scheme
3.3.17).
3.3.4. Synthesis of 6-methoxy-2-[2-[(E)-3,5-unsubstituted/dimethoxy-2- 
phenyl-1 -ethenyl]benzyl]-1,2,3,4-tetrahydro-1 -naphthalenone (105)/(106):
• General chem istry:
The synthesis of 6-methoxy-2-[2-[(£)-2-unsubstituted/substituted phenyl-1- 
ethenyl]benzyl]-1,2,3,-4-tetrahydro-l -naphthalenone was carried out according to a 
sequence of 4 steps (Scheme 3.3.18):
1) The preparation ethyl 6-methoxy-1-oxo-1,2,3,4-tetrahydro-2-naphthalene- 
carboxylate.
2) The preparation of ethyl 2-(2-bromobenzyl)-6-methoxy-1-oxo-1,2,3,4- 
tetrahydro-2-naphthalenecarboxylate.
3) The decarboxylation of ethyl 2-(2-bromobenzyl)-6-methoxy-1-oxo-1,2,3,4- 
tetrahydro-2-naphthalenecarboxylate.
4) Suzuki coupling of the decarboxylated compound with boronic acid 
compound.
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HjC.HjC. HjC.
(88) ( 100)
Br'
(102 )
(iv)
HjC.
HjC.
(105)/(106)
(105) R = H (106) R = OCH3.
Scheme 3.3.18. Scheme for synthesis of 6-Methoxy-2-[2-[(£)-3,5- 
unsubstituted/dimethoxy-2-phenyl-1 -ethenyl] benzyl] -1,2,3,4-tetrahydro-1 -naphthalen­
one (105)/(106): (i) NaH, diethyl carbonate; (ii) NaH, 2-bromobenzyl bromide; (iii) 
48% HBr, 96% AcOH; (iv) (95) Pd(PPh3)4 , /ra«s-2-phenylvinylboronic acid, Na2C03, 
(96) ToP, Pd(OAC)2, Et3N, 80 °C.
(1) Preparation of ethyl 6-methoxy-l-oxo-l,2,3?4-tetrahydro-2-naphthalene 
carboxylate (100):
6-Methoxy-1 -oxo-1,2,3,4-tetrahydro-2-naphthalenecarboxylate (100) was
synthesised (Scheme 3.3.19) through the reaction between 6-methoxy-1-tetralone (88) 
and diethyl carbonate in the presence of NaH as a strong base to abstract the acidic 
proton from the tetralone ring. The desired compound was produced in a yield of 
70%.
(88)
ch3
NaH  ►
(EtO)2CO H3C.
(100)
Scheme 3.3.19. Preparation of ethyl 6-methoxy-1-oxo-1,2,3,4-tetrahydro-2- 
naphthalene carboxylate (100).
(2) Preparation of ethyl 2-(2-bromobenzyl)-6-methoxy-l-oxo-l,2,3i4-tetrahydro- 
2-naphthalenecarboxylate (102):
Once again NaH was used to abstract acidic proton at the 2-position of the 
tetralone, and hence this position was attacked by 2-bromobenzyl bromide (101) to
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form ethyl 2-(2-bromobenzyl)-6-methoxy- 1-oxo-1,2,3,4-tetrahydro-2-
naphthalenecarboxylate (102) (Scheme 3.3.20) in a yield of 69%.
Br
(100 ) (101 ) (10 2 )
Scheme 3.3.20. Preparation of ethyl 2-(2-bromobenzyl)-6-methoxy- 1-oxo-1,2,3,4- 
tetrahydro-2 -naphthalenecarboxylate (1 0 2 ).
(3) Preparation of 2-(2-bromobenzyI)-6-methoxy-l,2,3,4-tetrahydro-l- 
naphthalenone (103):
This synthesis involved a decarboxylation of 2-(2-bromobenzyl)-6-methoxy-l- 
oxo-l,2,3,4-tetrahydro-2-naphthalenecarboxylate (102) using 48% HBr and 96% 
AcOH. Unfortunately, while these conditions decarboxylate compound (102); they 
also demethylated the methoxy group (Scheme 3.3.21). The two compounds were 
separated using flash chromatography, and they were produced in a ratio of 1.45:1 of
2-(2-bromobenzyl)-6-hydroxy-1,2,3,4-tetrahydro-l-naphthalenone (104) to 2-(2- 
bromobenzyl)-6 -methoxy-l,2,3,4-tetrahydro-l-naphthalenone (103) respectively.
HBr
AcOH HjC'
(103)
,CHj
HjC.
(102)
HO-
(104)
Scheme 3.3.21. Synthesis of 2-(2-bromobenzyl)-6-methoxy-l,2,3,4-tetrahydro-l- 
naphthalenone (103) and 2-(2-bromobenzyl)-6-hydroxy-l,2,3,4-tetrahydro-l- 
naphthalenone (104).
The 2-(2-bromobenzyl)-6-hydroxy-1,2,3,4-tetrahydro-1 -naphthalenone (104) 
was remethylated using Mel in the presence of IC2CO3 (Scheme 3.3.22).
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Br
Mel
^  h3c .
HO'
(103)(104)
Scheme 3.3.22. Methylation of 2-(2-bromobenzyl)-6-hydroxy-l,2,3,4-tetrahydro-l- 
naphthalenone (104).
(4a) Preparation of 6-methoxy-2-[2-[(£)-2-phenyl-l-ethenyl]benzyl]-l,2,3,4- 
tetrahydro-1 -naphthalenone (105):
This synthesis was performed by Suzuki reaction using trans-2- 
phenylvinylboronic acid (7 (Scheme 3.3.23). The cross-coupling of boronic acid with 
aryl bromide was reported (228) in the presence of palladium catalysts and base. After 
the reaction was complete, 30% H2O2 , as an oxidizing agent, was added to remove the 
residual boronic acid.
4"’
H,C
r
HO
(103) (97)
5"'!
2" '6". I
1 " '
H3C.
(105)
Scheme 3.3.23. Preparation of 6-methoxy-2-[2-[(is)-2-phenyl-l-ethenyl]benzyl]- 
1,2,3,4-tetrahydro-1 -naphthalenone (105).
(4b) Preparation of 2-{2-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzyl}-6- 
methoxy -1,2,3,4-tetrahydro-l-naphthalenone (106):
The synthesis of 2-{2-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzyl}-6- 
methoxy -1,2,3,4-tetrahydro-l-naphthalenone (106) involves the coupling of 1,3- 
dimethoxy-5-vinylbenzene (68) with 2-(2-bromobenzyl)-6-methoxy-l,2,3,4- 
tetrahydro-1-naphthalenone (103) via palladium-catalysed Heck reaction (Scheme 
3.3.24). The reaction was performed in a basic medium using EtsN and at 80 °C for 
72 h to give the desired compound in a yield of 64%.
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TOP, Pd(OAC)j
Scheme 3.3.24. Preparation of 2-{2-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzyl}- 
6-methoxy -1,2,3,4-tetrahydro-l-naphthalenone (106).
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3.4.CYP26A1  
B io lo g ic a l  
r e s u l t s
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3.4.1. Cell Based Assay:
Initially, the CYP26A1 cell based assay was done in our labs using methods 
previously developed by our group.
The IC50 of final compounds was measured using HPLC linked to a p-RAM 
detector and Laura software. Two major peaks can be observed on the HPLC. The 
first peak (retention time 1.5-2.5 min) corresponds to the metabolites of ATRA (4- 
oxo-ATRA, 4-hydroxy-ATRA and other polar metabolites), which are metabolised by 
the action of CYP26A1 on ATRA and the second peak (retention time 5-6.5 min) 
corresponds to ATRA itself.
Consequently, disappearance of the first peak would be observed if an 
inhibitor was added to the medium. The separated metabolites were quantitatively 
calculated from the area under the curves and the percentage inhibition was calculated 
from: 100[(%metabolites (control) -  %metabolites (inhibitors) / %(metabolites 
control)]. The results of the assay are summarised in Table 3.4.1.
Table 3.4.1.: IC50 of the tested compounds:
Structure IC50 ClogP NAME
ON 0
CH3 CH3
N
H
30 nM 4.92
Lead
compd.*
ON 0
c h 3 c h 3
H
>20 pM 4.46
MCC
186*
Cl c h .
H
>10 pM 3.35 14
O
H
>10 pM 3.35 15
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Structure IC 50 ClogP NAME
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c c u x -
H
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"-Aj  y _ 8 — — ch,
C O . X J ' -
H
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4.55
—  —
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our group
From these results, and by comparing the IC50 of the lead compound and 
compounds (14), (15), (19) and (20); it seems that the dimethyl substitution at the cx- 
carbon is much more preferable than the mono-methyl substitution as can be seen 
from the huge decrease in inhibitory activity by about 30 fold. As the free acid seems
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not to be the active form of our compounds, it may be the presence of the dimethyl 
group has a steric effect that restrains the attack of the esterase enzyme. Of course, 
this steric effect decreases with the introduction of the mono-methyl group resulting 
in more rapid removal of the esters to give the free acid, this may explain the loss in 
inhibitory activity. Also from the IC50 of the compounds (14), (15), (19) and (20), it 
appears that the difference in the diastereoisomerism does not affect the inhibitory 
activity.
The presence of the imidazole is essential for the inhibitory activity, removal 
of the imidazole as in compound (28) or replacement with the 1,3,4-oxadiazole ring, 
such as compounds (52, 56 and 60) or introducing of a link between the imidazole and 
the (3-carbon such as compound (24), dramatically decreases the activity. Introduction 
of a link between the imidazole and the p-carbon may make the compound too big to 
enter the active site cavity of the enzyme. As for the replacement of the imidazole 
with the 1,3,4-oxadiazole part, although these compounds dock very well in the 
CYP26A1 homology model, the decrease in the flexibility of the molecules could 
explain the decrease in the activity. The non-conformity between the biological results 
and the modelling suggest a limitation of the CYP26A1 model.
3.4.2. Biochemical Assay:
The CYP26A1 biochemical assay of the most promising compounds (14, 15, 
19 and 20) versus CYP26A1 was performed by Dr Caroline Bridgens, Northern 
Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom. 
Microsomes were prepared by differential centrifugation of MCF-7 homogenised 
cells. The results of the assay are presented in table 3.4.2.
Table 3.4.2.: IC50 of the tested compounds:
ClogP NAMEStructure
Lead
compd.
4.922.8 nM-CH,
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Structure IC50 ClogP NAME
H
26 nM 3.35 14
H
50 nM 3.35 15
0
O X C r x * ~
H
100 nM 4.52 19
O
= ft
H
120 nM 4.52 20
Liarozole 6 pM 3.24 -
R115866 4 nM 5.78 -
These results showed that compounds 14, 15, 19 and 20 are good CYP26A1 
inhibitors being about 70-100 times more active than the well-known CYP26A1 
inhibitor liarazole (IC5o= 6 pM). However, they were still less active than R115866. 
Also, these compounds are much less active than our lead compound which showed 
an IC50 of 2.8 nM. The non-conformity of the cell based assay and the biochemical 
assay, in which the phenyl and the naphthyl derivatives were more active, could be 
explained in terms of the easier uptake of compounds (19 and 20) by the cells than 
compounds (14 and 15) due to the higher lipophilicity. Although those results were 
surprising, they were favourable, as there was not a huge difference between the lead 
compound with the dimethyl groups and the mono-methyl phenyl derivatives (14 and 
15) in terms of the CYP26A1 inhibitory activity. These results were favourable, 
because compounds (14 and 15) are more preferred in terms of synthesis and yield.
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3.5.1. V79-CYP24 Assay:
The inhibitory activity of the novel compounds versus CYP24A1 was 
performed by Anna Robotham and Bart Makowski in the labs of Professor Glen 
Jones, Queen's University Kingston, Ontario, Canada. The results of the assay are 
presented in table 3.5.1.
Table 3.5.1.
Structure
CYP24A1
IC50
CYP27A1
IC50
NAME
" X
f  T  T  w
h„ n— 'J
0.3 pM - 86
O CHa
K J
480.1 pM -
MCC
173*
O CHj
126.9 pM -
MCC
174*
111.1 pM -
MCC
179*
127.6 pM -
MCC
180*
0  c f 3
11.22 pM - 90
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Structure
CYP24A1
ICso
CYP27A1
ICso
NAME
0 cf3
2.08 pM - 91
^ ch3
kJ 10.76 pM - 93
xh3
1.92 pM 8.32 pM 94
5.08 pM 5.96 pM 98
25.57 - 99
O Br
H‘cN , ^ O d j X l k
16.3 pM 0.059 pM 103
5.08 pM - 105
Ketoconazole 0.52 pM. - -
previously synthesised within our group (224).
The results showed that the inclusion of a double bond at the position of
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attachment between the tetralone and benzyl ring appeared to reduce the inhibitory 
effect of the inhibitors. For example, (94) (IC50 = 1.92 pM) was more potent than its 
double bond counterpart, (93) (IC50 =10.76 pM). The double bond will conjugate with 
the adjacent phenyl group resulting in decreased conformational flexibility of the 
structure. This loss of flexibility could inhibit the entrance of the inhibitor through the 
access channel of CYP24A1 (Figure 3.5.1), thus decreasing its access to the enzyme 
cavity where it would exert its inhibitory effect. Alternatively, the loss of 
conformational flexibility could prevent a favourable conformation that stabilises the 
inhibitor inside the enzyme cavity.
M CC 1
Figure 3.5.1. Docking of compound (94), MCC178 with CYP24A1 homology model
(129)
The strong inhibitory capacity of (91) could reflect a trend observed in 
inhibitor design; the addition of fluorine groups increases the inhibitory capacity of a 
compound. It has been suggested that this increase is not caused by a stronger 
enzyme-inhibitor complex, but by increasing the cell-membrane penetrating capacity 
and thus increasing the bio-availability. However, many of the compounds appear to 
be hydrophobic and should have little problem penetrating cell membranes. As such, 
the fluorination may have a stabilising effect on the inhibitor inside the enzyme 
resulting in more effective inhibition.
As for the azoles, from the results, it seems that the azoles would be much
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more active than the tetralone derivative with compound (8 6 ) displaying greater 
inhibitory activity than the standard ketoconazole. This activity may also be attributed 
to the resemblance between the structure of these azoles and calcitriol. At the time of 
submitting this thesis the CYP24/CYP27 data for compounds (85, 87 and 96) were 
not available.
CYP2 7A 1 Assays
A potent and specific inhibitor of CYP24A1 would display a low IC50 value 
towards CYP24A1 and a high IC50 value towards related cytochrome P450s. 
CYP27A1 is a good enzyme to test for specificity because of its structural similarity 
to CYP24A1, as well as the structural similarity of their respective substrates ( la -  
OH-D3 and la,25-(OH)2D3). Upon comparison of IC50 values between CYP24A1 and 
CYP27A1 (Table 3.5.1), it is clear that none of the most potent tetralone inhibitors of 
CYP24A1 is particularly specific, i.e. they have similar IC50 values for CYP27A1. 
The differences in IC50 should be on a similar scale to VID-400, which was reported 
to have an IC50 of 0.015 pM for CYP24A1, while having an IC50 of 0.616pM for 
CYP27B1 (115). Surprisingly, the 2-bromo-substituted benzyl tetralone (103) displayed 
a much greater potency towards CYP27A1 than CYP24A1 (276-fold selectivity).
3.5.2. VitD3 CLL Study:
Recent gene expression profiling experiments of B-cell chronic lymphocytic 
leukemia (B-CLL) cells have identified that the VDR is highly expressed in B-CLL 
compared with normal B and T lymphocytes (229). It was therefore of interest to 
evaluate our compounds in these cells.
The activity of the novel compounds versus these cells was performed by Dr 
Chris Pepper, University of Wales College of Medicine, Cardiff, United Kingdom. 
The results of the assay are presented in table 3.5.2.
Table 3.5.2.
Structure NAME
CH.
37 nM
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Structure LDso NAME
U &
66 nM 86
x  r r
iY y ^ J  on—
H,C/0
34 nM 87
^0X )in6
19 pM 96
The results showed that the azole compounds had very good antiproliferative 
activity against B-CLL. Introduction of the dimethoxy groups did not greatly affect 
the activity, with only a fold increase in the activity which was the same case for the 
introduction of the fluorine group, as both compounds with or without the fluorine 
group (85 and 87) showed comparable activity. Also, from the results, the tetralones 
seem to be much less active than the azoles, which suggest the low antiproliferative 
activity of these tetralones, this may reflect the difference in CYP24 inhibitory 
activity.
4. Experim en t a l
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■ General considerations:
All reactions were carried out under an atmosphere of nitrogen when 
necessary. All reagents and solvents employed were of general purpose or analytical 
grade and purchased from Sigma-Aldrich Chemical Company, Fluka and Acros 
Chemicals. Solvents were appropriately dried over molecular sieves (3A).
!H and 13C-NMR spectra were recorded on a Bruker Avance DP500 spectrometer 
at 500 MHz and 125 MHz respectively. The NMR solvent was CDCI3 for all cases 
unless mentioned otherwise. Each resonance signal was reported according to the 
following convention:
5) chemical shifts are given in parts per million (ppm) relative to the internal 
standard tetramethyl silane (Me4 Si).
6 ) coupling constants [J in hertz (Hz)].
7) multiplicity are denoted as s (singlet), d (doublet), t (triplet), m (multiplet) or 
combinations thereof.
Mass spectra were determined under El (Electron Impact) or Cl (Chemical 
Ionisation) conditions at the EPSRC National Mass Spectrometry Service Centre, 
University of Wales, Swansea. Accurate mass measurement was also performed at the 
EPSRC National Mass Spectrometry Service Centre. Microanalysis data were 
performed by Medac Ltd., Brunei Science Centre, Surrey.
For column chromatography, a glass column was slurry packed in the appropriate 
eluent with silica gel (Fluka Kieselgel 60). Flash column chromatography was 
performed with the aid of a pump. Analytical thin layer chromatography (TLC) was 
carried out on pre-coated silica plates (Merck Kieselgel 60 F254) with visualisation via 
UV light (254 nm), ninhydrin and/or vanillin stains.
Melting points were determined using a Gallenkamp melting point apparatus and 
are uncorrected.
All NMR characterisations were made by comparison with previous NMR spectra 
of the appropriate structure class and/or predictions from ACD/HNMR and 
ACD/CNMR (Advanced Chemistry Development Inc., Version 2.51, 1997) and 
ChemDraw Ultra™ 7.0 (CambridgeSoft).
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4.1.1. Methyl 3-hydroxy-3-(4-nitrophenyl)propanoate (3 )(178). 
(Mol. Formula: CioHnN 0 5, M. W.: 225.2)
(1)
i
= <
CH,
I 3
O—Si—t-But
I
CH,
o  CH3 
(2)
OH
Pyridine-A/-oxide
LiCI
o 2n 3’
(3)
To a stirred solution of pyridine-W-oxide (50 mg, 0.53 mmol) and LiCI (50 
mg, 1.2 mmol) in A(A^-dimethylformamide (DMF) (3 mL) were added 4- 
nitrobenzaldehyde (1) (1 g, 6.6 mmol) and l-(r-butyldimethylsilyloxy)-l-
methoxyethene (2) (7 mL, 33 mmol) at room temperature under nitrogen atmosphere 
and left for 24 h. The product was isolated by direct flash column chromatography of 
the crude reaction mixture (petroleum ether -  EtOAc 50:50 v/v) to give methyl 3- 
hydroxy-3-(4-nitrophenyl)propanoate (3) as a colourless oily product. Yield: 0.5 g 
(34%), t.l.c. system: petroleum ether -  EtOAc 1:1 v/v, RF: 0.55, vanillin stain positive.
‘H-NMR (CDCh). 8: 2.64 (d, 2H, J = 6.5 Hz, CH2), 3.60 (s, 3H, CH3), 3.93 (d, 
1H, J = 2.6 Hz, OH), 5.13-5.16 (m, 1H, CH), 7.46 (d, 2H, J = 8.6 Hz, H-2', H-6'), 8.05 
(d, 2H, J = 8.8 Hz, H-3', H-5').
13C NMR CCDClil. S: 42.94 (CH2, C-2), 52.30 (CH3, C-l"), 69.51 (CH, C-3), 
123.93 (CH, C-3', C-5'), 126.88 (CH, C-2', C-6'), 147.26 (C, C-l'), 150.14 (C, C-4'), 
172.10 (C, C-l).
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4.1.2. Ethyl 3-Hydroxy-3-(4-nitrophenyl)propanoate (5) (230) and butyl 3- 
hydroxy-3-(4-nitrophenyl)propanoate (6).
(Compound (5): Mol. Formula: Ci,Hi3N 0 5, M. W.: 239.2)
(Compound (6 ): Mol. Formula: C13H17NO5 , M. W.: 267.2)
N
(1 )
c h 3 c o o c 2 h 5
(4)
Diisopropylamine 
n-Butyllithium _ . ^  J2'
2 3-
(5)
To a cooled (-78 °C) solution of diisopropylamine (2.8 mL, 20 mmol) in THF 
(25 mL) was added w-butyllithium (18.2 mL, 30 mmol) dropwise over a period of 5 
min under nitrogen atmosphere. After the addition of «-butyllithium, the reaction 
mixture was stirred at -78 °C for 30 min.
EtOAc (4) (1.8 g, 20 mmol) in THF (10 mL) was added and stirring continued 
at -78 °C for 10 min. Then a solution of 4-nitrobenzaldehyde (1) (3.02 g, 20 mmol) in 
THF (10 mL) was added dropwise over a period of 10 min and the reaction stirred at 
room temperature overnight. The reaction was quenched with 10% aqueous HC1 (20 
mL) and the product was extracted with Et2 0  (2 x 50 mL). The organic layer was 
washed with H2O (2 x 50 mL), dried (MgSC>4) and concentrated under reduced 
pressure. The product was purified by column chromatography (petroleum ether -  
EtOAc 100:0 increasing to 70:30 v/v) to give ethyl 3-hydroxy-3-(4- 
nitrophenyl)propanoate (5) as a colourless oily product. Yield: 1.5 g (31%), t.l.c. 
system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.48, vanillin stain positive. Butyl 3- 
hydroxy-3-(4-nitrophenyl)propanoate (6 ) was obtained as a side product as a yellow 
oily product, Yield: 1.6 g (30%), Rf: 0.77, vanillin stain positive.
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• Ethyl 3-hydroxy-3-(4-nitrophenyl)propanoate (5):
'H-NMR CCDCU). S: 1.14 ( t ,  3H, J = 7.2 Hz, CH3), 2.65 (d, 2H, J = 6.5 Hz, O- 
CH2-CH3), 4.04-4.08 (m, 3H, OH + CO-CHj), 5.13-5.18 (m, 1H, CH), 7.48 (d, 2H, J 
= 8.7 Hz, H-2', H-6 '), 8.05 (d, 2H, J = 8 . 8  Hz, H-3', H-5’).
13C NMR (CDChl. 5: 14.01 (CH3, C-2 "), 43.48 (CH2, C-2), 61.33 (CH2, C-l"),
69.33 (CH, C-3), 123.84 (CH, C-3', C-5’), 126.34 (CH, C-2', C-6 '), 147.19 (C, C-l'), 
150.29 (C, C-4'), 171.42 (C, C-l).
• Butyl 3-hydroxy-3-(4-nitrophenyl)propanoate (6 ):
HRMS TED: Calculated mass: 267.1101 [M+H]+, Measured mass: 267.1098 
[M+H]+.
1 H-NMR (CDChl 5: 8.85 (t, J = 6.9 Hz, 3H, CH3), 1.24-1.31 (m, 2H, CUg- 
CH3), 1.51-1.56 (m, 2H, CH2- CH2- CH2), 2.69 (d, 2H, J = 1 .8  Hz, CH- CH2), 3.98 (d, 
1H, J = 3.4 Hz, OH), 4.05 (t, 2H, J = 6 .8 , O-CH2), 5.17-5.21 (m, 1H, CH-OH), 7.51 
(dt, 2H, J = 2.0 Hz, 8.7 Hz, H-2’, H-6 ’), 8.11 (dt, 2H, J = 2.3 Hz, 8 . 8  Hz, H-3', H-5’).
13C NMR (CDChL 5: 13.54 (CH3, C-4”), 18.98 (CH2, C-3”), 30.44 (CH2, C- 
2”), 43.09 (CH2, C -l”), 65.26 (CH2, C-2), 69.54 (CH, C-3), 123.85 (CH, C-3', C-5'),
126.55 (CH, C-2', C-6 '), 147.27 (C, C-l'), 150.14 (C, C-4'), 171.82 (C, C-l).
4.1.3. Methyl 3-hydroxy-2-methylene-3-(4-nitrophenyl) propanoate (8 )(189). 
(Mol. Formula: CnHnNOs, M. W.: 237.1)
OH O
O 5'
H 4. u  U / ' l j  aqueous Jj ^ | ( R ,  S) | j  *
trimethylamine ^
° 2 N ‘ 4 T  H a Hb
(1 ) (7 ) (8 )
To a stirred solution of 4-nitrobenzylaldehyde (1) (3.02 g, 20 mmol) and 
aqueous trimethylamine (5 mL, 25 mmol) in THF (20 mL) was added 
methylacrylate (7) (5.4 mL, 60 mmol) and the resulting clear mixture was stirred 
at room temperature for 24 h. Then CHC13 (40 mL) and H20  (25 mL) were added
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and the mixture was stirred for another 2 min. The organic phase was separated 
and the H2O phase was extracted with chloroform (2 x 30 mL). The combined 
organic layers were dried (MgSCL) and concentrated under reduced pressure. The 
crude product was purified by column chromatography (petroleum ether -  EtOAc 
100:0 increasing to 70:30 v/v) to afford the pure adduct, methyl 3-hydroxy-2- 
methylene-3-(4-nitrophenyl)propanoate (8 ) as a pale yellow solid. Yield: 4.7 g 
(98%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.77, vanillin stain 
positive.
Melting point: 71-73 °C (lit. m.p. 72-73 °C )(189).
1 H-NMR (CDCLL 5: 3.34 (s, 1H, OH), 3.68 (s, 3H, CH3), 5.56 (s, 1H, CH), 
5.81 (s, 1H, Ha), 6.32 (s, 1H, Hb), 7.50 (d, 2H, J = 8.5 Hz, H-2', H-6 '), 8.12 (d, 2H, J =
8 . 8  Hz, H-3', H-5').
13C NMR fCDCM. 5: 51.49 (CH3, C-l"), 74.18 (CH, C-3), 121.10 (CH, C- 
3',C-5'), 122.93 (CH2, C-4), 127.94 (CH, C-2', C-6 '), 140.28 (C, C-2), 147.35 (C, C- 
4'), 149.78 (C, C-l'), 171.25 (C, C-l).
4.1.4. Methyl 3-(4-aminophenyl)-3-hydroxy-2-methylpropanoate (9) and 
methyl 3-(4-aminophenyl)-2-methylpropanoate (10)(182).
(Compound (9): Mol. Formula: CnHisN03, M. W.: 209.2)
(Compound (10): Mol. Formula: C11H15NO2, M. W.: 193.3)
OH OH OH
CH CH(R, S) Pd-C/H
CH CH.
(9)-anti (9)-syn
CH
H2N
3'
(10)
To a suspension of 5% Pd-C (10 mol %) in EtOAc (5 mL) was added, under
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nitrogen, a solution of methyl 3-hydroxy-2-methylene-3-(4-nitrophenyl) propanoate 
(8 ) (2.4 g, 10 mmol) in EtOAc (30 mL). Then, the reaction atmosphere was changed 
to hydrogen and the reaction mixture stirred at room temperature. After a period of 1 
h, the suspension was filtered over a pad of celite and the solvent removed under 
reduced pressure. The product was purified by column chromatography (petroleum 
ether -  EtOAc 100:0 increasing to 70:30 v/v) to give a mixture of the (9 )-anti and (9)- 
syn diastereoisomers of methyl 3-(4-aminophenyl)-3-hydroxy-2-methylpropanoate (in 
a ratio of 8.5:5 respectively) as a brown solid. Yield: 1.0 g (48%), t.l.c. system: 
petroleum ether -  EtOAc 3:1 v/v, Rp: 0.23, ninhydrin stain positive and the 
hydrogenolysis product methyl 3-(4-aminophenyl)-2-methylpropanoate (10) as a 
colourless oily product. Yield: 0.8 g (43%), Rf: 0.76, ninhydrin stain positive.
• Methyl 3-(4-aminophenyl)-3-hydroxy-2-methylpropanoate (9)
Melting point: 116-118 °C (lit. m.p. 116-118 °C )(182).
Microanalvsis: Calculated for C11H 15NO3 (209.2), Theoretical: %C= 63.14, 
%H= 7.23, %N= 6.69, Found: %C= 63.45, %H= 7.33, %N= 6.31.
0.90 (d, 3H, J = 7.2 Hz, anti-CH-CH3), 1.09 (d, 3H, J =
7.1 Hz, syw-CH-CHs), 2.65-2.73 (m, 2H, anti and syn CH-CH3), 3.57 (s, 3H, syn-O- 
CH3), 3.66 (s, 3H, anti-0-CU3), 4.57 (d, 1H, J = 8.9 Hz, a^-CH-OH), 4.87 (d, 1H, J 
= 4.9 Hz, syn-CH-OK), 6.57-6.60 (m, 4H, anti and syn H-2', H-6 '), 7.04-7.06 (m, 4H, 
anti and syn H-3', H-5').
13C NMR (CDC10. 5: 11.31 (CH3, syn-C-4), 14.50 (CH3, anti-C-4), 46.69 
(CH, syn-C-2), 47.20 (CH, anti-C-2), 51.75 (CH3, syn-C-1"), 51.86 (CH3, anti-C-1"), 
73.85 (CH, syn-C-3), 76.32 (CH, anti-C-3), 114.91 (CH, syn-C-3', syn-C-5'), 115.05 
(CH, anti-C-3', anti-C-5'), 127.10 (CH, syn-C-2', syn-C-6 '), 127.82 (CH, anti-C-2', 
anti-C-6% 131.54 (C, syn-C-l'), 131.60 (C, anti-C-1’), 145.81 (C, syn-C-4'), 146.32 
(C, anti-C-4'), 176.12 (C, syn-C-1), 176.45 (C, anti-C-1).
• Methyl 3-(4-aminophenyl)-2-methylpropanoate (10)
'H-NMR CCDCIi). 5: 1.05 (s, CH3, 3H, 0-CH3), 2.45-2.49 (m, 1H, Ha), 2.56- 
2.60 (m, 1H, CH-CH3), 2.80-2.84 (m, 1H, Hb), 3.41-3.50 (bs, 2H, NH2), 3.55 (s, 3H, 
O-CH3), 6.52 (d, 2H, J = 8.4 Hz, H-2', H-6 '), 6.85 (d, 2H, J = 8.4 Hz, H-3', H-5').
I3C NMR ICDChl. S: 16.62 (CH3, C-4), 38.98 (CH2, C-3), 41.70 (CH, C-2),
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51.48 (CH3, C-l"), 115.17 (CH, C-3', C-5'), 129.27 (C, C-l'), 129.77 (CH, C-2', C-6 '), 
144.74 (C, C-4’), 176.76 (C, C-l).
4.1.5. Methyl 3-[4-(phenylamino)phenyl]-3-hydroxy-2-methyl propanoate 
(12 and 13).
(Mol. Formula: Ci7H 19N0 3 , M. W.: 285.3)
OH
O 5’
Pyridine CH
N
H3'
(12 )
HO
+
CH.
NH.'23'
(1 1 )
OH
O 5'
CH
N
H3'
(13)
To phenylboronic acid (11) (0.854 g, 7 mmol), methyl 3-(4-aminophenyl)-3- 
hydroxy-2-methylpropanoate (9) (1 g, 3.5 mmol), anhydrous cupric acetate (1.176 g, 
7 mmol), pyridine (0.553 g, 7 mmol) and 250 mg activated 4A molecular sieves under 
an atmosphere of air was added anhydrous CH2CI2 (20 mL) and the reaction stirred 
under air atmosphere at ambient temperature for 3 days. The product was isolated by 
flash column chromatography (petroleum ether -  EtOAc 100:0 v/v increasing to 70:30 
v/v) to give methyl 3-[4-(phenylamino)phenyl]-3-hydroxy-2-methylpropanoate in two 
forms: anti form as a brown solid (1 2 ) and the syn form as a colourles oily product 
(13) in a ratio of 2:1 respectively. Yield: 0.66 g (0.44 g anti (44%) and 0.22 g syn 
(22%)), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: anti = 0.55 and syn = 0.62, 
vanillin stain positive.
• anti-form:
Melting point for the anti form: 98-101 °C.
Microanalysis for the anti form: Calculated for C17H 19NO3 . O.IH2O (287.1),
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Theoretical: % 0  71.11, %H= 6.74, %N= 4.88, Found: %C= 71.19, %H= 6.75, %N= 
4.67.
‘H-NMR (CDC1V). S: 0.90 (d, 3H, J = 7.2 Hz, CH-CH^), 2.62-2.71 (m, 1H, 
CH-CH3), 2.95 (bs, 1H, OH), 3.58 (s, 3H, 0-CH3), 4.57 (d, 1H, J = 8 . 8  Hz, CH-OH), 
5.77 (s, 1H, NH), 6.77-6.82 (m, 1H, H-aromatic), 6.88-6.96 (m, 4H, H-aromatic), 
7.05-7.16 (m, 2H, H-aromatic), 7.18-7.20 (m, 2H, H-aromatic).
13C NMR (CDC10. 6 : 14.50 (CH3, C-4), 47.26 (CH, C-2 ), 51.95 (CH3, C-l'"),
76.21 (CH, C-3), 117.16, 118.29, 121.19, 127.60, 129.59 (CH, aromatic), 133.79 (C, 
C-l'), 142.95 (C, C-4'), 143.21 (C, C-l"), 176.49 (C, C-l).
• 5y«-form:
HRMS (El) for the syn form: Calculated mass: 308.1257 [M+Na]+, Measured 
mass: 308.1260 [M+Na]+.
'H-NMR (DMSO-dA 5: 1.07 (d, 3H, J = 6.9 Hz, CH-CHj), 2.34-2.70 (m, 1H, 
CH-CH3), 3.51 (s, 3H, 0-CH3), 4.74 (d, 1H, J = 5.5 Hz, CH-OH), 5.33 (d, 1H, J = 4.9 
Hz, OH), 6.79-6.81 (m, 1H, H-aromatic), 7.00-7.05 (m, 4H, H-aromatic), 7.14-7.17 
(m, 2H, H-aromatic), 7.20-7.23 (m, 2H, H-aromatic), 8.08 (s, 1H, NH).
13C NMR (PMSO-dA 6 : 11.87 (CH3, C-4), 47.23 (CH, C-2), 51.14 (CH3, C- 
1"'), 73.15 (CH, C-3), 116.41, 119.37, 126.89, 127.89, 129.10 (CH, aromatic), 135.06 
(C, C-l'), 142.14 (C, C-4’), 143.61 (C, C-l"), 174.18 (C, C-l).
4.1.6. Methyl antf-3-(1tf-1-imidazolyl)-3-[4-(phenylamino)phenyl]-2- 
methylpropanoate (14).
(Mol. Formula: C2oH2 iN30 2 , M. W.: 335.4)
OH
CH
ImidazoleCH
CH1,1'-Carbonyldiimidazole 3'
(12) (14)
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To a solution of methyl anti-3 - [4-(phenylamino)phenyl]-3 -hydroxy-2 - 
methylpropanoate (12) (0.42 g, 1.47 mmol) in anhydrous CH3CN (20 mL) was added 
imidazole (0.294 g, 4.41 mmol) and l,r-carbonyldiimidazole (0.356 g, 2.20 mmol). 
The mixture was then heated at 65 °C for lh  and stirred afterwards for 24 h at room 
temperature. The reaction mixture was allowed to cool and then extracted with 
CH2CI2 (3 x 50 mL) and H2O (3 x 100 mL). The organic layer was dried (MgSCU) and 
reduced in vacuo. The product was then purified by flash column chromatography 
(CH2CI2 -  MeOH 99:1 v/v increasing to 97:3 v/v) to give methyl anti-3-(\H -\- 
imidazolyl)-3-[4-(phenylamino)phenyl]-2-methylpropanoate (14) as a brown solid. 
Yield: 0.32 g (65 %), t.l.c. system: CH2CI2 -  MeOH 90:10 v/v, Rp: 0.4, vanillin stain 
positive.
Melting point: 118-122 °C.
Microanalvsis: Calculated for C20H21N3O2 . O.2 H2O (339.01), Theoretical: 
%C= 70.86%, %H= 6.36%, %N= 12.39%, Found: %C= 70.72, %H= 6.24, %N= 
12.31.
1 H-NMR (CDCU). S: 1.11 (d, 3H, J = 6.9 Hz, CH-CH3), 3.33-3.39 (m, 1H, 
CH-CH3), 3.52 (s, 3H, O C H 3), 5.18 (s, 1H, CH-imidazole), 7.79 (s, 1H, NH), 6.87- 
6.95 (m, 1H, H-aromatic), 6.97-7.01 (m, 4H, H-aromatic), 7.04-7.07 (m, 2H, H- 
aromatic), 7.20-7.24 (m, 2H, H-aromatic), 7.20-7.24 (m, 2H, H-aromatic), 7.57 (s, 1H, 
H-aromatic).
13C NMR rCDCIA 5: 15.98 (CH3, C-4), 44.95 (CH, C-2), 52.07 (CH3, C-l'"),
63.98 (CH, C-3), 116.78, 118.91, 121.89, 128.49, 129.54 (CH, aromatic), 128.22 (C, 
C-l'), 142.51 (C, C-4'), 144.28 (C, C-l"), 174.54 (C, C-l).
4.1.7. Methyl sy/?-3-(1 H-1 -imidazolyl)-3-[4-(phenylamino)phenyl]-2-
methylpropanoate (15).
(Mol. Formula: C20H21N3O2 , M. W.: 335.4)
OH
Imidazole
CH CH1,1'-Carbonyldiimidazole 3'
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To a solution of methyl s>y2-3 -[4 -(phenylamino)phenyl]-3 -hydroxy-2 - 
methylpropanoate (13) (0.21 g, 0.735 mmol) in anhydrous CH3CN (20 mL) was 
added imidazole (0.294 g, 2.20 mmol) and l,l'-carbonyldiimidazole (0.356 g, 1.10 
mmol). The mixture was then heated at 65 °C for lh  and stirred afterwards for 24 h at 
room temperature. The reaction mixture was allowed to cool and then extracted with 
CH2CI2 (3 x 50 mL) and H2O (3 x 100 mL). The organic layer was dried over MgSC>4 , 
filtered and reduced in vacuo. The product was then purified by flash column 
chromatography (CH2CI2 -  MeOH 99:1 v/v increasing to 97:3 v/v) to give methyl 
sy«-3-(lZ7-l-imidazolyl)-3-[4-(phenylamino)phenyl]-2-methylpropanoate (15) as a 
colourless oily product. Yield: 0.14 g (57 %), t.l.c. system: CH2CI2 -  MeOH 90:10 
v/v, Rp: 0.52, vanillin stain positive.
HRMS (ED: Calculated mass: 336.1707 [M+H]+, Measured mass : 336.1709 
[M+Hf.
1 H-NMR (CDCLL 5: 1.15 (d, 3H, J = 2.8 Hz, CH-CH3), 3.33-3.43 (m, 1H, 
CH-CH3), 3.59 (s, 3H, OCH3), 5.22 (d, 1H, J = 11.3 Hz, CH-imidazole), 6.25 (s, 1H, 
NH), 6.96-6.99 (m, 1H, H-aromatic), 7.01-7.05 (m, 4H, H-aromatic), 7.07-7.11 (m, 
2H, H-aromatic), 7.15-7.20 (m, 2H, H-aromatic), 7.25-7.33 (m, 2H, H-aromatic), 7.61 
(s, 1H, H-aromatic).
13C NMR (CDCU). 5: 16.02 (CH3, C-4), 44.99 (CH, C-2), 52.11 (CH3, C-l'"),
63.98 (CH, C-3), 116.90, 119.39, 122.18, 128.55, 129.92 (CH, aromatic), 124.76 (C, 
C-l'), 142.28 (C, C-4'), 144.15 (C, C -l”), 174.52 (C, C-l).
4.1.8. Methyl 3-[4-(2-naphthylamino)phenyl]-3-hydroxy-2-methyl 
propanoate (17 and 18).
(Mol. Formula: C21H21NO3, M. W.: 335.4)
h3c .
HO.
CH3
OHNH2
(9) (16)
O
(17)
H,C
(18)
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To naphthylboronic acid (16) (1.8 g, 10.5 mmol), methyl 3-(4-aminophenyl)-
3-hydroxy-2-methylpropanoate (9) (1 g, 3.5 mmol), anhydrous cupric acetate (1.176 
g, 7 mmol), pyridine (0.553 g, 7 mmol) and 250 mg activated 4A molecular sieves 
under an atmosphere of air was added anhydrous CH2 CI2 (20 mL) and the reaction 
stirred under air atmosphere at ambient temperature for 3 days. The product was 
isolated by direct flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 70:30 v/v) to give methyl 3-[4-(2-naphthylamino)phenyl]-3-hydroxy-2- 
methylpropanoate in two forms: anti form as a brown solid (17) and the syn form (18) 
as a colourless oily product in a ratio of 2:1 respectively. Yield: 0.60 g (0.4 g anti 
(40%) and 0.2 g syn (20%)), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: anti = 
0.74 and syn = 0.8, vanillin stain positive.
• anti-form:
Melting point for the anti form: 124-126 °C.
Microanalysis for the anti form: Calculated for C21H21NO3 . O.8 H2 O (349.80), 
Theoretical: %C= 72.10, %H= 6.51, %N= 4.00, Found: %C= 72.14, %H= 6.44, %N= 
3.64, N.b. this compound is very hygroscopic, and this microanalysis is the best one 
obtained after five days drying in the oven.
1 H-NMR fCDCLL 5: 0.97 (d, 3H, J = 7.2 Hz, CH-CH3), 2.73-2.79 (m, 2H, 
CH-CH3 , OH), 3.68 (s, 3H, O-CH3), 4.65 (d, 1H, J = 8 . 8  Hz, CH-OH), 5.83 (s, 1H, 
NH), 7.05-7.08 (m, 2H, H-aromatic), 7.15 (dd, 1H, J = 2.3 Hz, 8.7 Hz, H-aromatic), 
7.18-7.25 (m, 3H, H-aromatic), 7.32-7.37 (m, 2H, H-aromatic), 7.58 (d, 1H, J = 8.3 
Hz, H-aromatic), 7.66-7.68 (m, 2H, H-aromatic).
13C NMR (CDCh\ 5: 14.56 (CH3, C-4), 47.14 (CH, C-2), 51.94 (CH3, C-l"'),
76.21 (CH, C-3), 112.08, 117.90, 120.15, 123.66, 126.52, 127.66, 127.89, 129.24 
(CH, aromatic), 129.33 (C, C-5"), 134.24 (C, C-l'), 134.59 (C, C-10"), 140.54 (C, C- 
4'), 142.98 (C, C-2"), 176.37 (C, C-l).
• sytt-form:
HRMS (EI) for the svn form: Calculated mass: 336.1594 [M+FI]+, Measured 
mass: 336.1597 [M+H]+.
'H-NMR (CDCK1. 8 : 1.11 (d, 3H, J = 7.2 Hz, CH-CHj), 2.69-2.75 (m, 1H,
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CH-CH3), 2.78 (d, 1H, J = 3.3 Hz, OH), 3.59 (s, 3H, 0-CH3), 4.74 (d, 1H, J = 3.8 Hz, 
CH-OH), 5.80 (s, 1H, NH), 7.02-7.05 (m, 2H, H-aromatic), 7.11 (dd, 1H, J = 2,3 Hz,
8 . 8  Hz, H-aromatic), 7.16-7.23 (m, 3H, H-aromatic), 7.29-7.32 (m, 2H, H- aromatic),
7.55 (d, 1H, J = 8.2 Hz, H-aromatic), 7.60-7.71 (m, 2H, H-aromatic).
13C NMR (CDCL). 5: 10.15 (CH3, C-4), 45.52 (CH, C-2), 50.83 (CH3, C-l"'), 
72.64 (CH, C-3), 110.67, 116.90, 119.01, 122.51, 125.45, 126.14, 126.62, 128.16 
(CH, aromatic), 128.20 (C, C-5”), 133.32 (C, C-l'), 133.59 (C, C-10”), 139.74 (C, C- 
4’), 141.35 (C, C-2”), 175.14 (C, C-l).
4.1.9. Methyl anti- 3-(1 H-1 -imidazolyl)-3-[4-(2-naphthylamino)phenyl]-2- 
methylpropanoate (19).
(Mol. Formula: C24H23N3O2 , M. W.: 385.47)
ImidazoleCH. CH.1,1'-Carbonyldiimidazole 8"
(17) (19)
To a solution of methyl a«f/-3-[4-(2-naphthylamino)phenyl]-3-hydroxy-2- 
methylpropanoate (17) (0.4 g, 1.19 mmol) in anhydrous CH3CN (20 mL) was added 
imidazole (0.238 g, 3.57 mmol) and l,l'-carbonyldiimidazole (0.29 g, 1.79 mmol). 
The mixture was then heated at 65 °C for lh and stirred afterwards for 24 h at room 
temperature. The reaction mixture was allowed to cool and then extracted with 
CH2CI2 (3 x 50 mL) and H2O (3 x 100 mL). The organic layer was dried (MgS0 4 ) and 
reduced in vacuo. The product was then purified by flash column chromatography 
(CH2CI2 -  MeOH 99:1 v/v increasing to 97:3 v/v) to give methyl anti-3-(\H-l- 
imidazolyl)-3-[4-(2-naphthylamino)phenyl]-2-methylpropanoate (19) as a brown 
solid. Yield: 0.28 g (61%), t.l.c. system: CH2CI2 -  MeOH 90:10 v/v, RF: 0.62, vanillin 
stain positive.
Melting point: 131-133 °C.
HRMS TEI): Calculated mass: 386.1863 [M+H]+, Measured mass: 386.1858 
[M+H]+..
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'H-NMR CCDC10. 8 : 1.09 (d, 3H, J = 7.0 Hz, CH-CHj), 3.29-3.37 (m, 1 H, 
CH-CH3), 3.52 (s, 3H, 0-CH3), 5.16 (s, 1H, CH-imidazole), 5.96 (s, 1H, NH), 6.95-
7.04 (m, 2H, H-aromatic), 7.12-7.18 (m, 2H, H-aromatic), 7.24-7.27 (m, 3H, H- 
aromatic), 7.32-7.36 (m, 1H, H-aromatic), 7.38-7.39 (m, 2H, H-aromatic), 7.53 (s, 1H, 
H-aromatic), 7.59 (d, 1H, J = 8.2 Hz, H-aromatic), 7.67-7.69 (m, 2H, H-aromatic).
13C NMR (CDCh). 5: 16.04 (CH3, C-4), 44.99 (CH, C-2), 52.23 (CH3, C -l’”),
64.00 (CH, C-3), 113.16, 117.52, 120.47, 123.96, 126.61, 127.68, 128.66, 129.32 
(CH, aromatic), 129.16 (C, C-5"), 129.60 (C, C-l'), 134.50 (C, C-10"), 139.81.54 (C, 
C-4'), 143.84 (C, C-2"), 174.47 (C, C-l).
4.1.10. Methyl syn-3-(1 H-1 -imidazolyl)-3-[4-(2-naphthylamino)phenyl]-2- 
methylpropanoate (20).
(Mol. Formula: C24H23N3O2 , M. W.: 385.47)
Imidazole
10" 7; 2" N 4'9" 1" H 3‘
1,1 '-Carbonyldiim idazole 8"
(18) (20)
To a solution of methyl syn-3 -[4-(2-naphthylamino)phenyl]-3-hydroxy-2- 
methylpropanoate (18) (0.2 g, 0.595 mmol) in anhydrous CH3CN (20 mL) was added 
imidazole (0.119 g, 1.785 mmol) and l,l'-carbonyldiimidazole (0.144 g, 0.893 mmol). 
The mixture was then heated at 65 °C for lh  and stirred afterwards for 24 h at room 
temperature. The reaction mixture was allowed to cool and then extracted with 
CH2CI2 (3 x 50 mL) and H2O (3 x 100 mL). The organic layer was dried (MgSCU) 
reduced in vacuo. The product was then purified by flash column chromatography 
(CH2CI2 -  MeOH 99:1 v/v increasing to 97:3 v/v) to give methyl syn-3-(lH-l- 
imidazolyl)-3-[4-(2-naphthylamino)phenyl]-2-methylpropanoate (20) as a yellow oily 
product. Yield: 0.13 g (57%), tl.c. system: CH2C12 -  MeOH 90:10 v/v, RF: 0.66, 
vanillin stain positive.
HRMS (EI): Calculated mass: 386.1863 [M+H]+, Measured mass: 386.1862 
[M+H]+.
'H-NMR (CDCh). 6 : 1.08 (d, 3H, J = 7.0 Hz, CH-CHj), 3.29-3.37 (m, 1H,
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CH-CH3), 3.52 (s, 3H, O-CH3), 4.47 (d, 1H, J = 11.3 Hz, CH-imidazole), 5.90 (s, 1H, 
NH), 6.94-7.05 (m, 2H, H-aromatic), 7.13-7.19 (m, 2H, H-aromatic), 7.24-7.27 (m, 
3H, H-aromatic), 7.33-7.36 (m, 1H, H-aromatic), 7.39-7.41 (m, 2H, H-aromatic), 7.52 
(s, 1H, H-aromatic), 7.60 (d, 1H, J = 8.2 Hz, H-aromatic), 7.67-7.70 (m, 2H, H- 
aromatic).
13C NMR (CDCh\ 5: 16.05 (CH3, C-4), 44.99 (CH, C-2), 52.24 (CH3, C-l"'),
63.99 (CH, C-3), 113.19, 117.52, 120.47, 123.98, 126.61, 127.68, 128.66, 129.32 
(CH, aromatic), 129.16 (C, C-5"), 129.60 (C, C -l’), 134.50 (C, C-10"), 139.81.54 (C, 
C-4’), 143.84 (C, C-2"), 174.47 (C, C-l).
4.1.11. Methyl 3-hydroxy-2,2-dimethyl-3-(2-naphthyl) propanoate (37)(231). 
(Mol. Formula: Ci6Hi80 3, M. W.: 258.32)
O  Si— CH3
(21) (22)
OH
10'S'l
LiCI 7'
6' 4'
To a stirred solution of pyridine-A^-oxide (61 mg, 0.64 mmol) and LiCI (54 
mg, 1.28 mmol) in DMF (15 mL) was added naphthalene-2-carboxaldehyde (21) (1 g,
6.4 mmol) and methyl trimethylsilyldimethyl ketene acetal (22) (5.2 mL, 25.6 mmol) 
at room temperature under nitrogen atmosphere and left for 48 h. The product was 
isolated by direct flash column chromatography of the crude reaction mixture 
(petroleum ether -  EtOAc 70:30 v/v) to give methyl 3-hydroxy-2,2-dimethyl-3-(2- 
naphthyl)propanoate (23) as a colourless oily product. Yield: 1.21 g (73%), t.l.c. 
system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.47, vanillin stain positive.
‘H-NMR (CDCU). 5: 1.20 (s, 3H, C-CHj), 1.22 (s, 3H, C-CHj), 3.24 (d, 1H, J 
= 4.0 Hz, OH), 3.77 (s, 3H, O-CHj), 5.10 (d, 1H, J = 4.0 Hz, CH-OH), 7.48 (m, 3H, 
H-aromatic), 7.8 (s, 1H, H-aromatic), 7.85 (m, 3H, H-aromatic).
13C NMR (CDCh). 8: 19.23 (CH3, C-4), 23.16 (CH3, C-5), 47.98 (C, C-2),
52.14 (CH3, C-l"), 78.85, 125.68, 125.96, 126.07, 126.72, 127.32, 127.60, 128.06 
(CH, aromatic), 132.87 (C, C-5'), 133.06 (C, C-10'), 137.55 (C, C-2’), 178.23 (C, C-
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4.1.12. 3-Methoxy-2,2-dimethyl-1 -(2-naphthyl)-3-oxopropyl-1 H-1 -
imidazolecarboxylate (38).
(Mol. Formula: C20H20N2O4 , M. W.: 252.39)
3'
OH
. c h 310’
8’
Imidazole
-------------------------------------------------- ►  7 -1,1'-Carbonytdiimidazole '
6' 4'
(23)
To a solution of methyl 3 -hydroxy-2 ,2-dimethyl-3-(2-naphthyl)propanoate 
(23) (0.904 g, 3.5 mmol) in anhydrous CH3CN (20 mL) was added imidazole (0.714 
g, 10.5 mmol) and l,l'-carbonyldiimidazole (0.851 g, 5.25 mmol). The mixture was 
then heated at 65 °C for lh  and stirred afterwards for 24 h at room temperature. The 
reaction mixture was allowed to cool and then extracted with CH2CI2 (3 x 50 mL) and 
H2O (3 x 100 mL). The organic layer was dried over MgSC>4 , filtered and reduced in 
vacuo. The product was then purified by flash column chromatography (CH2CI2 -  
MeOH 99:1 v/v increasing to 97:3 v/v) to give 3-methoxy-2,2-dimethyl-l-(2- 
naphthyl)-3-oxopropyl-lH-\-imidazolecarboxylate (24) as a yellow oily product. 
Yield: 0.39 g (44 %), t.l.c. system: CH2CI2 -  MeOH 90:10 v/v, Rp: 0 .1 2 , vanillin stain 
negative.
HRMS (ED: Calculated mass: 353.14 [M+H]+, Measured mass: 353.30 
[M+H]+.
‘H-NMR (CDCIO. 6 : 1.13 (s, 3H, C-CHj), 1.29 (s, 3H, C-CH3), 3.60 (s, 3H, 
O-CHj), 6.28 (s, 1H, CH), 7.00 (s, 1H, H-aromatic), 7.32 (m, 2H, H-aromatic), 7.36 
(s, 1H, H-aromatic), 7.40 (m, 2H, H-aromatic), 7.70 (s, 1H, H-aromatic), 7.72 (m, 3H, 
H-4', H-aromatic), 8.10 (s, 1H, H-aromatic).
13C NMR (CDCM. 5: 19.90 (CH3, C-4), 22.63 (CH3, C-5), 47.50 (C, C-2), 
52.41 (CH3, C-l"), 83.87, 117.13, 124.73, 126.72, 126.94, 127.23, 127.72, 128.0, 
128.15, 128.47, 130.90 (CH, aromatic), 132.45 (C, C-10'), 132.73 (C, C-5'), 133.02 
(C, C-2'), 147.53 (C, C-l"), 175.34 (C, C-l).
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OH
.CH
Pyridine-N-oxide
LiCI
4'
4.1.13. Methyl 3-hydroxy-2,2-dimethyl-3-(2-pyridyl)propanoate (26)(202).
(Mol. Formula: CnH 15N 0 3, M. W.: 209.24) 
o  c h 3
N J i  H sC O  Si— CH3
I
c h 3
-c h 3 ^
(26)
2-Pyridinecarboxaldehyde (25) (0.48 mL, 5 mmol) was added to a suspension 
of methyl trimethylsilyldimethyl ketene acetal (22) (2 mL, 10 mmol) in H2O (20 mL). 
The suspension was stirred for 24 h at room temperature. The reaction mixture was 
extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with 
brine (50 mL), dried over anhydrous MgS0 4 , and the solvent evaporated in vacuo to 
give methyl 3-hydroxy-2,2-dimethyl-3-(2-pyridyl)propanoate (26) as a colourless oil. 
Yield: 0.89 g (85%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.44, vanillin 
stain positive.
'H-NMR (CDChl. S: 0.94 (s, 3H, C-CHj), 1.02 (s, 3H, C-CHj), 3.59 (s, 3H, 
O-CHj), 4.50 (s, 1H, OH), 4.81 (s, 1H, CH), 7.08 (m, 2H, H-aromatic), 7.51 (m, 1H, 
H-aromatic), 8.40 (d, 1H, J = 4.5 Hz, H-aromatic).
13C NMR (CPCIO. 8 : 20.84 (CH3, C-4), 20.91 (CH3, C-5), 48.47 (C, C-2),
51.89 (CH3, C-l"), 77.05 (CH, C-3), 122.12, 122.79, 136.16, 148.09 (CH, aromatic), 
158.43 (C, C-2'), 177.14 (C, C-l).
4.1.14. Methyl 3-hydroxy-2,2-dimethyl-3-(2-quinolyl) propanoate (28).
(Mol. Formula: C15H17NO3, M. W.: 259.30)
(27)
H-tCXc 
(22)
H3c  ° -
c h 3
-Si— CH3 
CH3
- c h 3
Pyridine-/V-oxide
3- H3C CH3
2-Quinolinecarboxaldehyde (27) (0.786 g, 5 mmol) was added to the 
suspension of methyl trimethylsilyldimethyl ketene acetal (22) (2 mL, 10 mmol) in a 
mixture of H2O / MeOH (3:1, 20 mL). The suspension was stirred for 24 h at room 
temperature. The reaction mixture was extracted with EtOAc (3X50 ml). The
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combined organic layers were washed with brine (50 mL), dried over anhydrous 
MgSCL, and the solvent evaporated in vacuo. Purification of crude product by flash 
chromatography (petroleum ether -  EtOAc 100:0 v/v increasing to 70:30 v/v) gave 
methyl 3-hydroxy-2,2-dimethyl-3-(2-quinolyl)propanoate (28) as a colourless oil. 
Yield: 0.80 g (62%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rf: 0.44, vanillin 
stain positive.
HRMS (El): Calculated mass: 260.1281 [M+H]+, Measured mass: 260.1283 
[M+H]+.
1 H-NMR (C D C 1 A  8 : 1.00 (s, 3H, C -C H 3 ), 1.12 (s, 3H, C -C H 3 ), 3.60 (s, 3H, 
O -C H a), 5.15 (s, 2H, CH, OH), 7.12 (d, 1H, J = 8.5 Hz, H-aromatic), 7.35 (t, 1H, J =
7.5 Hz, H-aromatic), 7.52 (t, 1H, J = 7.8 Hz, H-aromatic), 7.61 (d, 1H, J = 8.0 Hz, H- 
aromatic), 7.90 (m, 2H, H-aromatic).
13C NMR (CDC1A 6 : 19.50 (CH3, C-4), 20.29 (CH3, C-5), 47.51 (C, C-2), 
50.83 (CH3, C-l"), 76.21, 118.79, 125.48, 126.49, 127.83, 128.46, 135.44 (CH, 
aromatic), 126.54 (C, C-5'), 145.39 (C, C-10'), 157.98 (C, C-2'), 176.07 (C,C-1).
4.1.15. Methyl 3-hydroxy-2,2-dimethyl-3-(3-nitrophenyl) propanoate (30)
(178)_
(Mol. Formula: Ci2H l5N 0 5, M. W.: 253.25)
OH
O -------Si— CH3
Pyridine-TV-oxide
4'
0 2N
(29)
To a stirred solution of pyridine-A-oxide (61 mg, 0.64 mmol) and LiCI (54 
mg, 1.28 mmol) in DMF (15 mL) was added 3-nitrobenzaldehyde (29) (1 g, 6.62 
mmol) and methyl trimethylsilyldimethyl ketene acetal (22) (2.2 mL, 19.85 mmol) at 
room temperature under nitrogen atmosphere and left for 24 h. The product was 
isolated by direct flash column chromatography of the crude reaction mixture 
(petroleum ether -  EtOAc 70:30 v/v) to give methyl 3-hydroxy-2,2-dimethyl-3-(3- 
nitrophenyl) propanoate (30) as a colourless oily product. Yield: 1.65 g (98%), t.l.c. 
system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.44, vanillin stain positive.
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*H-NMR (CDCU). 5: 1.01 (s, 3H, C-CHj), 1.05 (s, 3H, C-CHa), 3.61 (s, 3H, 
O-CH3), 3.7 (s, 1H, OH), 4.92 (s, 1H, CH), 7.41 (t, 1H, J = 8.0 Hz, H-aromatic), 7.52 
(d, 1H, J = 8.0 Hz, H-aromatic), 8.01 (d, 1H, J = 8.5 Hz, H-aromatic), 8.05 (s, 1H, H- 
2’).
13C NMRfCDClO. 5: 19.30 (CH3, C-4), 22.19 (CH3, C-5), 47.78 (C, C-2),
52.21 (CH3, C-l"), 77.50 (CH, C-3), 122.40, 122.60, 128.64, 133.51 (CH, aromatic),
142.46 (C, C-l'), 147.79 (C, C-3'), 177.53 (C, C-l).
4.1.16. Methyl 3-(3-aminophenyl)-3-hydroxy-2,2-dimethyl propanoate 
(31).
(Mol. Formula: Ci2Hi7N 0 3, M. W.: 223.27)
OH O OH O
0 2N . ^  .  .C H 3 H,N.
H2/Pd
H3C c h 3 2. h 3c  c h 3
To a suspension of 5% Pd-C (10 mol %) in EtOH (5 mL) was added, under 
nitrogen, a solution of 3-hydroxy-2,2-dimethyl-3-(3-nitrophenyl) propanoate (30) 
(1.65 g, 6.52 mmol) in EtOH (20 mL). Then, the reaction atmosphere was changed to 
hydrogen and the reaction mixture stirred at room temperature. After a period of 3 h, 
the suspension was filtered over a pad of celite and the solvent removed under 
reduced pressure to give methyl 3-(3-aminophenyl)-3-hydroxy-2 ,2 -dimethyl 
propanoate (31) as a white solid. Yield: 1.5 g (99%), t.l.c. system: petroleum ether -  
EtOAc 3:1 v/v, RF: 0.20, vanillin stain positive.
Melting point: 173-176 °C.
Microanalvsis: Calculated for Ci2HnN 0 3 (223.27), Theoretical: %C= 64.55, 
%H= 7.67, %N= 6.27, Found: %C= 64.31, %H= 7.74, %N= 5.98.
‘H-NMR (CDC1V). 8 : 1.01 (s, 3H, C-CH3 ), 1.08 (s, 3H, C-CH3), 3.29 (s, 3H, 
OH, NHj), 3.62 (s, 3H, O-CHj), 4.72 (s, 1H, CH), 6.51 (d, 1H, J = 8.0 Hz, H- 
aromatic), 6.60 (m, 2H, H-aromatic), 7.01 (t, 1H, J = 7.5 Hz, H-aromatic).
13C NMR (CDCh). 5: 19.15 (CH3, C-4), 23.13 (CH3, C-5), 47.68 (C, C-2), 
52.06 (CH3, C-l"), 78.73 (CH, C-3), 114.46, 114.66, 118.28, 128.63 (CH, aromatic),
141.33 (C, C-l'), 145.80 (C, C-3'), 178.26 (C, C-l).
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4.1.17. Methyl 3-hydroxy-2,2-dimethyl-3-[3-(2-naphthylamino) 
phenyl]propanoate (32).
(Mol. Formula: C22H23NO3 , M. W.: 349.42)
OH OH O OH O
Cu acetate
pyridine
(16) (31) 6 4 (32)
To naphthylboronic acid (16) (3.47 g, 20.15 mmol), methyl 3-(3- 
aminophenyl)-3-hydroxy-2,2-dimethyl propanoate (31) (1.5 g, 6.72 mmol), anhydrous 
cupric acetate (2.44 g, 13.44 mmol), pyridine (1.09 mL, 13.44 mmol) and 250 mg 
activated 4A molecular sieves under an atmosphere of air was added anhydrous 
CH2CI2 (20 mL) and the reaction stirred under air atmosphere at ambient temperature 
for 3 days. The product was isolated by direct flash column chromatography 
(petroleum ether -  EtOAc 100:0 v/v increasing to 70:30 v/v) to give methyl 3- 
hydroxy-2,2-dimethyl-3-[3-(2-naphthylamino)phenyl]propanoate (32) as a colourless 
oily product. Yield: 1.3 g (57%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 
0.50, vanillin stain positive.
HRMS (ED: Calculated mass: 350.1751 [M+H]+, Measured mass: 350.1749 
[M+H]+.
‘H-NMR CCDC1A 8 : 1.09 (s, 3H, C-CHj), 1.11 (s, 3H, C-CHj), 3.00 (s, 1H, 
OH,), 3.62 (s, 3H, O-CHj), 4.78 (s, 1H, CH), 5.81 (s, 1H, NH), 6.82 (d, 1H, J = 8.0 
Hz, H-aromatic), 7.00 (d, 1H, J = 7.0 Hz, H-aromatic), 7.02 (s, 1H, H-aromatic), 7.11 
(d, 1H, J = 8 . 8  Hz, H-aromatic), 7.17 (m, 1H, H-aromatic), 7.21 (t, 1H, J = 6 . 8  Hz, H- 
aromatic), 7.32 (m, 2H, H-aromatic), 7.54 (d, 1H, J = 8.0 Hz, H-aromatic), 7.65 (d, 
2H, J = 8.5 Hz, H-aromatic).
13C NMR (CDCM. 5: 19.33 (CH3, C-4), 23.16 (CH3, C-5), 47.80 (C, C-2),
52.14 (CH3, C-l"), 78.73 (CH, C-3), 111.63 (CH, C-4'), 117.61 (CH, C-2, C- 
aromatic), 120.05, 120.83, 126.48, 126.50, 127.65, 128.82, 129.20 (CH, aromatic), 
123.54 (C, C-6 ), 129.23 (C, C-5’), 134.62 (C, C-10"), 140.82 (C, C-l'), 141.49 (C, C- 
2"), 142.57 (C, C-3'), 178.17 (C, C-l).
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4.1.18. Methyl 3-hydroxy-2-methylene-3-(2-naphthyl)propanoate (33)(203). 
(Mol. Formula: C 15H 14O3 , M. W.: 242.28)
+ H,C .CH 3 Pyridine-jY-oxide 
LiCI
(7)
OH 0
9'
n i l
/ K  /CH3 
1 °
6’ 5 V  H-
1
(33)
DABCO (0.275 g, 2.5 mmol) was added to a solution containing 2- 
naphthaldehyde (21) (1.3 g, 8.3 mmol) in methyl acrylate (7) (1.5 mL, 16.66 mmol) 
and the mixture was allowed to stir for 72 h at 25 °C. The reaction was then diluted in 
CH2CI2 (50 mL), washed with 5% aqueous HC1 (25 mL) and H2O (25 mL), dried with 
MgSCU, and concentrated under reduced pressure. The solid residue obtained was 
purified using flash column chromatography (CH2CI2 -  MeOH 99:1 v/v increasing to 
97:3 v/v) to give methyl 3-hydroxy-2-methylene-3-(2-naphthyl)propanoate (33) as a 
white solid. Yield: 1.6 g (79%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 
0.63, vanillin stain positive.
Melting noint: 97-99 °C (lit. m.p. 97-99 °C)(203).
'H-NMR I'CDChl. 5: 3.18 (d, 1H, J = 5.6 Hz, OH), 3.75 (s, 3H, O-CHj), 5.77 
(d, 1H, J = 5.6 Hz, CH-OH), 5.90-5.91 (m, 1H, Ha), 6.40-6.41 (m, 1H, Hb), 7.48-7.51 
(m, 3H, H-aromatic), 7.84-7.89 (m, 4H, H-aromatic).
13C NMR (CDCU\ 5: 51.99 (CH3, C-l"), 73.38 (CH, C-3), 124.59, 125.54,
126.06, 126.16, 127.66, 128.13, 128.20 (CH, aromatic), 126.35 (CH2, C-4), 133.06 
(C, C-5'), 133.27 (C, C-10'), 138.63 (C, C-2’), 141.93 (C, C-2), 166.81 (C, C-l).
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4.1.19. Methyl 3-(1H-1-imidazolyl)-2-methylene-3-(2-naphthyl) propanoate 
(34).
(Mol. Formula: C ig H ^ C ^ , M. W.: 292.34)
OH
•CH3 10’
Im idazole   >
l,l'-C a rb o n y ld iim id a zo le
(34)(33)
To a solution of methyl 3-hydroxy-2-methylene-3-(2-naphthyl)propanoate 
(33) (0.824 g, 3.4 mmol) in anhydrous CH3CN (30 mL) was added imidazole (0.68 g,
10.2 mmol) and l,l'-carbonyldiimidazole (0.822 g, 5.1 mmol). The mixture was then 
heated at 65 °C for lh  and stirred afterwards for 24 h at room temperature. The 
reaction mixture was allowed to cool and then extracted with CH2CI2 (3 x 50 mL) and 
H2O (3 x 100 mL). The organic layer was dried (MgSC>4) and reduced in vacuo. The 
product was then purified by flash column chromatography (CH2CI2 -  MeOH 99:1 
v/v increasing to 97:3 v/v) to give methyl 3-( 1 //-1 -imidazolyl)-2-methylene-3-(2- 
naphthyl) propanoate (34) as a white solid. Yield: 0.62 g (70%), t.l.c. system: CH2CI2 
-  MeOH 90:10 v/v, Rp: 0.43, vanillin stain positive.
Melting point: 99-101 °C.
Microanalvsis: Calculated for C18H16N2O2 (349.8), Theoretical: %C= 73.96, 
%H= 5.52, %N= 9.58, Found: %C= 73.59, %H= 5.46, %N= 9.71.
‘H-NMR (CDCM. 5: 3.77 (s, 1H, CHj), 4.97 (s, 2H, N-CH, Ha), 5.21 (s, 1H, 
Hb), 6.82-6.83 (m, 1H, H-aromatic), 6.94-6.99 (m, 1H, H-aromatic), 7.43-7.48 (m, 
3H, H-aromatic), 7.70 (s, 1H, H-aromatic), 7.74-7.82 (m, 3H, H-aromatic), 8.11 (s, 
1H, H-aromatic).
13C NMR (CDC1V). S: 43.10 (CH2, C-4), 52.54 (CH3, C-l"), 118.76, 125.66, 
127.01, 127.47, 127.67, 127.79, 128.44, 128.86, 129.49, 144.97 (CH, aromatic), 
127.19 (C, C-5'), 131.39 (C, C-10'), 133.04 (C, C-2'), 133.47 (C, C-2), 167.05 (C, C- 
1 ).
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4.1.20. Methyl 4-[(2-benzoxazolyl)amino]benzoate (37).
(Mol. Formula: C15H12N2O3, M. W.: 268.27)
.CH .CH
Phenol
(35) (36) (37)
A mixture of 2-chlorobenzoxazole (35) (1.2 mL, 10 mmol) and phenol ( 6  g) 
was heated at 100 °C under nitrogen. When 2-chlorobenzoxazole was dissolved in 
phenol, methyl 4-aminobenzoate (36) (1.5 g, 10 mmol) was introduced into the 
reaction mixture. The mixture was stirred at 80 °C for 4 h, cooled to room 
temperature and poured into H2O (25 mL). The precipitate was then filtered, washed 
well with H2O and recrystallised from EtOH to give methyl 4-[(2- 
benzoxazolyl)amino]benzoate (37) as white crystals. Yield: 2.4 g (90%), t.l.c. system: 
petroleum ether -  EtOAc 3:1 v/v, Rp: 0.58, vanillin stain positive.
Melting point: 214-216 °C.
Microanalvsis: Calculated for C15H 12N2O3 (268.27), Theoretical: %C= 67.16, 
%H= 4.51, %N= 10.44, Found: %C= 67.32, %H= 4.50, %N= 10.28.
‘H-NMR (DMSO-dA S: 3.84 (s, 3H, CHj), 7.17-7.20 (t, 1H, J = 7.8 Hz, H- 
aromatic), 7.25-7.28 (t, 1H, J = 7.6 Hz, H-aromatic), 7.52-7.54 (m, 2H, H-aromatic),
7.89 (d, 2H, J = 8 . 8  Hz, H-aromatic), 7.99 (d, 2H, J = 8.7 Hz, H-aromatic), 11.07 (s, 
1H, NH).
13C NMR (DMSO-dA 5: 51.71 (CH3, C-l"’), 109.16, 116.90, 117.00, 122.21,
124.16, 130.53 (CH, aromatic), 122.76 (C, C-l'), 141.97 (C, C-4"), 143.07 (C, C-4’),
146.96 (C, C-9"), 157.25 (C, C-2"), 165.85 (C, C-l).
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4.1.21.4-[(2-Benzoxazolyl)amino]acetophenone (39).
(Mol. Formula: C15H12N2O2 , M. W.: 252.28)
CH
Phenol
Cl H2N
(35) (38) (39)
A mixture of 2-chlorobenzoxazole (24) (1.2 mL, 10 mmol) and phenol ( 6  g) 
was heated at 100 °C under nitrogen. When the 2-chlorobenzoxazole was dissolved in 
phenol, 4-aminoacetophenone (27) (1.35 g, 10 mmol) was introduced into the reaction 
mixture. The mixture was stirred at 80 °C for 4 h, cooled to room temperature and 
poured into H2O. The precipitate was then filtered, washed with H2O and 
recrystallised from EtOH to give 4-[(2-benzoxazolyl)amino]acetophenone (28) as 
yellow crystals. Yield: 1.4 g (56%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, 
R f : 0.38, vanillin stain positive.
Melting point: 205-207 °C.
Microanalvsis: Calculated for C15H 12N2O2 (252.28), Theoretical: %C= 71.42, 
%H= 4.79, %N= 11.10, Found: %C= 71.35, %H= 4.82, %N= 10.94.
‘H-NMR (DMSO-dA 6 : 2.54 (s, 3H, CHj), 7.17-7.20 (dt, 1H, J = 1.2 Hz, 7.8 
Hz, H-aromatic), 7.25-7.28 (dt, 1H, J = 1.1 Hz, 7.7 Hz, H-aromatic), 7.52-7.54 (m, 
2H, H-aromatic), 7.89 (d, 2H, J = 8 . 8  Hz, H-aromatic), 8.00 (d, 2H, J = 8.7 Hz, H- 
aromatic), 11.07 (s, 1H,NH).
13C NMR fDMSO-dA 8 : 26.32 (CH3, C-2), 109.16, 116.77, 117.01, 122.21,
124.17, 129.75 (CH, aromatic), 130.69 (C, C-l'), 141.98 (C, C-4"), 143.01 (C, C-4’),
146.97 (C, C-9"), 157.27 (C, C-2"), 196.24 (C, C-l).
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4.1.22. M-(1,3-Benzoxazol-2-yl)-A/-[4-(phenoxymethyl)phenyl]amine (41).
(Mol. Formula: C20H16N2O2, M. W.: 316.36)
3
Phenol
(41)
OH
(40)(35)
A mixture of 2-chlorobenzoxazole (24) (1.2 mL, 10 mmol) and phenol ( 6  g) 
was heated at 100 °C under nitrogen. When the 2-chlorobenzoxazole was dissolved in 
phenol, 4-aminobenzylalcohol (29) (1.23 g, 10 mmol) was introduced into the 
reaction mixture. The mixture was stirred at 80 °C for 4 h, cooled to room 
temperature and poured into H2O. The precipitate was then filtered, washed with H2O 
and the product was isolated by flash column chromatography (petroleum ether -  
EtOAc 100:0 v/v increasing to 70:30 v/v) to give A-(l,3-benzoxazol-2-yl)-7V-[4- 
(phenoxymethyl)phenyl]amine as white solid (30). Yield: 0.9 g (28%), t.l.c. system: 
petroleum ether -  EtOAc 3:1 v/v, Rp: 0.64, vanillin stain positive.
Melting point: 151-156 °C.
HRMS (ED: Calculated mass: 317.1285 [M+H]+, Measured mass: 317.1289 
[M+H]+.
‘H-NMR I'DMSO-dft'l. S: 3.79 (s, 2H, CH*), 6 . 6 8  (d, 2H, J = 7.4 Hz, H- 
aromatic), 7.1 (d, 2H, J = 8.5 Hz, H-aromatic), 7.12 (t, J = 7.5 Hz, H-aromatic), 7.19 
(m, 3H, H-aromatic), 8.00 (d, 2H, J = 8.7 Hz, H-aromatic), 11.07 (s, 1H, NH).
13C NMR (DMSO-dfi). 5: 71.72 (CH2, C-l"’), 108.84, 115.11, 116.46, 117.75, 
121.48, 123.70, 129.03, 129.43 (CH, aromatic), 131.64 (C, C -l’), 135.73 (C, C-4'), 
142.49 (C, C-4"), 147.00 (C, C-9"), 155.44 (C, C-2"), 158.09 (C, C-l).
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4.1.23.4-[(2-Benzoxazolyl)amino]benzyl alcohol (42).
(Mol. Formula: C 15H12N2O2, M. W.: 252.28)
O
.CH
LiAIH,
N
H
(37) (42)
To a cooled (ice) solution of methyl 4-[(2-benzoxazolyl)amino]benzoate (26) 
(1.85 g, 6.9 mmol) in anhydrous THF (60 mL) was added 1M (THF) LiAlKL (14.0 
mL, 14.0 mmol) dropwise. Once addition was complete the reaction was stirred at 
room temperature for 20 min then EtOAc (20 mL) added slowly, with cooling, to 
quench the reaction. H2 O (20 mL) was added to dissolve the lithium salts, and then 
the organic layer separated. The organic layer was washed with H2O (2 x 100 mL), 
then the combined aqueous washes back extracted with EtOAc (2 x 100 mL). The 
combined organic layers were dried (MgS0 4 ) and concentrated under reduced 
pressure to give a pale orange/brown residue. The residue was washed with EtOH, 
filtered and dried in vacuo at 70 °C to give 4-[(2-benzoxazolyl)amino]benzyl alcohol 
(31) as a cream coloured solid, pure enough for use in the next reaction. Yield: 1.194 
g (72 %), t.l.c. system: petroleum ether- EtOAc 1:1 v/v, Rp: 0.18.
Melting point: 205-207 °C.
'H-NMR iDMSO-dA 8 : 4.47 (d, 2H, J = 5.3 Hz, CHjOH), 5.14 (t, 1H, J = 5.6 
Hz, CH2OH), 7.12 (dt, 1H, J = 1.2 Hz, 7.8 Hz, H-aromatic), 7.22 (dt, 1H, J = 1.1 Hz, 
7.7 Hz, H-aromatic), 7.47 (dd, 2H, J = 7.7 Hz, 12.2 Hz, H-aromatic), 7.52-7.54 (m, 
2H, H-aromatic), 7.72 (d, 2H, J = 8 . 6  Hz, H-aromatic), 10.59 (s, 1H, NH).
13C NMR (DMSO-dA 6 : 62.6 (CH2, C-l), 108.9, 116.5, 117.3, 121.5, 127.3 
(CH, aromatic), 123.9 (C, C-l'), 136.3 (C, C-l'), 137.3 (C, C-4"), 142.5 (C, C-4'),
147.0 (C, C-9"), 158.0 (C, C-2").
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4.1.24. 4-[(2-Benzoxazol)amino]benzaldehyde (43).
(Mol. Formula: C14H10N2O2 , M. W.: 238.07)
S03-Py
DMSO
(42) (43)
To a cooled (ice) solution of 4-[(2-benzoxazolyl)amino]benzyl alcohol (31) 
(0.5 g, 2.08 mmol) in dry DMSO (5 mL) and Et3N (2.9 mL, 20.8 mmol) was added a 
solution of pyridine-sulphur trioxide complex (1.40 g, 8 . 8  mmol) in dry DMSO (5 
mL) dropwise. The reaction was stirred at 0 °C for 5 min then at room temperature for 
25 min. The reaction was cooled in ice and quenched by the dropwise addition of 1M 
aqueous HC1 (~ 10 mL) to pH5. H2O (50 mL) was added and this solution extracted 
with EtOAc (2 x 100 mL). The organic layers were combined, washed with aq. 
NaHC0 3  solution (100 mL), H2O (100 mL), dried (MgS0 4 ) and concentrated under 
reduced pressure. The resulting residue was washed with Et2 0  to give 4-[(2- 
benzoxazol)amino]benzaldehyde (32) as a pale yellow solid which was dried in vacuo 
at 70 °C. Yield: 96 mg (19%), t.l.c. system: petroleum ether- EtOAc 1:2 v/v, Rp: 0.89. 
Melting point: 183-186 °C.
'H-NMR fDMSO-dA 6 : 7.25 (t, 1H, J = 7.8 Hz, H-aromatic), 7.33 (v|rt, 1H, J =
7.2 Hz, 8.0 Hz, H-aromatic), 7.60 (dd, 2H, J = 2.9 Hz, 7.9 Hz, H-aromatic), 8.01 (m, 
4H, H-aromatic), 9.94 (s, 1H, NH), 11.28 (s, 1 H, CHO).
13C NMR tDMSO-dA 5: 109.2, 117.1, 117.2, 122.4, 130.3 (CH, aromatic),
124.2 (C, C-l'), 131.1 (C, C -l’), 141.9 (C, C-4"), 144.2 (C, C-4'), 147.0 (C, C-9"),
158.1 (C, C-2 "), 191.24 (C, C-l).
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4.1.25. ferf-Butyl A/-(4-acetylphenyl)carbamate (44)(232).
(Mol. Formula: Ci3H 17N 0 3, M. W.: 235.29)
o o
BOC-anhydride
(38) (44)
4-Aminoacetophenone (38) (1.096 g, 8.12 mmol) was dissolved in a mixture 
of dioxane (5 mL), H2O (5 mL), and IN aqueous NaOH ( 8  mL) and cooled in an ice 
bath. Di-tert-butyl pyrocarbonate (BOC-anhydride, 2.66 g, 12.18 mol) was added in 
one portion, and stirring was continued at room temperature for 48 h. The dioxane 
was removed in vacuo and the aqueous layer chilled, acidified with IN aqueous HC1. 
The precipitate was then filtered and washed with H2O to give tert-butyl N-(4- 
acetylphenyl)carbamate (44) as a white solid which was dried in vacuo at 70 °C. 
Yield: 1.1 g (58%) t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.71, vanillin 
stain positive.
Melting point: 137-139 °C (lit. m.p. 137-138 °C)(232).
*H-NMR (DMSO-dA 5: 1.50 (s, 9H, QCH^b), 2.5 (s, 3H, CO-CH^), 7.58 (d, 
2H, J = 9.0 Hz, H-aromatic), 7.88 (d, 2H, J = 9.0 Hz, H-aromatic), 9.76 (s, 1H, NH).
13C NMR (DMSO-d*). 5: 26.28 (CH3, C-2), 27.99 (CH3, C-3', C-4', C-5'), 
79.72 (C, C-2'), 117.15, 129.41 (CH, aromatic), 130.69 (C, C-4"), 144.07 (C, C-l"),
152.47 (C, C-l'), 196.38 (C, C-l).
4.1.26. ferf-Butyl A/-[4-(2-bromoacetyl)phenyl]carbamate (45)(232)
(Mol. Formula: Ci3Hi7N 0 3, M. W.: 235.29)
O
A JC H ,\ O 1 N 1
CH3
5'
To a solution of tert-butyl AL(4-acetylphenyl)carbamate (44) (0.943g, 3 mmol) 
in THF (30 mL) containing a catalytic amount of A1C13 (20 mg, 0.15 mmol) was
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added Br2 (0.2 mL, 3.9 mmol in 5 mL THF) dropwise for 30 min at 0 °C. Then, the 
mixture was allowed to warm to room temperature. After 60 min, the solvent was 
removed in vacuo, followed by extraction of the resulting solid with EtOAc- H2O 
(1:1, 50 mL). The aqueous layer was subsequently extracted with EtOAc (2 x 50 mL), 
and the organic layers were combined, concentrated, dried (MgS0 4 ) and purified 
using flash column chromatography (petroleum ether -  EtOAc 100:0 v/v increasing to 
70:30 v/v) to give tert-butyl Ar-[4-(2-bromoacetyl)phenyl]carbamate (45) as a white 
solid. Yield: 0.12 g (17%) t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.54, 
vanillin stain positive.
Melting point: 164-167 °C (166-167 °C )(232).
‘H-NMR (DMSO-dA S: 1.55 (s, 9H, C(CHa)j), 3.34 (s, 2H, CHj), 7.65 (d, 2H, 
J = 9.0 Hz, H-aromatic), 7.99 (d, 2H, J = 9.0 Hz, H-aromatic), 9.87 (s, 1H, NH).
13C NMR (DMSO-da 5: 27.99 (CH3, C-3’, C-4', C-5'), 33.57 (CH2, C-2), 
79.88 (C, C-2'), 117.25, 130.15 (CH, aromatic), 127.58 (C, C-4"), 144.76 (C, C-l"), 
152.42 (C, C-l'), 190.16 (C, C-l).
4.1.27. 4-(1,3-Benzoxazol-2-ylamino)-1-benzoylhydrazide (46).
(Mol. Formula: C 14H 12N4O2 , M. W.: 268.28)
.CH .NH,
H
(37)
Hydrazine hydrate (0.4 mL, 12.5 mol) was added to a stirred solution of 
methyl 4-[(2-benzoxazolyl)amino]benzoate (37) (1.34 g, 5 mmol) in EtOH (25 mL). 
The reaction mixture was refluxed for 3 h, diluted with H2O and cooled in an ice bath. 
Diluted AcOH (30 mL, 10%) was added to the reaction mixture, where a yellow 
precipitate was formed, filtered, washed with cold EtOH then recrystallised from 
aqueous EtOH to give 4-(l,3-benzoxazol-2-ylamino)-l-benzenecarbohydrazide (46) 
as yellow crystals. Yield: 2.4 g (45%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, 
Rf: 0 .2 , vanillin stain positive.
Melting point: 213-216 °C.
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HRMS (ED\ Calculated mass: 269.1033 [M+H]+, Measured mass: 269.1035 
[M+H]+.
'H-NMR (DMSO-dA 5: 4.43 (s, 2H, NHj), 7.16 (m, 1H, H-aromatic), 7.24 (t, 
1H, J = 8.5 Hz, H-aromatic), 7.04 (t, 2H, J = 8 . 8  Hz, H-aromatic), 7.80 (d, 2H, J = 8.9 
Hz, H-aromatic), 7.87 (d, 2H, J = 8.9 Hz, H-aromatic), 9.68 (s, 1H, Ar-NH-Ar), 10.91 
(s, 1 H, CO-NH-NH2).
13C NMR (DMSO-da 5: 109.09, 116.70, 116.84, 122, 124.11 (CH, aromatic), 
126.65 (C, C-l'), 128.03 (CH, C-2', C-6 '), 141.14 (C, C-4’), 142.12 (C, C-4”), 146.94 
(C, C-9"), 157.51 (C, C-2"), 165.54 (C, C-l).
4.1.28. 5-(4-Nitrophenyl)-1,3,4-oxadiazoline-2-thione (48)(233).
(Mol. Formula: C8H5N30 3 S, M. W.: 223.21)
NH
CS.
KOH
(48)(47)
To a solution of KOH (0.31 g, 5.5 mmol) in EtOH (20 mL), was added 4- 
nitrobenzoylhydrazide (47) (1 g, 5.5 mmol) with stirring. Then an excess of CS2 (1.13 
mL, 18.7 mmol) was added and the mixture refluxed until the evolution of H2 S ceases 
(about 20 h). The solvent was removed in vacuo and the residue dissolved in H2O (20 
mL), cooled in ice and acidified with IN aqueous HC1 to give 5-(4-nitrophenyl)-l,3,4- 
oxadiazoline-2-thione (48) as a yellow solid which was filtered off, dried and 
recrystallised from aqueous EtOH. Yield: 0.925 g (75%), t.l.c. system: petroleum 
ether -  EtOAc 3:1 v/v, Rp: 0.1, vanillin stain negative.
Melting point: 202-205 °C (lit. m.p. 202-204 °C) (232).
'H-NMR (DMSO-dA 8 : 3.36 (s, 1H, NH), 8.11 (d, 2H, J = 9.0 Hz, H-3', H-5'), 
8.40 (d, 2H, J = 9.0 Hz, H-2’, H-6 ’).
13C NMR (DMSO-dA S: 124.51 (CH, C-2', C-6 '), 127.59 (CH, C-3', C-5'),
128.01 (C, C-l'), 149.11 (C, C-4'), 158.88 (C, C-2), 177.76 (C, C-l').
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4.1.29. 2-(4-Nitrophenyl)-5-(phenethylsulfanyl)-1,3,4-oxadiazole (50).
(Mol. Formula: C16H 13N3O3 S, M. W.: 327.36)
i—'N.
SH
Bi+
0 2N
(48) (49) (50)
A mixture of 5-(4-nitrophenyl)-l,3,4-oxadiazoline-2-thione (48) (0.31 g, 1.39 
mmol), l-(2-bromoethyl)benzene (0.2 mL, 1.39 mmol) and K2CO3 (0.29 g, 2.09 
mmol) in DMF (20 ml) was stirred for 24 h at room temperature. The reaction mixture 
was poured into H2O (20 mL) and the precipitate formed filtered, washed with EtOH 
and recrystallised from aqueous EtOH to give 2-(4-nitrophenyl)-5- 
(phenethylsulfanyl)-l,3,4-oxadiazole (50) as yellow crystals. Yield: 0.31 g (69%), 
t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.87, vanillin stain negative.
Melting point: 95-98 °C.
HRMS (ED: Calculated mass: 328.0751 [M+H]+, Measured mass: 328.0749 
[M+H]+.
‘H-NMR ('DMSO-cIaI. 5: 3.11 (t, 2H, J = 7.0 Hz, S-Ot-CHj-Ar), 3.61 (t, 2H, 
J = 7.5 Hz, S-CH2 -CH2-Ar), 7.3 (m, 5H, H-aromatic), 8.21 (d, 2H, J = 9.0 Hz, H- 
aromatic), 8.41 (d, 2H, J = 9.0 Hz, H-aromatic).
I3C NMR (DMSO-dA 5: 33.34 (CH2, C-3), 34.93 (CH2, C-3), 124.55, 126.53,
127.69, 128.35, 128.66 (CH, aromatic), 128.30 (C, C -l’), 139.08 (C, C-l"), 149.06 (C, 
C-4’), 163.71 (C, C-2), 165.10 (C, C-l).
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4.1.30. 4-[5-(Phenethylsulfanyl)-1,3,4-oxadiazol-2-yl]aniline (51).
(Mol. Formula: Ci6Hi5N3OS, M. W.: 297.37)
(50) (51)
To a refluxed mixture of Fe (0.57 g, 10.23 mmol) and NH4CI (0.128 g, 2.39 
mmol) in 10:1 of EtOHiFhO (30 mL), 2-(4-nitrophenyl)-5-(phenethylsulfanyl)-l,3,4- 
oxadiazole (50) (1.11 g, 3.41 mmol) was added. The reaction mixture was stirred 
under reflux for 3 h and then allowed to cool to room temperature. The solution was 
filtered through celite and the solvent removed under reduced pressure. The residue 
then dissolved in CH2CL2 (50 mL), washed with saturated aq. NaHC03 (2 x 50 mL). 
The organic layer then dried (MgSCU) and concentrated in vacuo. The product was 
isolated by flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 80:20 v/v) to give pure 4-[5-(phenethylsulfanyl)-l,3,4-oxadiazol-2- 
yl]aniline (51) as a yellow solid. Yield: 0.8 g (89%), t.l.c. system: CH2CI2 -  MeOH 
9:1 v/v, Rp: 0.7, ninhydrin stain positive.
Melting point: 97-98 °C.
HRMS (El): Calculated mass: 298.1009 [M+H]+, Measured mass: 298.1007 
[M+H]+.
‘H-NMR fCDCK). 6 : 3.02 (t, 2H, J = 7.0 Hz, S-CHrCHj-Ar), 3.39 (t, J = 7.5 
Hz, 2H, S-CHj-CHj-Ar), 4.10 (s, 2H, NHj), 6.59 (d, J = 8.0 Hz, 2H, H-aromatic), 
7.13 (m, 3H, H-aromatic), 7.2 (m, 2H, H-aromatic), 7.67 (d, 2H, J = 8.0 Hz, H- 
aromatic).
I3C NMR rCDCh). 5: 33.88 (CH2, C-3), 35.73 (CH2, C-3), 113.08 (C, C-l'), 
114.65, 126.82, 128.38, 128.66, 128.72 (CH, aromatic), 139.19 (C, C-l"), 149.96 (C, 
C-4'), 162.71 (C, C-2), 166.30 (C, C-l).
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4.1.31. N-(2-Naphthyl)-A/-{4-[5-(phenethylsulfanyl)-1,3,4-oxadiazol-2-
yl]phenyl}amine (52).
(Mol. Formula: C26H21N3OS, M. W.: 423.53)
Cu acetate
pyridine
To naphthylboronic acid (16) (1.1 g, 6.4 mmol), 4-[5-(phenethylsulfanyl)-
l,3,4-oxadiazol-2-yl]aniline (51) (0.63 g, 2.1 mmol), anhydrous cupric acetate (0.76 
g, 4.2 mmol), pyridine (0.4 mL, 4.2 mmol) and 250 mg activated 4A molecular sieves 
under an atmosphere of air was added anhydrous CH2CI2 (30 mL) and the reaction 
stirred under air atmosphere at ambient temperature for 3 days. The product was 
isolated by direct flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 80:20 v/v) to give AL(2-naphthyl)-7V-4-[5-(phenethylsulfanyl)-l,3,4- 
oxadiazol-2-yl]phenylamine (52) as a yellow solid. Yield: 0.63 g (71%), t.l.c. system: 
petroleum ether -  EtOAc 3:1 v/v, Rp: 0.65, vanillin stain positive.
Melting point: 132-134 °C.
Microanalvsis: Calculated for C26H21N3OS. O.IH2O (425.33), Theoretical: 
%C= 73.42, %H= 5.02, %N= 9.88, Found: %C= 73.20, %H= 4.72, %N= 9.51, N.b. 
this compound is very hygroscopic, and this microanalysis is the best one obtained 
after five days drying in the oven.
1 H-NMR (CDCIO. 5: 3.19 (t, 2 H, J = 7.9 Hz, -S-CH2-CH2 -Ph), 3.55 (t, 2 H, J =
7.4 Hz, -S-CH2 -CH2-PI1), 6.27 (s, 1H, NH), 7.19 (d, 2H, J = 8 . 8  Hz, H-aromatic), 
7.25-7.31 (m, 3H, H-aromatic), 7.33-7.37 (m, 3H, H-aromatic), 7.41 (m, 1H, H- 
aromatic), 7.49 (m, 1H, H-aromatic), 7.60 (d, 1H, J = 2.0 Hz, H-aromatic), 7.75 (d, 
1H, J = 8.2 Hz, H-aromatic), 7.83 (t, 2H, J = 8.9 Hz, H-aromatic), 7.92 (d, 2H, J = 8 . 8  
Hz, H-aromatic).
13C NMR (CDChL 5: 33.89 (CH2, C-3), 35.72 (CH2, C-4), 115.14 (C, C-2"'), 
115.38, 115.98, 121.15, 124.53, 126.70, 126.82, 126.85, 127.73, 128.34, 128.65, 
128.72, 129.47 (CH, aromatic), 130.13 (C, C-l'), 134.36 (C, C-5m), 138.58 (C, C- 
10,,,), 139.17 (C, C-l"), 146.77 (C, C-4'), 163.10 (C, C-2), 165.95 (C, C-l).
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4.1.32. 2-(4-Nitrophenyl)-5-(pentylsulfanyl)-1,3,4-oxadiazole (54).
(Mol. Formula: C 1 3 H 1 5 N 3 O 3 S ,  M .  W.: 293.34)
k2c o 3
(53) 0,N 4'
A mixture of 5-(4-nitrophenyl)-l,3,4-oxadiazoline-2-thione (48) (0.94 g, 4.21 
mmol), 1-bromopentane (0.5 mL, 4.21 mmol) and K2CO3 (0.9 g, 6.31 mmol) in DMF 
(20 ml) was stirred for 24 h at room temperature. The reaction mixture was poured 
into H2O and the precipitate formed filtered, washed with EtOH and recrystallised 
from aqueous EtOH to give 2-(4-nitrophenyl)-5-(pentylsulfanyl)-l,3,4-oxadiazole 
(54) as yellow crystals. Yield: 0.65 g (69%), t.l.c. system: petroleum ether -  EtOAc 
3:1 v/v, Rf : 0.86, vanillin stain negative.
Melting point: 80-82 °C.
Microanalvsis: Calculated for C13H15N3O3S (293.34), Theoretical: %C= 53.23, 
%H= 5.15, %N= 14.32, Found: %C= 53.30, %H= 5.33, %N= 13.93.
'H-NMR fCDClA 8 : 0.83 (t, 3H, J = 7.5 Hz, -CH2-CH3 ), 1.31 (m, 2H, -CH2- 
CH2-CH3), 1.39 (m, 2H, -CH2-CH2-CH3), 1.81 (m, 2H, S-CH2-CH2-CH2), 3.27 (m, 
2H, S-CH2 -CH2-CH2), 8.11 (d, 2H, J = 9.0 Hz, H-2', H-6 '), 8.30 (d, 2H, J = 9.0 Hz, H- 
3', H-5').
I3C NMR fCDChl. 6 : 13.87 (CH3, C-7), 22.10 (CH2, C-6 ), 28.86 (CH2, C-3),
30.70 (CH2, C-5), 32.65 (CH2, C-4), 124.38 (CH, C-2 ', C-6 '), 127.46 (CH, C-3', C-5'), 
129.18 (C, C-l'), 149.42 (C, C-4'), 163.87 (C, C-2), 166.40 (C, C-l).
4.1.33. 4-[5-(Pentylsulfanyl)-1,3,4-oxadiazol-2-yl]aniline (54).
(Mol. Formula: C13H17N3OS, M. W.: 263.36)
•c h 3
h 2n
(54) (55)
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To a refluxed mixture of Fe (0.57 g, 10.23 mmol) and NH4CI (0.128 g, 2.39 
mmol) in 10:1 of EtOHiHbO (30 mL), 2-(4-nitrophenyl)-5-(pentylsulfanyl)-l,3,4- 
oxadiazole (54) (1.00 g, 3.41 mmol) was added. The reaction mixture was stirred 
under reflux for 3 h and then allowed to cool to room temperature. The solution was 
filtered through celite and the solvent removed under reduced pressure. The residue 
then dissolved in CH2CL2 (50 mL), washed with saturated aq. NaHC0 3  ( 2  x 50 mL). 
The organic layer then dried (MgSOzO and concentrated in vacuo. The product was 
isolated by flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 80:20 v/v) to give pure 4-[5-(pentylsulfanyl)-l,3,4-oxadiazol-2- 
yl]aniline (55) as a white solid. Yield: 0.8 g (89%), t.l.c. system: CH2CI2 -  MeOH 9:1 
v/v, Rp: 0.7, ninhydrin stain positive.
Melting point: 116-118 °C.
HRMS (ED: Calculated mass: 264.1166 [M+H]+, Measured mass: 264.1169 
[M+H]+.
1 H-NMR (CDCLL 5: 0.93 (t, 3H, J = 7.5 Hz, -CH2-CH3), 1.34-1.42 (m, 2 H, - 
CH2-CH2-CH3), 1.43-1.49 (m, 2H, -CH2-CH2-CH3), 1.81-1.87 (m, 2H, S-CH2-CH2- 
CH2), 3.27 (t, 2 H, J = 7.4 Hz, S-CH2-CH2-CH2), 4.09 (s, 2 H, NH2), 6.73 (d, 2H, J =
9.0 Hz, H-3', H-5'), 7.80 (d, 2H, J = 8 . 6  Hz, H-2', H-6 ').
13C NMR (CDCM. 5: 13.88 (CH3, C-7), 22.11 (CH2, C-6 ), 29.03 (CH2, C-3),
30.71 (CH2, C-5), 32.66 (CH2, C-4), 113.47 (C, C-l'), 114.64 (CH, C-3', C-5’), 128.35 
(CH, C-2', C-6 '), 149.63 (C, C-4'), 163.09 (C, C-2), 166.09 (C, C-l).
4.1.34. A/’(2-Naphthyl)-A/-{4-[5-(pentylsulfanyl)-1,3,4-oxadiazol-2-
yl]phenyl}amine (55).
(Mol. Formula: C23H23N3OS, M. W.: 389.51)
pyridine
To naphthylboronic acid (16) (0.9 g, 5.2 mmol), 4-[5-(pentylsulfanyl)-1,3,4- 
oxadiazol-2-yl]aniline (55) (0.45 g, 1.74 mmol), anhydrous cupric acetate (0.63 g, 
3.47 mmol), pyridine (0.3 mL, 3.47 mmol) and 250 mg activated 4A molecular sieves 
under an atmosphere of air was added anhydrous CH2CI2 (30 mL) and the reaction
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stirred under air atmosphere at ambient temperature for 3 days. The product was 
isolated by direct flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 80:20 v/v) to give A-(2-naphthyl)-A^-4-[5-(pentylsulfanyl)-1,3,4- 
oxadiazol-2-yl]phenylamine (56) as a yellow solid. Yield: 0.45 g (65%), t.l.c. system: 
petroleum ether -  EtOAc 3:1 v/v, Rp: 0.7, vanillin stain positive.
Melting point: 138-139 °C.
HRMS fEIT Calculated mass: 390.1636 [M+H]+, Measured mass: 390.1635 
[M+Hf.
1 H-NMR (CDCLL 5: 0.95 (t, 3H, J = 7.2 Hz, -CH2-CH3), 1.38-1.45 (m, 2H, - 
CH2 -CH2-CH3), 1.47-1.58 (m, 2 H, -CH2-CH2 -CH3), 1.84-1.90 (m, 2H, S-CH2-CH2 - 
CH2), 3.30 (t, 2H, J = 7.5 Hz, S-CH2-CH2-CH2), 6 . 2 1  (s, 1 H, NH), 7.81 (d, 2H, J = 6.9 
Hz, H-aromatic), 7.33 (d, 1H, J = 6.5 Hz, H-aromatic), 7.39-7.43 (m, 1H, H- 
aromatic), 7.47-7.50 (m, 1H, H-aromatic), 7.60 (d, 1H, J = 2.1 Hz, H-aromatic), 7.74 
(d, 1H, J = 8.2 Hz, H-aromatic), 7.81-7.85 (m, 2H, H-aromatic), 7.92 (d, 2H, J = 5.1 
Hz, H-aromatic).
13C NMR fCDCLL 5: 13.89 (CH3, C-l), 22.13 (CH2, C-6 ), 29.03 (CH2, C-3), 
30.73 (CH2, C-5), 32.68 (CH2, C-4), 115.14 (C, C-2"), 115.33, 116.00, 1 2 1 .1 1 , 
124.51, 126.69, 126.83, 127.72, 128.32, 129.47 (CH, aromatic), 130.12 (C, C-l'), 
134.36 (C, C-5"), 138.60 (C, C-10"), 146.67 (C, C-4'), 163.09 (C, C-2), 166.09 (C, C-
1).
4.1.35. Ethyl 2-{[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetate
(58).
(Mol. Formula: Ci2HnN 30 5S, M. W.: 309.30)
N - " '
(58)
N---
■SH
o2n
(48)
A mixture of 5-(4-nitrophenyl)-l,3,4-oxadiazoline-2-thione (48) (1.5 g, 6.7 
mmol), ethyl 2-bromoacetate (57) (0.7 mL, 6.7 mmol) and K2C 0 3 (1.39 g, 10.05 
mmol) in DMF (25 mL) was stirred for 24 h at room temperature. The reaction 
mixture is poured into H20  and the precipitate formed filtered, washed with EtOH and
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recrystallised from EtOH to give ethyl 2-{[5-(4-nitrophenyl)-l,3,4-oxadiazol-2- 
yl]sulfanyl}acetate (58) as yellow crystals. Yield: 1.3 g (62%), t.l.c. system: 
petroleum ether -  EtOAc 3:1 v/v, RF: 0.41, vanillin stain positive.
Melting point: 109-110 °C.
Microanalvsis: Calculated for C 12H 11N3O5S (309.30), Theoretical: %C= 46.60, 
%H= 3.58, %N= 13.58, Found: %C= 46.73, %H= 3.32, %N= 13.59.
iHzNMEICDCbLS: 1.33 (t, 3H, J = 7.2 Hz, -CH2-CH3 ), 4.16 (s, 2H, S-CH2- 
CO), 4.29 (q, 2H, J = 7.2 Hz, 21.4 Hz, -CH2-CH3), 8.21 (d, 2H, J = 9.0 Hz, H-2', H- 
6 '), 8.38 (d. 2H, J = 9.0 Hz, H-3', H-5').
13C NMR (CDC1A 8 : 14.09 (CH3, C-6 ), 34.42 (CH2, C-3), 62.55 (CH2, C-5), 
124.42 (CH, C-2', C-6 '), 127.59 (CH, C-3', C-5'), 128.91 (C, C-l'), 149.57 (C, C-4'), 
164.32 (C, C-2), 164.67 (C, C-l), 167.15 (C, C-4).
4.1.36. Ethyl 2-{[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}acetate
(59).
(Mol. Formula: C 12H 13N3O3 S, M. W.: 279.07)
To a refluxed mixture of Fe (0.54 g, 9.69 mmol) and NH4CI (0.121 g, 2.26 
mmol) in 10:1 of EtOH:H2 0  (30 mL), ethyl 2-{[5-(4-nitrophenyl)-l,3,4-oxadiazol-2- 
yljsulfanyl)acetate (58) (1.00 g, 3.23 mmol) was added. The reaction mixture was 
stirred under reflux for 3 h and then allowed to cool to room temperature. The 
solution was filtered through celite and the solvent removed under reduced pressure. 
The residue then dissolved in CH2CL2 (50 mL), washed with saturated aq. NaHCC>3 (2 
x 50 mL). The organic layer then dried (MgSCL) and concentrated in vacuo. The 
product was isolated by flash column chromatography (petroleum ether -  EtOAc 
100:0 v/v increasing to 80:20 v/v) to give pure ethyl 2-{[5-(4-aminophenyl)-l,3,4- 
oxadiazol-2-yl]sulfanyl}acetate (59) as white solid. Yield: 0.7 g (78%), t.l.c. system: 
CH2CI2 -  MeOH 9:1 v/v, RF: 0.35, ninhydrin stain positive.
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Melting point: 146-148 °C.
Microanalysis: Calculated for C 12H 13N3O3S (279.07), Theoretical: %C= 51.60, 
%H= 4.69, %N= 15.04, Found: %C= 51.32, %H= 4.81, %N= 14.80.
'H-NMR (DMSO-dA 5: 1.19 (t, 3H, J = 7.1 Hz, -CH2-CH3), 4.15 (q, 2H, J =
7.1 Hz, 21.3 Hz, -CH2-CH3), 4.22 (s, 2H, S-CH2 -CO), 5.94 (s, 2H, NH2), 6.67 (d, 2H, 
J = 8 . 6  Hz, H-3', H-5’), 7.61 (d, 2H, J = 8 . 6  Hz, H-2’, H-6 ').
13C NMR (DMSO-dA 5: 13.91 (CH3, C-6 ), 33.83 (CH2, C-3), 61.48 (CH2, C- 
5). 109.19 (C, C-l'), 113.52 (CH, C-3', C-5'), 127.88 (CH, C-2', C-6 '), 152.40 (C, C- 
4'), 160.53 (C, C-2), 166.04 (C, C-l), 167.79 (C, C-4).
4.1.37. Ethyl 2-({5-[4-(2-naphthylamino)phenyl]-1,3,4-oxadiazol-2- 
yl}sulfanyl)acetate (60).
(Mol. Formula: C22H 19N3O3 S, M. W.: 405.47)
pyridine
To naphthylboronic acid (16) (0.92 g, 5.37 mmol), ethyl 2-{[5-(4- 
aminophenyl)-l,3,4-oxadiazol-2-yl]sulfanyl} acetate (59) (0.5 g, 1.79 mmol), 
anhydrous cupric acetate (0.65 g, 3.58 mmol), pyridine (0.3 mL, 3.58 mmol) and 250 
mg activated 4A molecular sieves under an atmosphere of air was added anhydrous 
CH2CI2 (30 mL) and the reaction stirred under air atmosphere at ambient temperature 
for 3 days. The product was isolated by direct flash column chromatography 
(petroleum ether -  EtOAc 100:0 v/v increasing to 80:20 v/v) to give ethyl 2-({5-[4-(2- 
naphthylamino)phenyl]-l,3,4-oxadiazol-2-yl}sulfanyl)acetate (60) as a yellow solid. 
Yield: 0.45 g (65%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.7, vanillin 
stain positive.
Melting point: 150-152 °C.
Microanalysis: Calculated for C22H19N3O3S (405.47), Theoretical: %C= 65.17, 
%H= 4.72, %N= 10.36, Found: %C= 65.00, %H= 4.74, %N= 10.58.
'H-NMR ICDChl. S: 1.33 (t, 3H, J = 7.1 Hz, -CHa-CHj), 4.11 (s, 2H, S-CH2- 
CO), 4.28 (q, 2H, J = 7.2 Hz, 21.4 Hz, -CH2 -CH3), 6.25 (s, 1H, NH), 7.18 (d, 2H, J =
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8 . 8  Hz, H-aromatic), 7.32-7.34 (m, 1H, H-aromatic), 7.40-7.43 (m, 1H, H-aromatic), 
7.47-7.51 (m, 1H, H-aromatic), 7.60 (d, 1H, J = 1.8 Hz, H-aromatic), 7.75 (d, 1H, J =
8.2 Hz, H-aromatic), 7.81-7.85 (m, 2H, H-aromatic), 7.91 (d, 2H, J = 8.7 Hz, H- 
aromatic).
13C NMR (CDC10. 5: 14.09 (CH3, C-6 ), 34.48 (CH2, C-3), 62.37 (CH2, C-5), 
114.89 (C, C-2"), 115.49, 115.91, 121.17, 124.56, 126.70, 126.86, 127.73, 128.41, 
129.48 (CH, aromatic), 130.15 (C, C -l’), 134.34 (C, C-5"), 138.49 (C, C-10"), 146.90 
(C, C-4'), 161.72 (C, C-2), 166.29 (C, C-l), 167.58 (C, C-4).
Experimental 15 7
4 . 2 .  S y n th e s is  
o f  CYP24A1
Experimental 158
4.2.1. 3-(Acetyloxy)-5-m ethylphenylacetate (62)(215).
(Mol. Formula: Cn Hi2 0 4, M. W.: 208.21)
CH
H CH
(62)
CH
H 0 ‘ OH
(61)
A solution of orcinol (5-methylresorcinol) (61) (2 g, 17.07 mmol) in pyridine 
(20 mL) and AC2O ( 8  mL, 84.6 mmol) was stirred at room temperature for 17 h then 
evaporated in vacuo. The residue was dissolved in CH2CI2 (50 mL) and the solution 
was washed with saturated aqueous NaHC03 (50mL), H2O (50 mL), dried (MgS04) 
and evaporated under reduced pressure giving 3-(acetyloxy)-5-methylphenyl acetate 
(62) as a colourless oil. Yield: 2.9 g (99%), t.l.c. system: petroleum ether -  EtOAc 3:1 
v/v, Rp: 0.54, vanillin stain positive.
1 H-NMR (CDClri. 5: 2.29 (s, 6 H, 2 CO-CH3), 2.37 (s, 3H, Ar-CEh), 6.74 (t, 
1H, J = 2.1 Hz, H-2), 6.81-6.82 (m, 2H, H-4, H-6 ).
13C NMR (CDCLL 5: 21.33 (CH3, C-2', C-4'), 22.13 (CH3, C-5'), 112.45 (CH, 
C-2), 119.69 (CH, C-4, C-6 ), 140.34 (C, C-5), 150.90 (C, C-l, C-3), 169.09 (C, C-l', 
C-3').
4.2.2. 3-(Acetyloxy)-5-(bromomethyl)phenyl acetate (63)(215).
(Mol. Formula: CnHn Br04, M. W.: 287.11)
CH2BrCH;
N-Bromosuccinimide
Benzoyl-peroxide
OH3 CH3
(63)(62)
3,5-Diacetoxytoluene (62) (2.9 g, 14.07 mmol) was dissolved in dry CC14 (50 
mL). After addition of freshly recrystallised A^-bromosuccinimide (2.56 g, 14.38 
mmol) and a catalytic amount of benzoyl peroxide (0.2 g, 0.83 mmol), the mixture 
was refluxed for 3 h. After the mixture had cooled, the succinimide was removed by
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filtration, and the solvent was removed under reduced pressure to give 3-(acetyloxy)- 
5-(bromomethyl)phenyl acetate (63) as a colourless oil. Yield: 4 g (99%), t.l.c. 
system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.43, vanillin stain positive.
1 H-NMR (CDCLL 5: 2.31 (s, 6 H, 2 CO-CH3 ), 4.45 (s, 2H, Ar-Cf^-Br), 6.91 
(t, 1H, J = 2.2 Hz, H-2), 7.05-7.06 (m, 2H, H-4, H-6 ).
13C NMR (CDCM. 5: 21.06 (CH3, C-2', C-4'), 31.78 (CH2, C-5'), 115.43 (CH, 
C-2), 119.55 (CH, C-4, C-6 ), 139.82 (C, C-5), 151.1 (C, C-l, C-3), 169.10 (C, C-l', 
C-31).
4.2.3. 3,5-Diacetoxybenzyl-(tripheny1)phosphonium bromide (65)(215). 
(Mol. Formula: C29H26Br04P, M. W.: 549.39)
4”
(63) (64) (65)
3,5-Diacetoxybenzyl bromide (63) (4 g, 14 mmol) and triphenylphosphine 
(64) (3.67 g, 14 mmol) were dissolved in dry benzene (25 mL). The mixture was then 
refluxed for 6  h, to form a precipitate which upon washing with benzene gave 3,5- 
diacetoxybenzyl-(triphenyl)phosphonium bromide (65) as a white solid. Yield: 4.38 g 
(57%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.00, vanillin stain 
negative.
Melting point: 246-249 °C (lit. m.p. 247 °C )(215).
'H-NMR rPMSO-d^l. S: 2.21 (s, 6 H, 2 CO-CH,), 3.78 (d, 2H, J = 15.8 Hz),
6 . 6 8  (t, 2H, J = 2.3 Hz, H-aromatic), 7.00 (t, 1H, J = 2.1 Hz, H-aromatic), 7.66-7.71 
(m. 6 H, H-aromatic), 7.34-7.77 (m, 6 H, H-aromatic), 7.91-7.94 (m, 3H, H-aromatic).
13C NMR IDMSO-da. 8 : 20.65 (CH3, C-2', C-4’), 28.01 (CH2, C-5’), 116.14, 
121.75, 130.22, 134.06, 135.16 (CH, aromatic), 117.35 (C, C-l"), 130.32 (C, C-5),
Experimental 160
150.75 (C, C-l, C-3), 168.58 (C, C-l', C-3').
4.2.4.1,3-Dimethoxy-5-vinylbenzene (68)(2I7). 
(Mol. Formula: CioHnO?, M. W.: 164.2)
CHO
H,C
® © 
Ph3PCH3Br f-BuOK
H,C CH
(68)(6 6 ) (67)
A solution of 3,5-dimethoxybenzaldehyde (6 6 ) (2.93 g, 17.5 mmol), methyl- 
triphenylphosphonium bromide (67) (6.95 g, 19.5 mmol) and r-BuOK (2.19 g, 19.5 
mmol) in dry THF (50 mL) was stirred for 2 h at room temperature under nitrogen. 
Then, the reaction was quenched by adding 10 mL of a saturated aqueous solution of 
NH4C1. The solvents were removed under vacuum. The crude product was extracted
with CH2CI2 (50 mL) and the organic layer was washed with H2O (50 mL), dried over 
MgS04 and the solvent removed under reduced pressure. The product then was
isolated by flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 70:30 v/v) to give l,3-dimethoxy-5-vinylbenzene (6 8 ) as a colourless 
oil. Yield: 2 g (70%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.67, vanillin 
stain positive.
1 H-NMR (CDCU\ 5: 3.83 (s, 6 H, CHj), 5.28 (d, 1H, J = 10.9 Hz, Ha), 5.76 (d, 
1H, J = 17.2 Hz, Hb), 6.42 (t, 1H, J = 2.3 Hz, H-2), 6.60 (d, 2H, J = 2.3 Hz, H-4, H-6 ), 
6 . 6 6  (dd, 1H, J = 10.8 Hz, 17.5 Hz, H-3’).
13C NMR (CDCIA. 5: 55.32 (CH3, C-l', C-2'), 100.11 (CH, C-2), 104.35 (CH, 
C-4, C-6 ), 114.31 (CH2, C-4'), 136.88 (CH, C-3'), 139.64 (C, C-5), 160.94 (C, C-1,C-
3).
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4.2.5. Methyl 4-[(£)-2-(3,5-dimethoxyphenyl)-1-ethenyl]benzoate (70 )(234).
(Mol. Formula: Ci8Hi80 4, M. W.: 298.33)
H ,C
. c h 3
c h 3
(70)(69)(68 )
A solution of l,3-dimethoxy-5-vinylbenzene (6 8 ) (2 g, 12.18 mmol), 
Pd(OAc) 2 (0.108 g, 0.48 mmol), tri(o-tolyl)phosphine (ToP, 0.22 g, 0.72 mmol) and
4-iodo-methylbenzyl ester (69) (2.88 g, 11 mmol) in dry Et3N (25 mL) was stirred for
2 h at 60 °C under nitrogen. Then the mixture was stirred for 1 day at 80 °C. After the 
reaction was complete, the solvent was evaporated. The crude product was dissolved 
in CH2CI2 (50 mL) and washed with H2O (50 mL), dried over MgS04 and the solvent
evaporated. The crude product was purified by flash column chromatography 
(petroleum ether -  EtOAc 100:0 v/v increasing to 70:30 v/v) to give methyl 4-[(£)-2- 
(3,5-dimethoxyphenyl)-l-ethenyl] benzoate (70) as a colourless oil. Yield: 3.12 g 
(8 6 %), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.65, vanillin stain positive.
'H-NMR fCDCIA 6 : 3.86 (s, 6 H, 2 O-CHj), 3.95 (s, 3H, COOCHj), 6.46 (t, 
1H, J = 2.0 Hz, H-aromatic), 6.71 (d, 2H, J = 2.1 Hz, H-aromatic), 7.14 (d, 2H, J = 9.7 
Hz, Ha, Hb), 7.57 (d, 2H, J = 8.3 Hz, H-aromatic), 8.05 (d, 2H, J = 8.3 Hz, H- 
aromatic).
I3C NMR rCDChl. S: 52.05 (CH3, C-2 '), 55.39 (CH3, C-5', C-6 '), 100.59 (CH, 
C-4"), 104.89, 126.38, 128.08, 130.02, 131.24 (CH, aromatic and alkene), 129.04 (C, 
C-l), 138.77 (C, C-l"), 141.65 (C, C-4), 161.07 (C, C-3”, C-5"), 166.84 (C, C-l').
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4.2.6. 4-[(£)-2-(3,5-Dimethoxyphenyl)-1-ethenyl]benzoic acid (71)(234).
(Mol. Formula: Ci4H,60 4 , M. W.: 284.31)
.c h 3
c h3 ch3 oh
2M NaOH
(70)
A solution of methyl 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl] benzoate (70) 
(1 g, 3.35 mmol) in EtOH (30 mL) was treated with 2M aqueous NaOH (7 mL) and 
stirred at room temperature. Progress of the reaction was monitored by observing the 
disappearance of methyl 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl] benzoate (71) by 
t.l.c. After hydrolysis was complete (1 h), the reaction solution was acidified to pH 1 
by the dropwise addition of concentrated HC1 (3 mL). The solution was then extracted 
with Et2 0  (3 x 50 mL) and the organic layer dried (MgS04) and concentrated under 
reduced pressure to give a crude brown solid. The crude product was washed with 
H2O, dried and recrystallised from EtOH to give pure 4-[(£)-2-(3,5- 
dimethoxyphenyl)-l-ethenyl]benzoic acid (69) as transparent crystals. Yield: 0.95 g 
(100%), t.l.c. system: petroleum ether -  EtOAc 2:3 v/v, Rp: 0.14, vanillin stain 
negative.
Melting point: 186-189°C (lit m.p. 189 °C )(234).
‘H-NMR (DMSO-dA S: 3.79 (s, 6 H, 2 O-CHj), 6.46 (t, 1H, J = 2.2 Hz, H- 
aromatic), 6.83 (d, 2H, J = 2.3 Hz, H-aromatic), 7.34 (d, 2H, J = 3.7 Hz, Ha, Hb), 7.71 
(d, 2H, J = 8.5 Hz, H-aromatic), 7.94 (d, 2H, J = 8.5 Hz, H-aromatic), 11.91-13.42 
(bs, 1H, COOH).
13C NMR (DMSO-d^. 5: 55.23 (CH3, C-4’, C-5'), 100.40, 104.81, 126.46, 
128.08, 129.73, 130.97 (CH, aromatic and alkene), 129.52 (C, C-l), 138.63 (C, C-4), 
141.95 (C, C-l"), 160.67 (C, C-3", C-5"), 167.03 (C, C -l’).
Experimental 163
4.2.7. 4-[(E)-2-Phenyl-1-ethenyl]benzoic acid (74)(235).
(Mol. Formula: Ci5H 120 2, M. W.: 224.26)
OH
+
Br
Pd(OAc)2/ ToP 1
NEty 125 C
(72) (73)
OH
(74)
A mixture of 4-bromobenzoic acid (73) (2 g, 10 mmol), styrene (72) (1.4 mL,
12.5 mmol), triethylamine (3.5 mL, 25 mmol), Pd(OAc) 2 (0.022 g, 0.1 mmol), and
tri(o-tolyl)phosphine (ToP, 0.122 g, 0.4 mmol) were heated in capped heavy-walled 
glass tubes under nitrogen at 100 °C for 3.5 h. After completion of the reaction as 
judged by the disappearance of one of the reactants by TLC, cold dilute hydrochloric 
acid (1 M, 10 mL) was added to the mixture. The crude solid was filtered and 
recrystallised from ethanol to give 4-[(£)-2-phenyl-l -ethenyljbenzoic acid (74) as 
white crystals. Yield: 1.9 g (85%), t.l.c. system: petroleum ether-EtOAc 1:1 v/v, Rp: 
0 .1 , vanillin stain negative.
Melting point: 251-253 °C (lit. m.p. 254-255 °C )(235).
*H-NMR (DM SO-da 5: 7.28-7.34 (m, 3H, Ha, Hb, H-aromatic), 7.36-7.42 (m, 
4H, H-aromatic), 7.72 (d, 2H, J = 8.4 Hz, H-aromatic), 7.95 (d, 2H, J = 6 . 8  Hz, H- 
aromatic), 11.91-13.42 (bs, 1H, COOH).
13C NMR (DMSO-d*). 5: 126.30, 126.44, 126.55, 127.35, 129.43, 130.25 (CH, 
aromatic, and alkene), 128.47 (C, C-3'), 128.98 (C, C -l”), 136.56 (C, C-4), 141.37 (C, 
C-l), 167.07 (C, C-l').
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4.2.8. A/-(2-Hydroxy-2-phenylethyl)-4-[(£)-2-(3,5-dimethoxyphenyl)-1-
ethenyljbenzam ide (75).
(Mol. Formula: C 2 5 H 2 5 N O 4 ,  M. W.: 403.47)
4'"
CH3
OH
H3C
(75)
CH3 ‘OH
1) 1,1'-cart>onyldHmidazole, rt. 1h
, rt, overnight
HjC
(71)
To a suspension of 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoic acid 
(71) (0.6 g, 2.11 mmol) in anhydrous DMF (20 mL) was added 1,1'- 
carbonyldiimidazole (0.34 g, 2.11 mmol) and the reaction stirred at room temperature 
for 1 h. The reaction was then cooled to 0 °C and subsequently combined with a 
solution of 2-amino-1-phenylethanol (0.29 g, 2.11 mmol), in DMF (5 mL). The 
mixture was stirred at room temperature overnight. After the reaction was complete, 
ice was added into the flask to precipitate out the product which was then filtered and 
washed with ice-cold H2O, dried under vacuum to give pure 7v^-(2-hydroxy-2- 
phenylethyl)-4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzamide (75) as a white 
solid. Yield: 0.8 g (94%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.39, 
vanillin stain positive.
Melting point: 222-224 °C.
Microanalvsis: Calculated for C25H25NO4 (403.47), Theoretical: %C= 74.42, 
%H= 6.25, %N= 3.47, Found: %C= 74.15, %H= 6.21, %N= 3.53.
‘H-NMR (DMSO-dO. S: 3.34-3.53 (m, 2H, CHa), 3.80 (s, 6 H, 2 O-CHj), 4.80-
4.82 (m, 1H, CH-OH), 5.38 (d, 1H, J = 4.1 Hz, OH), 6.45 (s, 1H, H-aromatic), 6.82 (s, 
2H, H-aromatic), 7.25-7.27 (m, 1H, H-aromatic), 7.32-7.40 (m, 6 H, Ha, Hb, H- 
aromatic), 7.68 (d, 2H, J = 8.1 Hz, H-aromatic), 7.87 (d, 2H, J = 8.1 Hz, H-aromatic), 
8.51 (t, 1H, J = 5.2 Hz, NH).
13C NMR (DMSO-dA 5: 47.69 (CH2, C-6 '), 55.21 (CH3, C-4', C-5'), 71.20 
(CH, C-7'), 100.24, 104.81, 126.96, 126.20, 126.99, 127.67, 128.00, 128.05, 130.97 
(CH, aromatic and alkene), 133.31 (C, C-l), 138.79 (C, C-l"), 139.62 (C, C-4), 
143.77 (C, C-l'"), 160.67 (C, C-3", C-5"), 166.00 (C, C-l').
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4.2.9. M-(2-Hydroxy-2-phenylethyl)-4-[(£)-2-phenyM-ethenyl]benzamide 
(76).
(Mol. Formula: C23H21NO0, M. W.: 343.42)
5“
“OH 6" '
1) 1,1‘-carbonyldlimidazole, rt, 1h
OH
, rt, overnight
To a suspension of 4-[(£)-2-phenyl-l-ethenyl]benzoic acid (74) (0.6 g, 2.68 
mmol) in anhydrous DMF (20 mL) was added 1,1 '-carbonyldiimidazole (0.43 g, 2.68 
mmol) and the reaction stirred at room temperature for 1 h. The reaction was then 
cooled to 0 °C and subsequently combined with a solution of 2-amino-1- 
phenylethanol (0.37 g, 2.68 mmol), in DMF (5 mL). The mixture was stirred at room 
temperature overnight. After the reaction was complete, ice was added into the flask 
to precipitate out the product which was then filtered and washed with ice-cold FLO, 
dried under vacuum to give pure Ar-(2-hydroxy-2-phenylethyl)-4-[(FT)-2-phenyl-1 - 
ethenyljbenzamide (76) as a white solid. Yield: 0.8 g (87%), t.l.c. system: petroleum 
ether -  EtOAc 3:1 v/v, Rp: 0.39, vanillin stain positive.
Melting point: 218-219 °C.
Microanalvsis: Calculated for C23H21NO2 (343.42), Theoretical: %C= 80.44, 
%H= 6.16, %N= 4.08, Found: %C= 80.27, %H= 6.21, %N= 3.88.
'H-NMR (DMSO-dA 5: 3.34-3.43 (m, 2H, CH2 ), 3.47-3.51 (m, 1 H, CH-OH), 
5.53 (s, 1H, OH), 7.25-7.42 (m, 10H, H-aromatic and alkene), 7.64 (d, 2H, J = 7.5 Hz, 
H-aromatic), 7.69 (d, 2H, J = 8.0 Hz, H-aromatic), 7.88 (d, 2H, J = 8.0 Hz, H- 
aromatic), 8.52 (s, 1H, NH).
I3C NMR (DMSO-d/d. S: 47.72 (CH2, C-4'), 71.21 (CH, C-5’), 125.96, 126.08, 
126.18, 126.66, 126.99, 127.53, 127.67, 128.01, 128.73, 130.12 (CH, aromatic and 
alkene), 133.26 (C, C-l), 136.75 (C, C-l"), 139.71 (C, C-4), 143.78 (CH, C-l'"),
166.03 (C, C-l').
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4 .2 .1 0 .1-(4-Fluorophenyl)-2-nitro-1 -ethanol (79)(236).
(Mol. Formula: CgHgFNOs, M. W.: 185.15)
F
(77)
H
OH
NO
CH
0* C /24 h F 3
(78) (79)
To a cooled solution (0 °C) of 4-fluorobenzaldehyde (77) (4.25mL, 40.29 
mmol) in MeOH (75 mL) was added nitromethane (78) (4.35 mL, 80.57 mmol) and 
aq. NaOH (1.6 mL of a lOOg/lOOmL solution). The resulting suspension was stirred at 
0 °C for 3.5 h then left in the fridge overnight. The produced orange suspension was 
treated with a solution of AcOH (10 mL, 4.6 mL of AcOH in 10 mL H2O) at 0 °C for 
30 min. The solvent was removed under reduced pressure and the residue dissolved in 
CH2CI2 (100 mL), washed with H2O (75 mL) and brine (75 mL). The organic layer 
was dried (MgS0 4 ) and concentrated to give a brown syrup, which was purified by 
flash column chromatography (petroleum ether -  EtOAc 100:0 v/v increasing to 70:30 
v/v) to give pure l-(4-fluorophenyl)-2-nitro-l-ethanol (79) as dark orange liquid. 
Yield: 6.5 g (87%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v„ Rp: 0.33, vanillin 
stain positive.
*H-NMR (DMSO-d^L 5: 4.58 (dd, 1H, J = 2.8 Hz, 12.5 Hz, Hc), 4.84 (dd, 1H, 
J = 9.5 Hz, 12.5 Hz, Hd), 5.27-5.31 (m, 1H, H-l'), 6.14 (d, 1H, J = 5.0 Hz, OH), 7.18- 
7.23 (m, 2H, H-3, H-5), 7.47-7.51 (m, 2H, H-2, H-4).
13C NMR (DMSO-dA 8 : 69.26 (CH, C-L), 81.72 (CH2, C-2'), 114.99 and 
115.16 (CH, C-3 and C-5), 128.26 and 128.32 (CH, C-2 and C-6 ), 136.61 and 136.63 
(C, C-l), 160.75 and 162.69 (C, C-4).
Experimental \61
4.2.11. 2-Amino-1-(4-fluorophenyl)-1 -ethanol (80)(237)
(Mol. Formula: CsHmFNO. M. W.: 155.17)
OH
NO
Formic acid 50 % v/v,
Raney Ni, H2rt, 24 h
F
(79) (80)
Raney nickel (50 % slurry in H2O, 6  mL), was added to a solution of l-(4- 
fluorophenyl)-2-nitro-l-ethanol (79) (7.0 g, 37.83 mmol) in MeOH (100 mL) and aq. 
HCOOH (50 % v/v, 8  mL). The reaction flask was then degassed and purged with 
hydrogen. The reaction was carried out under 40 psi H2 atmosphere using a Paar 
hydrogenator. The reaction flask was shaken at room temperature for 24 h until all 
starting material had been consumed. After removal of hydrogen the reaction mixture 
was filtered and the solvent removed in vacuo. The aqueous residue was made 
alkaline with NH4 OH (28 %) and extracted with EtOAc (2 x 100 mL). The organic 
layer was then washed with brine (2 x 50 mL), dried (MgS0 4 ), and concentrated 
under reduced pressure. The crude product was then purified by flash column 
chromatography (CLLCh-MeOH-EtaN 100: 0: 0.05 v/v increasing to 95: 5 :0.05 v/v) 
to give pure 2-amino-l-(4-fluorophenyl)-l -ethanol (80) as a yellow solid. Yield: 2.60 
g (47%), t.l.c. system: CH2CI2 -  MeOH 9:1 v/v, RF: 0.08, vanillin stain positive.
Melting point: 59-61 °C (lit. m.p. 60-61 °C )(237).
*H-NMR (DM SO-da 5: 2.63 (dd, 1H, J = 2.8 Hz, 12.5 Hz, Hc), 2.76 (dd, 1H, 
J = 9.5 Hz, 12.5 Hz, Hd), 4.87 (dd, J = 4.5 Hz, 7.3 Hz, 1H, H-l'), 4.65 (t, 2H, J = 6.1 
Hz, NH2), 6.14 (d, 1H, J = 5.0 Hz, OH), 7.10-7.16 (m, 2H, H-3, H-5), 7.34-7.38 (m, 
2H, H-2, H-4).
13C NMR (DMSO-d^). §: 59.41 (CH2, C-2’), 73.20 (CH, C-l'), 114.46 and 114.49 
(CH, C-3 and C-5), 127.70 and 127.71 (CH, C-2 and C-6 ), 140.32 and 140.64 (C, C- 
1), 160.17 and 162.09 (C, C-4).
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4.2.12. M-[2-(4-Fluorophenyl)-2-hydroxyethyl]-4-[(E)-2-(3,5-dimethoxy-
phenyl)-1-ethenyl]benzam ide (81).
(Mol. Formula: C 2 5 H 2 4 F N O 4 ,  M. W.: 421.46)
r .
g...
OH
HjC'
(8 1 )
CHj ‘OH
rt, overnight
HjN,
(71)
To a suspension of 4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]benzoic acid 
(71) (0.6 g, 2.11 mmol) in anhydrous DMF (20 mL) was added 1,1'- 
carbonyldiimidazole (0.34 g, 2.11 mmol) and the reaction stirred at room temperature 
for 1 h. The reaction was then cooled to 0 °C and subsequently combined with a 
solution of 2-amino-l-(4-flourophenyl)ethanol (80) (0.33 g, 2.11 mmol), in DMF (5 
mL). The mixture was stirred at room temperature overnight. After the reaction was 
complete, ice was added into the flask to precipitate out the product which was then 
filtered and washed with ice-cold H2O, dried under vacuum to give pure N-(2- 
hydroxy-2-phenylethyl)-4-[(£)-2-(3,5-dimethoxyphenyl)-1 -ethenyl]benzamide (81) as 
a white solid. Yield: 0.65 g (73%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 
0.38, vanillin stain positive.
Melting point: 202-205 °C.
Microanalvsis: Calculated for C25H24FNO4 (421.46), Theoretical: %C= 71.25, 
%H= 5.74, %N= 3.32, Found: %C= 71.05, %H= 5.77, %N= 3.32.
‘H-NMR (DMSO-dA S: 3.34-3.51 (m, 2H, CH2 ), 3.80 (s, 6 H, 2 O-CHj), 4.80-
4.82 (m, 1H, CH-OH), 5.46 (s, 1H, OH), 6.45 (s, 1H, H-aromatic), 6.82 (d, 2H, J =
1.5 Hz, H-aromatic), 7.61 (t, 2H, J = 8 . 8  Hz, H-aromatic), 7.32 (d, 2H, J = 2.8 Hz, Ha, 
Hb), 7.4124 (t, 2H, J = 6.9 Hz, H-aromatic), 7.68 (d, 2H, J = 8.2 Hz, H-aromatic), 7.86 
(d, 2H, J = 8.2 Hz, H-aromatic), 8.50 (t, 1H, J = 5.2 Hz, NH).
I3C NMR (DMSO-dQ. S: 47.56 (CH2, C-6 ’), 55.21 (CH3, C-4', C-5'), 70.55 
(CH, C-7'), 100.25, 104.69, 114.69, 126.20, 127.66, 127.91, 128.04, 130.17, 138.78 
(CH, aromatic and alkene), 133.27 (C, C-l), 139.63 (C, C-l"), 139.91 (C, C-4),
160.67 (C, C-3", C-5"), 162.23 (C, C-l'), 165.99 (C, C-4'").
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4.2.13. 2-{4-[(E)-2-(3,5-Dimethoxyphenyl)-1 -ethenyl]phenyl-5-phenyl}-4,5-
dihydro-1,3-oxazole (82).
(Mol. Formula: C25H23NO3 , M. W.: 385.46)
CHj
OH
HjC'
CH]
HjC'
(82)
To a suspension of /V-(2-hydroxy-2-phenylethyl)-4-[(£)-2-(3,5-dimethoxy- 
phenyl)-l-ethenyl]benzamide (75) (0.8 g, 2 mmol) in anhydrous THF (15 mL) was 
added methanesulphonic anhydride (0.52 g, 3 mmol) dissolved in anhydrous THF (5 
mL). The mixture was stirred at 0 °C for 15 min, then NEt3 (0.84 mL, 6  mmol) was 
added dropwise to the mixture, which results in a homogenous solution. The 
homogenous solution was kept in the fridge at 0 °C for 24 h. The mixture was 
quenched by the addition of aqueous NH3 solution (28%, 1 mL). After stirring at 
room temperature for 15 min, the mixture was concentrated in vacuo and finally 
distributed between EtOAc (150 mL) and aqueous NaHC0 3  solution (2 x 100 mL). 
The organic phase was dried (MgS0 4 ), concentrated under reduced pressure and the 
crude product purified by flash column chromatography (petroleum ether -  EtOAc 
100:0 v/v increasing to 70:30 v/v) to give pure 2-4-[(ET)-2-(3,5-dimethoxyphenyl)-l- 
ethenyl]phenyl-5-phenyl-4,5-dihydro-1,3-oxazole (82) as a yellow oily product. 
Yield: 0.8 g (100%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.31, vanillin 
stain positive.
HRMS (ED: Calculated mass: 386.1751 [M+H]+, Measured mass: 386.1753 
[M+H]+.
'H-NMR (CDCM. S: 3.86 (s, 6 H, 2 O-CHj), 4.03 (dd, 1H, J = 8.0 Hz, 14.8 Hz, 
Hc), 4.51 (dd, 1H, J = 10.2 Hz, 14.8 Hz, Hd), 5.69 (t, 1H , J = 9.1 Hz, O-CH), 6.45 (s, 
1H, H-aromatic), 6.72 (d, 2H, J = 2.0 Hz, H-aromatic). 7.14 (d, 2H, J = 3.9 Hz, Ha, 
Hb), 7.36-7.43 (m, 5H, H-aromatic), 7.59 (d, 2H, J = 8.3 Hz, H-aromatic), 8.03 (d, 2 H, 
J = 8.2 Hz, H-aromatic).
13C NMR (CDCH). S: 55.40 (CH3, C-4’, C-5'), 63.16 (CH2, C-6 ’), 81.11 (CH,
Experimental 170
C-7'), 100.49, 104.81, 125.76, 126.35, 127.53, 128.33, 128.57, 128.73, 130.79 (CH, 
aromatic and alkene), 126.51 (C, C-l), 138.93 (C, C-l'"), 140.26 (C, C-4), 141.02 (C, 
C-l"), 161.05 (C, C-3", C-5"), 163.88 (C, C-l').
4.2.14. 5-Phenyl-2-{4-[(E)-2-phenyl-1 -ethenyl]phenyl}-4,5-dihydro-1,3-
oxazole (83).
(Mol. Formula: C23H 19NO, M. W.: 325.40)
N E t,.0’c, 24hOH
4"'
(83)
To a suspension of iV-(2-hydroxy-2-phenylethyl)-4-[(£)-2-phenyl-l- 
ethenyljbenzamide (76) (0.65 g, 1.9 mmol) in anhydrous THF (15 mL) was added 
methanesulphonic anhydride (0.5 g, 2.8 mmol) dissolved in anhydrous THF (5 mL). 
The mixture was stirred at 0 °C for 15 min, then NEt3 (0.8 mL, 5.7 mmol) was added 
dropwise to the mixture, which results in a homogenous solution. The homogenous 
solution was kept in the fridge at 0 °C for 24 h. The mixture was quenched by the 
addition of aqueous NH3 solution (28%, 1 mL). After stirring at room temperature for 
15 min, the mixture was concentrated in vacuo and finally distributed between EtOAc 
(150 mL) and aqueous NaHC0 3  solution (2 x 100 mL). The organic phase was then 
dried (MgSO^ and concentrated under reduced pressure. The crude product was then 
recrystallised from ethanol to give pure 5-phenyl-2 - {4-[(£)-2 -phenyl-l-
ethenyl]phenyl}-4,5-dihydro-1,3-oxazole (83) as white crystals. Yield: 0.6 g (97%), 
t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.57, vanillin stain positive.
Melting point: 126-127 °C.
Microanalysis: Calculated for C23H 19NO (325.40), Theoretical: %C= 84.89, 
%H= 5.88, %N= 4.30, Found: %C= 84.70, %H= 5.94, %N= 4.11.
‘H-NMR (DMSO-dkl. 5: 3.88 (dd, 1 H, J = 7.5 Hz, 14.9 Hz, Hc), 4.48 (dd, 1 H, 
J = 10.1 Hz, 14.9 Hz, Hd), 5.80 (dd, 1H , J = 7.7 Hz, 9.9 Hz, O-CH), 7.46-7.33 (m, 
10H, H-aromatic and alkene), 7.67 (d, 2H, J = 7.5 Hz, H-aromatic), 7.76 (d, 2H, J =
8.3 Hz, H-aromatic), 7.97 (d, 2H, J = 8.3 Hz, H-aromatic).
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13C N M R  (D M S O -d A  5 : 62.60 (C H 2, C-4'), 80.10 (CH, C-5'), 125.60, 126.60,
126.70, 127.50, 128.05, 128.10, 128.20, 128.70, 130.40 (CH, arom atic and alkene), 
126.20 (C, C - l) , 136.70 (C, C -l"), 140.10 (C , C -l '" ) , 141.30 (C, C-4), 162.20 (C, C- 
! ' ) •
4.2.15. 2-{4-[(E)-2-(3,5-Dimethoxyphenyl)-1 -ethenyl]phenyl}-5-(4-fluoro-
phenyl)-4,5-dihydro-1,3-oxazole (84).
(M ol. Form ula : C 25H 22FN O 3 , M. W .: 403.45)
To a suspension o f  A ^-(2-hydroxy-2-phenylethyl)-4-[(£)-2-(3,5-dim ethoxy- 
pheny l)-l-e theny l]benzam ide (81) (0.63 g, 1.5 m m ol) in  anhydrous TH F (15 m L) was 
added m ethanesulphonic anhydride (0.39 g, 2.25 m m ol) d isso lved  in anhydrous TH F 
(5 m L). The m ixture w as stirred at 0 °C for 15 m in, th en  N E t3 (0.63 m L, 4.5 m m ol) 
w as added dropw ise to  the m ixture, w hich results in  a  hom ogenous solution. The 
hom ogenous solution w as kept in the fridge at 0 °C for 24 h. The m ixture w as 
quenched by the addition o f  aqueous N H 3 so lu tion  (28% , 1 m L). A fter stirring at 
room  tem perature for 15 m in, the m ixture w as concen trated  in vacuo  and finally 
d istributed betw een EtO A c (150 m L) and aqueous N a H C 0 3  so lution (2 x 100 mL). 
The organic phase w as then  dried (M gS 0 4 ) and concen trated  under reduced pressure. 
T he crude product w as then purified by flash co lum n chrom atography (petroleum  
ether -  E tO A c 100:0 v/v increasing to 70:30 v/v) to  give pure 2-4-[(£)-2-(3 ,5- 
d im ethoxyphenyl)-l-e theny l]pheny l-5 -(4 -fluorophenyl)-4 ,5 -d ihydro-l,3 -oxazo le  (84) 
as a yellow  oily product. Yield: 0.6 g (98% ), t.l.c . system : petroleum  ether -  EtO A c 
3:1 v/v, Rp: 0.25, vanillin  stain positive.
H RM S (El): C alculated mass: 404 .1656 [M +H ]+, M easured m ass: 404.1652 
[M +H ]+.
‘H -N M R  ('CDCl-,1. 8 : 3.86 (s, 6 H, 2 O -C H j), 4 .00 (dd, 1H, J = 7.9 H z, 14.8 Hz,
Methansulphonic anhydride
N
(81) (84)
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Hc), 4.50 (dd, 1H, J = 10.1 Hz, 14.9 Hz, Hd), 5.66 (t, 1H , J = 9.0 Hz, O-CH), 6.45 (t, 
1H, J = 2.2 Hz, H-aromatic), 6.71 (d, 2H, J = 2.2 Hz, H-aromatic), 7.08-7.11 (m, 2H, 
H-aromatic), 7.14 (d, 2H, J = 4.4 Hz, Ha, Hb), 7.34-7.7.37 (m, 2H, H-aromatic), 7.59 
(d, 2H, J = 8.4 Hz, H-aromatic), 8.01 (d, 2H, J = 8.4 Hz, H-aromatic).
13C NMR (CDC1-0. 8 : 55.39 (CH3, C-4', C-5'), 63.22 (CH2, C-6 ’), 80.45 (CH, 
C-7’), 100.49, 104.82, 115.77, 126.51, 128.25, 128.69, 128.69, 130.58, 138.90 (CH, 
aromatic and alkene), 136.85 (C, C-l), 140.31 (C, C-4), 161.06 (C, C-3", C-5"),
161.68 (C, C-l"), 163.88 (C, C-l'), 163.73 (C, C-4'").
4.2.16. A/-[2-(1H-1-lmidazolyl)-2-phenylethyl]-4-[(£)-2-(3,5-dimethoxy- 
phenyl)-1-ethenyl]benzam ide (85).
(Mol. Formula: C28H27N3O3 , M. W.: 453.53)
CHj
Imidazole
12S *C, 24 h
HjCHjC'
(82) (88 )
A mixture of 2-4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]phenyl-5-phenyl-
4,5-dihydro-1,3-oxazole (82) (0.6 g, 1.56 mmol) and imidazole ( 4.2 g, 62.26 mmol) 
dissolved in isopropyl acetate (10 mL) was heated at 125 °C for 24 h. After 
completion of the reaction, the mixture was partitioned between H2 O (100 mL) and 
EtOAc (150 mL). The organic layer was washed with H2O (3 x 100 mL), dried 
(MgS0 4 ) and concentrated under reduced pressure. The residue was recrystallised 
from aqueous EtOH to give yellow crystals of A-[2-(l//-l-imidazolyl)-2- 
phenylethyl]-4-[(£)-2-(3,5-dimethoxy- phenyl)-1-ethenyljbenzamide (85). Yield: 0.48 
g (6 8 %), t.l.c. system: CH2CI2 -  MeOH 90:10 v/v, Rp: 0.77, vanillin stain positive.
Melting point: 216-218 °C.
HRMS (El): Calculated mass: 454.2125 [M+H]+, Measured mass: 454.2120 
[M+H]+.
'H-NMR (DMSO-da. S: 3.79 (s, 6 H, 2 O-CHj), 3.97-4.02 (m, 1H, Hc), 4.07- 
4.17 (m, 1H, Hd), 5.68-5.70 (m, 1H, CH2-CH-Ar), 6.45 (t, 1H, J = 2.2 Hz, H- 
aromatic), 6.82 (d, 2H, J = 2.2 Hz, H-aromatic), 6.91 (s, 1H, H-aromatic), 7.31 (d, 2H,
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J = 3.4 Hz, Ha, Hb), 7.32-7.34 (m, 2H, H-aromatic), 7.38-7.40 (m, 4H, H-aromatic),
7.67 (d, 2H, J = 8.4 Hz, H-aromatic), 7.78 (d, 2H, J = 8.4 Hz, H-aromatic), 8.84 (s, 
1H, H-aromatic), 8.74 (t, 1H, J = 5.5 Hz, NH).
I3C NMR (DM SO-da S: 43.46 (CH2, C-6 '), 55.21 (CH3, C-4', C-5'), 59.43 
(CH, C-7'), 100.31, 104.69, 118.34, 126.24, 126.81, 127.63, 127.97, 128.04, 128.49,
128.70, 130.32, 136.75 (CH, aromatic and alkene), 132.81 (C, C-l), 138.73 (C, C-l"), 
139.31 (C, C-4), 139.88 (C, C -l”'), 160.66 (C, C-3", C-5"), 166.26 (C, C-l').
4.2.17. A/-[2-(1 H-1 -lmidazolyl)-2-phenylethyl]-4-[(E)-2-phenyl-1 -ethenyl]
benzam ide (86).
(Mol. Formula: C26H23N3O, M. W.: 393.48)
Imidazole
125 *C, 24 h
(83)
6 ” '
4
(86)
A mixture of 5-phenyl-2-{4-[(£)-2-phenyl-l-ethenyl]phenyl}-4,5-dihydro-1,3- 
oxazole (83) (0.34 g, 1.04 mmol) and imidazole (1.42 g, 20.90 mmol) dissolved in 
isopropyl acetate (10 mL) was heated at 125 °C for 24 h. After completion of the 
reaction, the mixture was partitioned between H2O (100 mL) and EtOAc (150 mL). 
The organic layer was washed with H2O (3 x 100 mL), dried (MgS0 4 ) and 
concentrated under reduced pressure. The residue was then purified by flash column 
chromatography (CH2CI2 -  MeOH 99:1 v/v increasing to 97:3 v/v) to give N-[2-(lH- 
l-imidazolyl)-2-phenylethyl]-4-[(is)-2-phenyl-l-ethenyl]benzamide (8 6 ). Yield: 0.2 g 
(47%), t.l.c. system: CH2CI2 -  MeOH 90:10 v/v, Rp: 0.77, vanillin stain positive.
Melting point: 190-192 °C.
Microanalysis: Calculated for C26H23N3O (393.48), Theoretical: %C= 79.36, 
%H= 5.89. %N= 10.67, Found: %C= 79.10, %H= 5.80, %N= 10.43.
'H-NMR (DMSO-dA S: 3.97-4.02 (m, 1H, Hc), 4.07-4.17 (m, 1H, Hd), 5.73 
(dd, 1H, J = 5.8 Hz, 8.7 Hz, CH2-CH-Ar), 6.96 (s, 1H, imidazole), 7.32-7.43 (m, 11H, 
H-aromatic and akene), 7.66 (d, 2H, J = 7.4 Hz, H-aromatic), 7.71 (d, 2H, J = 8.0 Hz, 
H-aromatic), 7.81 (d, 2H, J = 8.0 Hz, H-aromatic), 7.89 (s, 1H, imidazole), 8.77 (s,
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1H, NH).
13C NMR (DMSO-dA 5: 43.46 (CH2, C-4'), 59.43 (CH, C-5’), 126.20, 126.70, 
126.80, 127.40, 127.60, 128.00, 128.10, 128.50, 128.70, 128.73, 130.30 (CH, 
aromatic and alkene), 132.81 (C, C-l), 136.73 (C, C-l"), 139.31 (C, C-4), 140.00 
(CH, C-l'"), 166.30 (C, C-l').
4.2.18. W-[2-(4-Fluorophenyl)-2-(1H-1-imidazolyl)ethyl]-4-[(E)-2-(3,5-di-
methoxyphenyl)-1 -ethenyljbenzam ide (87).
(Mol. Formula: C28H26FN3O3 , M. W.: 471.52)
CHj 6" ’
125'C, 24 h
HjC'HjC'
(84) (87)
A mixture of 2-4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyl]phenyl-5-(4- 
fluorophenyl)-4,5-dihydro-l,3-oxazole (84) (0.6 g, 1.5 mmol) and imidazole ( 4 g,
59.4 mmol) dissolved in isopropyl acetate (10 mL) was heated at 125 °C for 24 h. 
After completion of the reaction, the mixture was partitioned between H2O (100 mL) 
and EtOAc (150 mL). The organic layer was washed with H2O (3 x 100 mL), dried 
(MgS0 4 ) and concentrated under reduced pressure. The residue was recrystallised 
from aqueous EtOH to give yellow crystals of A-[2-(4-fluorophenyl)-2-(177-l- 
imidazolyl)ethyl]-4-[(£)-2-(3,5-dimethoxyphenyl)-l-ethenyljbenzamide (87). Yield: 
0.25 g (35%), t.l.c. system: CH2CI2 -  MeOH 90:10 v/v, Rp: 0.77, vanillin stain 
positive.
Melting point: 193-196 °C.
HRMS (El): Calculated mass: 472.2031 [M+H]+, Measured mass: 472.2026 
[M+H]+.
'H-NMR (CDCUI. S: 3.84 (s, 6 H, 2 O-CHj), 3.86-3.90 (m, 1H, Hc), 4.32-4.36 
(m, 1H, Hd), 5.63-5.66 (m, 1H, CH2-CH-Ar), 6.44 (t, 1H, J = 2.2 Hz, H-aromatic),
6 . 6 8  (d, 2H, J = 2.3 Hz, H-aromatic), 7.00 (s, 1H, H-aromatic), 7.07-7.12 (m, 5H, Ha, 
Hb, H-aromatic), 7.24-7.27 (m, 2H, H-aromatic), 7.29 (t, 1H, J = 5.5 Hz, NH), 7.50 (d,
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2H, J = 8.4 Hz, H-aromatic), 7.54 (s, 1H, H-aromatic), 7.72 (d, 2H, J = 8.4 Hz, H- 
aromatic).
I3C NMR fCDCUI. 8 : 44.56 (CH2, C-6 '), 55.39 (CH3, C-4’, C-5'), 59.69 (CH, 
C-7’), 100.57, 104.85, 116.14, 118.32, 126.59, 127.56, 127.83, 128.45, 129.6, 130.99, 
132.39 (CH, aromatic and alkene), 132.39 (C, C-l), 133.47 (C, C-l"), 138.70 (C, C-
4), 140.75 (C, C-l"'), 161.06 (C, C-3", C-5"), 163.66 (C, C-l'), 167.75 (C, C-4"’).
4.2.19. 6-Methoxy-2-{1 -[2-(trifluorom ethyl)phenyl]m ethylidene}-1,2,3,4- 
tetrahydro-1-naphthalenone (90).
(Mol. Formula: C ^ H ^ C b , M. W.: 334.33)
h3c .
(88)
H 4% KOH/EtOH+
h3c .
(89) (90)
A mixture of the 6 -methoxytetralone (8 8 ) (2.0 g, 11 mmol) and 2- 
(trifluoromethyl)benzaldehyde (89) (1.45 mL, 11 mmol) in 4 % ethanolic KOH (100 
mL) was stirred at room temperature for 1 h. The resulting precipitate was collected, 
washed with water and finally recrystallised from EtOH to give 6-methoxy-2-{l-[2- 
(trifluoromethyl)phenyl]methylidene}-l,2,3,4-tetrahydro-l-naphthalenone (90) as a 
cream crystalline solid. Yield: 2.48 g ( 6 8  %), t.l.c. system: petroleum ether -  EtOAc 
3:1 v/v, Rp: 0.54, vanillin stain positive.
Melting point: 81-83 °C.
Microanalysis: Calculated for C19H 15F3O2 (334.33): Theoretical: %C= 68.67, 
%H= 4.59, Found: %C= 68.24, %H= 4.55.
'H-NMR (CDChl. S: 2.83-2.87 (m, 2H, CHj-C-CO), 2.90-2.93 (m, 2H, Ar- 
CHj- CH2), 3.89 (s, 3H, OCH3), 6.72 (d, 1H, J = 2.4 Hz, H-aromatic), 6.91 (dd, 1H, J 
= 2.5 Hz, 8 . 8  Hz, H-aromatic), 7.34 (d, 1H, J = 7.6 Hz, H-aromatic), 7.47 (t, 1H, J =
7.7 Hz, H-aromatic), 7.58 (t, 1H, J = 7.6 Hz, H-aromatic), 7.75 (d, 1H, J = 7.9 Hz, H- 
aromatic), 7.96 (s, 1H, -C=CH-Ph), 8.17 (d, 1H, J = 8 . 8  Hz, H-aromatic).
13C NMR tCDCht. S: 27.4 (CH2, C-3), 29.5 (CH2, C-4), 55.5 (CH3, C-4’),
112.4, 113.5. 126.1, 127.9, 130.4, 130.9, 131.5 (CH, aromatic), 122.9, 129.1, 129.34 
(C, C-F), 125.0 (C, C-2"), 126.8 (C, C-8 a), 132.3 (CH, C -l’), 135.2 (C, C-l"), 138.2
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(C, C-2), 146.0 (C, C-4a), 163.8 (C, C-6 ), 189.2 (C, C-l).
4.2.20. 6-Methoxy-2-[2-(trifluoromethyl)benzyl]-1,2,3,4-tetrahydro-1 -
naph thalenone (91).
(Mol. Formula: C 19H 17F3O2 , M. W.: 334.337)
c f3
h 3c .
(90) (91)
To a suspension of 5% Pd-C (10 mol %) in MeOH (100 mL) was added, under 
nitrogen, a solution of 6 -methoxy-2 -(£)-l-[2 -(trifluoromethyl)phenyl]methylidene-
1.2.3.4-tetrahydro-l-naphthalenone (90) (2.0 g, 6  mmol) in MeOH (20 mL). Then, the 
reaction atmosphere was changed to hydrogen and the reaction mixture stirred at 
room temperature. After a period of 1 h, the suspension was filtered over a pad of 
celite and the solvent removed under reduced pressure to give a yellow residue. The 
residue was purified by flash column chromatography (petroleum ether -  EtOAc 
100:0 increasing to 90:10 v/v) to give 6-methoxy-2-[2-(trifluoromethyl)benzyl]-
1.2.3.4-tetrahydro-l-naphthalenone (91) as a cream crystalline solid. Yield: 1.03 g (53 
%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.60, vanillin stain positive.
Melting point: 82-84 °C.
Microanalvsis: Calculated for C 19H 17F3O2 (334.33): Theoretical: %C= 68.26, 
%H= 5.12, Found: %C= 68.03, %H= 5.13.
'H-NMR (CDCh). S: 1.84-1.87 (m, 1H, Ha), 2.05-2.07 (m, 1H, Hb), 2.81-2.83 
(m, 2H, CO-CH-CHj-Ar), 2.91-2.95 (m, 2H, Hc, Hd), 3.80 (m, 1H, CO-CH-CH2 -Ar)
3.88 (s, 3H, O-CHi), 6.69 (d, 1H, J = 2.4 Hz, H-aromatic), 6.87 (dd, 1H, J = 2.5 Hz,
8 . 8  Hz, H-aromatic), 7.34 (t, 1H, J = 7.6 Hz, H-aromatic), 7.42 (d, 1H, J = 7.7 Hz, H- 
aromatic), 7.51 (t, 1H, J = 7.6 Hz, H-aromatic), 7.68 (d, 1H, J = 7.9 Hz, H-aromatic),
8.08 (d, 1H, J = 8 . 8  Hz, H-aromatic).
13C NMR (CDC1A 8 : 28.2 (CH2, C-4), 29.4 (CH2, C-3), 32.3 (CH2, C -l’), 49.0 
(CH, C-2), 55.4 (CH3, C-4'), 112.4, 113.2, 126.15, 126.2, 130.0, 131.6, 131.7 (CH, 
aromatic), 123.5, 125.7, 129.1, 129.3 (C, C-F), 126.1 (C, C-8 a), 136.1 (C, C-2"), 139.3 
(C, C -l”), 146.4 (C, C-4a), 163.5 (C, C-6 ), 197.6 (C, C-l).
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4.2.21. 2-[1 -(2-Ethylphenyl)m ethylidene]-6-m ethoxy-1,2,3,4-tetrahydro-1 -
naphthalenone (93).
(Mol. Formula: C20H20O2 , M. W .: 292.37)
3'
.ch3
H 4% KOH/EtOH+
(92) (93)(88)
A mixture of the 6 -methoxytetralone (88) (2.0 g, 11 mmol) and 2-ethyl 
benzaldehyde (92) (1.5 mL, 11 mmol) in 4 % ethanolic KOH (100 mL) was stirred at 
room temperature for 1 h. The resulting precipitate was collected, washed with water 
and finally recrystallised from EtOH to give 2-[l-(2-ethylphenyl)methylidene]-6- 
methoxy-1,2,3,4-tetrahydro-l-naphthalenone (93) as a light yellow crystals. Yield:
2.33 g (72 %), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.74, vanillin stain 
positive.
Melting point: 77-80 °C.
Microanalysis: Calculated for C20H20O2 (292.37): Theoretical: %C= 82.16, 
%H= 6.89, Found: %C= 82.25, %H= 7.15.
'H-NMR iCDCh). S: 1.21 (t, 3H, J = 7.6 Hz, Cft-CRb), 2.72 (q, 2H, J = 7.6 
Hz, 21.4 Hz, CH2 CH3), 2.89-2.91 (m, 2H, CHj-C-CO), 2.95-2.98 (m, 2H, Ar-CHj- 
CH2), 3.90 (s, 3H, OCH3), 6.73 (d, 1H, J = 2.4 Hz, H-aromatic), 6.91 (dd, 1H, J = 2.5 
Hz, 8 . 8  Hz, H-aromatic), 7.28-7.34 (m, 4H, H-aromatic), 7.97 (s, 1H, -C=CH-Ph), 
8.18 (d, 1H, J = 8 . 8  Hz, H-aromatic).
I3C NMR (CDCh). S: 15.1 (CH3, C-3’), 26.7 (CH2, C-2'), 27.3 (CH2, C-3), 
29.7 (CH2, C-4), 55.5 (CH3, C-4'), 112.4, 113.4, 125.5, 127.1, 128.5, 129.1, 130.8 
(CH, aromatic), 125.6 (C, C-8 a), 134.6 (C, C-2), 135.0 (CH, C-l'), 136.4 (C, C-2"),
143.8 (C, C-4a), 146.0 (C, C-l"), 163.6 (C, C-6 ), 186.8 (C, C-l).
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4.2.22. 2-(2-Ethylbenzyl)-6-m ethoxy-1,2,3,4-tetra hydro-1 -naphthalenone 
(94).
(Mol. Formula: C20H22O2 , M. W.: 294.39)
c h 3 c h3
h 3c .
(93) (94)
To a suspension of 5% Pd-C (10 mol %) in MeOH (100 mL) was added, under 
nitrogen, a solution of 2-[l-(2-ethylphenyl)methylidene]-6-methoxy-l,2,3,4- 
tetrahydro-1-naphthalenone (93) (2.0 g, 6.85 mmol) in MeOH (20 mL). Then, the 
reaction atmosphere was changed to hydrogen and the reaction mixture stirred at 
room temperature. After a period of 1 h, the suspension was filtered over a pad of 
celite and the solvent removed under reduced pressure to give a yellow residue. The 
residue was purified by flash column chromatography (petroleum ether -  EtOAc 
100:0 increasing to 90:10 v/v) to give 2-(2-ethylbenzyl)-6-methoxy-l,2,3,4- 
tetrahydro-1-naphthalenone (94) as a dark orange syrup. Yield: 1.49 g (64 %), t.l.c. 
system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.71, vanillin stain positive.
HRMS (El): Calculated mass: 295.1693 [M+H]+, Measured mass: 295.1695 
[M+H]+.
}H-NMR fCDCM. 5: 1.27 (t, 3H, J = 7.6 Hz, CH2CH3 ), 1.84-1.87 (m, 1H, Ha), 
2.09-2.12 (m, 1H, Hb), 2.55 (dd, 1H, J = 10.5 Hz, 14.2 Hz, CO-CH-CH2-Ar), 2.61- 
2.72 (m, 4H, CH2CH3 , CO-CH-CH^-Ar), 2.91-2.95 (m, 2H, Hc, Hd), 3.88 (s, 3H, O- 
CH3 ), 6.70 (d, 1H, J = 2.4 Hz, H-aromatic), 6.87 (dd, 1H, J = 2.5 Hz, 8 . 8  Hz, H- 
aromatic), 7.29-7.12 (m, 4H, Ar), 8.09 (d, 1H, J = 8 . 8  Hz, H-aromatic).
13C NMR (CDChX 5: 15.4 (CH3, C-3'), 25.5 (CH2, C-2’), 28.0 (CH2, C-4),
29.3 (CH2, C-3), 33.7 (CH2, C-l'), 48.7 (CH, C-2), 55.4 (CH3, C-4’), 112.5, 113.2, 
126.2, 126.4, 128.6, 130.0, 130.2 (CH, aromatic), 125.6 (C, C-8 a), 137.8 (C, C-2"), 
142.5 (C, C-l"), 146.5 (C, C-4a), 163.5 (C, C-6 ), 198.2 (C, C-l).
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4.2.23. 2-[1 -(2-Brom ophenyl)m ethylidene]-6-m ethoxy-1,2,3,4-tetrahydro-
1-naph thalenone (96 )(224).
(Mol. Formula: C l8Hi5Br0 2 , M. W.: 343.21)
(88 )
H 4% KOH/EtOH
rt, 2 h
(95)
A mixture of the 6 -methoxytetralone (8 8 ) (2.0 g, 11 mmol) and 2-bromo 
benzaldehyde (95) (1.3 mL, 11 mmol) in 4 % ethanolic KOH (100 mL) was stirred at 
room temperature for 2 h. The resulting precipitate was collected, washed with water 
and finally recrystallised from EtOH to give 2-[l-(2-bromophenyl)methylidene]-6- 
methoxy-1,2,3,4-tetrahydro-l-naphthalenone (96) as a light yellow crystals. Yield:
2.61 g (76 %), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.62, vanillin stain 
positive.
Melting point: 77-80 ‘C (lit. m.p. 78-80 °C )<224).
‘H-NMR (CDCh). S: 2.89-2.91 (m, 2H, CHj-C-CO), 2.95-2.98 (m, 2H, Ar- 
CHj- CH2), 3.92 (s. 3H, OCHj), 6.75 (d, 1H, J = 2.4 Hz, H-aromatic), 6.93 (dd, 1 H, J 
= 2.5 Hz, 8 . 8  Hz, H-aromatic), 7.26-7.28 (m, 1H, H-aromatic), 7.35-7.37 (m, 2H, H- 
aromatic), 7.69 (d, 1H, J = 7.9 Hz, H-aromatic), 7.85 (s, 1H, -C=CH-Ph), 8.19 (d, 1H, 
J = 8 . 8  Hz, H-aromatic).
I3C NMR tCDCh). 5: 27.8 (CH2, C-4), 29.9 (CH2, C-3), 55.9 (CH3, C-4'), 
112.8, 113.9, 127.4, 130.2, 130.9, 131.23, 133.3 (CH, aromatic), 125.3 (C, C-2"),
127.3 (C, C-8 a), 135.4 (CH, C-l'), 136.9 (C, C-l"), 137.5 (C, C-2), 146.0 (C, C-4a), 
164.2 (C, C-6 ), 186.9 (C, C-l).
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4.2.24. 6-Methoxy-2-(1 -{2-[(E)-2-phenyl-1 -ethenyl]phenyl}m ethylidene)-
1,2,3,4-tetrahydro-1 -naphthalenone (98).
(Mol. Formula: C26H22O2 , M. W.: 366.45)
OH
HO-
♦
HjC.
(96) (97)
2M aqueous Na2CC>3 (8.50 mL) was added to a solution of 2-[l-(2- 
bromophenyl)methylidene]-6-methoxy-1,2,3,4-tetrahydro-l -naphthalenone (96) (1.0 
g, 2.42 mmol) in toluene (20 mL). To the mixture Pd(PPh3)4 (0.14 g, 0.12 mmol), and 
then rnms--2-phenylvinylboronic acid (97) (0.72 g, 4.84 mmol) in ethanol (5 mL) were 
added. The reaction mixture was refluxed at 90 °C for 5 h. After the reaction was 
complete, the residual borane was oxidized by the addition of H2O2 (30 %, 2.5 mL) at 
room temperature for 1 h. The crude product was extracted with CH2CI2 (100 mL) and 
H2O (3 x 100 mL). The organic layer was dried with MgSCL and reduced in vacuo to 
give a light yellow oily residue which was purified by flash column chromatography 
(petroleum ether -  EtOAc 100:0 v/v increasing to 90:10 v/v) to give 6-methoxy-2-(l- 
{2-[(£)-2-phenyl-l-ethenyl]phenyl}methylidene)-1,2,3,4-tetrahydro-l-naphthalenone 
(98) as a light brown solid which was recrystallised with EtOH. Yield: 0.45 g (51 %), 
t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.68, vanillin stain positive.
Melting point: 120-122 °C.
Microanalvsis: C26H22O2 . O.2 H2O (370.062): Theoretical: %C= 84.39, %H= 
6.10, Found: %C= 84.57, %H= 6.49, N.b. this compound is very hygroscopic, and this 
microanalysis is the best one obtained after five days drying in the oven.
*H-NMR (CDCLL §: 2.93-2.98 (m, 4H, Ha, Hb, Hc and Hd), 3.89 (s, 3H, O-CH3), 6.72 
(d, 1H, J = 2.5 Hz, H-aromatic), 6.92 (dd, 1H, J = 2.5 Hz, 8.7 Hz, H-aromatic), 7.08 
(d. 1H, J = 16.1 Hz, Hg), 7.11 (d, 1H, J = 16.1 Hz, Hh), 7.26-7.41 (m, 8 H, H- 
aromatic), 7.51 (d, 1H, J = 7.3 Hz, H-aromatic), 7.76 (d, 1H, J = 7.8 Hz, H-aromatic),
8.06 (s, 1H, -C=CH-Ph). 8.20 (d, 1H, J = 8.7 Hz, H-aromatic).
13C NMR (CDChl. S: 27. 51 (CH2, C-3), 29.62 (CH2, C-4), 55.54 (CH3, C-4’),
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112.40, 113.50, 125.7, 126.33, 126.76, 126.98, 127.92, 128.46, 128.73, 129.60, 
130.81, 130.92, 134.72 (CH, aromatic and alkene), 127.12 (C, C-8a), 134.80 (C, C-2),
136.88 (C. C-l"'), 137.22 (C, C-4a), 137.25 (C, C-l"), 146.14 (C, C-2"), 163.70 (C, C- 
6). 186.75 (C, C-l).
4.2.25. 6-M ethoxy-2-(2-phenethylbenzyl)-1,2,3,4-tetrahydro-1 -naph thalen­
one (99).
fMol. Formula: C26H26O2 , M. W.: 370.48)
H jC HjC.
(98) (99)
To a suspension of 5% Pd-C (10 mol %) in MeOH (100 mL) was added, under 
nitrogen, a solution of 6-methoxy-2-(l-{2-[(is)-2-phenyl-l-ethenyl]phenyl} 
methylidene)-1,2,3,4-tetrahydro-l-naphthalenone (98) (0.5 g, 1.36 mmol) in MeOH 
(20 mL). Then, the reaction atmosphere was changed to hydrogen and the reaction 
mixture stirred at room temperature. After a period of 1 h, the suspension was filtered 
over a pad of celite and the solvent removed under reduced pressure to give a yellow 
residue. The residue was purified by flash column chromatography (petroleum ether -  
EtOAc 100:0 increasing to 90:10 v/v) to give 6-methoxy-2-(2-phenethylbenzyl)-
1,2,3,4-tetrahydro-l-naphthalenone (99) as a pale orange waxy solid. Yield: 0.32 g 
(72 %), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.69, vanillin stain 
positive.
HRMS (EI): Calculated mass: 371.2006 [M+H]+, Measured mass: 371.2004 
[M+H]+.
*H-NMR (CDC10, 5: 1.80-1.87 (m, 1H, Ha), 2.13-2.08 (m, 1H, Hb), 2.53-2.65 
(m. 2H, Ph-CH2-CH2-Ph-CHeHf), 2.83-3.05 (m, 6H, Cj^-Ph-CHeHf, Hc, Hd), 3.69 
(dd, 1H, J = 3.0 Hz, 13.6 Hz, CO-CH-CH2-Ar), 3.88 (s, 3H, O-CH3), 6.70 (d, 1H. J =
2.3 Hz, H-aromatic), 6 . 8 8  (dd, 1H, J = 2.3 Hz, 8 . 8  Hz, H-aromatic), 7.20-7.31 (m, 9H, 
H-aromatic), 8.20 (d, 1H, J = 8 . 8  Hz, H-aromatic).
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13C NMR (CDC1A. 5: 28. 07 (CH2, C-4), 29.26 (CH2, C-3), 32.39 (CH2, C-l'), 
34.83 (CH2, C-2’), 37.74 (CH2, C-3'), 48.80 (CH, C-2), 55.41 (CH3, C-4'), 112.46, 
113.20, 126.16, 126.37, 127.11, 128.49, 129.28, 128.49, 129.54, 129.91, 130.03, 
130.30 (CH, aromatic), 136.88 (C, C-8 a), 138.14 (C, C-l"), 140.15 (C, C -l’"), 141.15 
(C, C-2"), 146.47 (C, C-4a), 163.51 (C, C-6 ), 197.96 (C, C-l).
4.2.26. Ethyl 6-m ethoxy-1-oxo-1,2,3,4-tetrahydro-2-naphthalene-
carboxylate (100)(238).
(Mol. Formula: Ci4Hi60 4, M. W.: 248.27)
o o o
CH
NaH
H,CH,C
(88) (100)
A solution of 6 -methoxy-l-tetralone (88) (2.6 g, 15 mmol) in anhydrous 
toluene (50 mL) was slowly added to a mixture of NaH (2.22 g of 60% dispersion in 
oil, 55.5 mmol) and diethyl carbonate (5.5 mL, 45 mmol) in anhydrous toluene (10 
mL) under reflux. The mixture was stirred for 18 h under reflux, cooled to room 
temperature and treated with H20  (50 mL) and glacial AcOH (5 mL) and 
subsequently extracted with Et20  (3 x lOOmL). The combined organic layers were 
washed with brine (50 mL), dried (MgS04) and concentrated under reduced pressure. 
The oily residue was then purified by flash column chromatography (petroleum ether 
-  EtOAc 100:0 v/v increasing to 80:20 v/v) to give ethyl 6-methoxy-l-oxo-l,2,3,4- 
tetrahydro-2-naphthalenecarboxylate (100) as a colourless solid. Yield: 2.6 g (70%), 
t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.69, vanillin stain positive.
Melting noint: 49-52 °C (lit. m.p. 50-52 °C) <238).
'H-NMR (CDClil. S: 1.32 (t, 3H, J = 7.2 Hz, CH2-CHj), 2.33-2.37 (m, 1H, 
Ha), 2.46-2.51 (m, 1H, Hb), 2.94-3.07 (m, 2H, Ar-CH2 -CHaHb), 3.57 (dd, 1 H, J = 4.7 
Hz, 10.2 Hz, CO-CH-CO), 3.87 (s, 3H, O-CH3 ), 4.23-4.28 (m, 2H, O-CH2 -CH3 ), 6.71 
(d, 1H, J = 2.4 Hz, H-aromatic), 6.85 (dd, 1H, J = 2.5 Hz, 8 . 8  Hz, H-aromatic), 8.04 
(d, 1H, J = 8 . 8  Hz, H-aromatic).
13C NMR tCDChl. 5: 14.36 (CH3, C-3'), 26.46 (CH2, C-3), 28.04 (CH2, C-4),
54.33 (CH, C-2), 55.46 (CH3, C-4'), 61.18 (CH2, C-2'), 112.60, 113.44, 130.26 (CH,
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aromatic), 125.40 (C, C-8 a), 146.15 (C, C-4a), 163.93 (C, C-6 ), 170.42 (C, C-l'),
191.88 (C, C-l).
4.2.27. Ethyl 2-(2-bromobenzyl)-6-methoxy-1-oxo-1,2,3,4-tetrahydro-2- 
naphthalenecarboxylate (102).
(Mol. Formula: C2 iH2 iBr0 4 , M. W.: 417.29)
C H j
HjC. H3C.
(102)
A mixture of NaH (0.415 g of 60% dispersion in oil, 10.37 mmol) and ethyl 6 - 
methoxy-l-oxo-l,2,3,4-tetrahydro-2-naphthalenecarboxylate (100) (2.5 g, 10.07 
mmol) in DMF (30 mL) was heated at 60 °C for 1 h. A solution of 2-bromobenzyl 
bromide (101) (2.67 g, 10.67 mmol) in DMF (10 mL) was added and the mixture was 
heated at 60 °C for 8  h. A few drops of H2O were added and the suspension was 
extracted with Et2 0  (3 x 50 mL). The combined organic layers were washed with 
brine (50 mL), dried (MgSCU) and concentrated in vacuo. The oily residue was 
purified by flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 80:20 v/v) to give ethyl 2-(2-bromobenzyl)-6-methoxy-l-oxo-l,2,3,4- 
tetrahydro-2-naphthalenecarboxylate (102) as a thick yellow oil. Yield: 2.9 g (69%), 
t.l.c. system: petroleum ether-EtOA c 3:1 v/v, Rp: 0.69, vanillin stain positive.
HRMS (El): Calculated mass: 417.0696 (79Br) [M+H]+, Measured mass: 
417.0694 [M+H]+.
*H-NMR (CDCh). 5 : 1.17 (t, 3H, J = 7.1 Hz, CH2-CH3), 2.01-208 (m, 1H, Ha), 
2.59-2.63 (m, 1H, Hb), 2.76-2.81 (m, 1H, Hc), 3.03-3.09 (m, 1 H, Hd), 3.69 (dd, 2H, J 
= 14.2 Hz, 24.4 Hz, C-CT^-Ar), 3.85 (s, 3H, O-CH3), 4.14-4.18 (m, 2 H, O-CH2-CH3),
6.62 (d, 1H, J = 2.5 Hz, H-aromatic), 6.85 (dd, 1H, J = 2.5 Hz, 8 . 8  Hz, H-aromatic),
7.06 (m, 1H, H-aromatic), 7.19 (td, 1H, H-aromatic), 7.30 (dd, 1H, J = 1.7 Hz, 7.8 Hz, 
H-aromatic), 7.55 (dd, 1H, J = 1.3 Hz, 8.0 Hz, H-aromatic), 8.09 (d, 1H, J = 8 . 8  Hz, 
H-aromatic).
13C NMR (CDCL), 5: 13.98 (CH3, C-3'), 26.45 (CH2, C-3), 30.07 (CH2, C-4), 
38.41 (CH2, C-5'), 55.41 (CH3, C-4'), 58.67 (C, C-2 ), 61.56 (CH2, C-2'), 112.26,
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113.46 (CH, aromatic), 125.94 (C, C-2"), 125.40 (C, C-8 a), 127.26, 128.25, 130.66, 
132.17, 132.89 (CH, aromatic), 136.89 (C, C-l"), 145.75 (C, C-4a), 163.67 (C, C-6 ), 
171.28 (C, C -l’), 193.21 (C, C-l).
4.2.28. 2-(2-Bromobenzyl)-6-methoxy-1,2,3,4-tetrahydro-1 -naphthalenone 
(103) and 2-(2-bromobenzyl)-6-hydroxy-1,2,3,4-tetrahydro-1- 
naphthalenone (104).
(Compound (103): Mol. Formula: CigHnBrC^, M. W.: 345.23)
(Compound (104): Mol. Formula: CnH^BrOi, M. W.: 331.20)
.c h 3
Br‘
(102)
HBr 4 ’
AcOH H3°
(103)
Br
HO
(104)
A suspension of ethyl 2-(2-bromobenzyl)-6-methoxy-l-oxo-l,2,3,4- 
tetrahydro-2-naphthalenecarboxylate (102) (2.6 g, 6.23 mmol), 48% HBr (13.76 mL) 
and 96% AcOH (11.5 mL) was stirred at 120 °C for 1.5 h. The mixture was cooled 
and diluted with water (5 mL). The reaction mixture was extracted with Et2 0  (3 x 50 
mL) and the combined organic extracts were dried (MgS0 4 ) and concentrated in 
vacuo. The solid was purified by flash column chromatography (petroleum ether -  
EtOAc 100:0 v/v increasing to 80:20 v/v) to give 2-(2-bromobenzyl)-6-methoxy-
1,2,3,4-tetrahydro-l-naphthalenone (103) as a yellow oily product. Yield: 0.55 g 
(26%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.82, vanillin stain positive. 
Also 2-(2-bromobenzyl)-6-hydroxy-1,2,3,4-tetrahydro-l-naphthalenone (104) was 
produced as a major product in the form of a white solid Yield: 0.8 g (39%), t.l.c. 
system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.61, vanillin stain positive.
• 2-(2-Bromobenzyl)-6-methoxy-l ,2,3.4-tetrahydro-l -naphthalenone (103):
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HRMS (Ell: Calculated mass: 345.0485 (79Br) [M+H]+, Measured mass: 
345.0484 [M +H]\
'H-NMR (CDCh). 5: 1.86-1.90 (m, 1H, Ha), 2.07-2.11 (m, 1H, Hb), 2.73-2.78 
(m. 1 H. Hc). 2.85-2.95 (m, 3H. Hd. CO-CH-CHj-Ar), 3.72 (dd, 1H, J = 4.4 Hz, 13.9 
Hz. CO-CH-CH:-Ar), 3.87 (s, 3H. O-CHj), 6.69 (d, 1H, J = 2.5 Hz, H-aromatic), 6.85 
(dd. 1H. J = 2.5 Hz. 8 . 8  Hz, H-aromatic), 7.11 (m, 1H, H-aromatic), 7.27-7.31 (m, 2H, 
H-aromatic). 7.58 (dd. 1H. J = 1.0 Hz, 7.9 Hz, H-aromatic), 8.07 (d, 1H, J = 8 . 8  Hz. 
H-aromatic).
13C NMR (CDClil- 6 : 28.11 (CH2. C-4). 29.34 (CH2. C-3), 36.08 (CH2. C-l'), 
47.67 (CH. C-2). 55.41 (CH3. C-4’). 112.45 (CH. C-7). 113.19 (CH, C-5), 124.91 (C, 
C-2"). 126.15 (C. C-8 a). 127.30 (CH. C-4"). 127.86 (CH, C-5"), 129.97 (CH, C-3"), 
131.70 (CH. C-8 ), 132.96 (CH, C-6 ”), 139.85 (C. C-l"), 146.45 (C, C-4a), 163.50 (C, 
C-6 ). 197.77 (C. C-l).
• 2-(2-Bromobenzyl)-6-hydroxy-l .2,3,4-tetrahydro-l -naphthalenone (104):
Melting point: 171-174 °C.
Microanalysis: Calculated for CnHisBrCK (331.2), Theoretical: %C= 61.65, 
%H= 4.56, Found: %C= 61.59, %H= 4.58.
'H-NMR fDMSO-dA 5: 1.70-1.77 (m, 1H, Ha), 1.86-1.99 (m, 1H, Hb), 2.61- 
2.66 (m, 1H, Hc), 2.75-2.86 (m, 3H, Hd. CO-CH-CH2 -Ar). 3.35 (s, 3H, O-CH3 ), 3.52 
(dd, 1H, J = 4.4 Hz, 13.8 Hz, CO-CH-CH2-Ar), 6.63 (d, 1H, J = 2.3 Hz, H-aromatic), 
6.74 (dd, 1H. J = 2.4 Hz, 8 . 6  Hz, H-aromatic), 7.17 (m, 1H, H-aromatic), 7.31-7.37 
(m. 2H, H-aromatic), 7.60 (dd, 1H, J = 1.0 Hz, 8.0 Hz, H-aromatic), 7.80 (d, 1H, J =
8 . 6  Hz, H-aromatic), 10.32 ( s, 1H, OH).
I3C NMR (DMSO-dJ. S: 27.47 (CH2, C-4), 28.15 (CH2, C-3), 35.40 (CH2, C- 
1’). 46.57 (CH. C-2). 114.10. 114.40 (CH, aromatic), 124.09 (C, C-2"), 124.16 (C, C- 
8 a). 127.60. 128.23. 129.40, 131.78, 132.59 (CH, aromatic), 139.28 (C, C-l"), 146.72 
(C, C-4a). 162.05 (C, C-6 ), 196.47 (C, C-l).
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4.2.29. 2-(2-Bromobenzyl)-6-methoxy-1,2,3,4-tetrahydro-1 -naphthaienone 
(103).
(Mol. Formula: CigHnBrC^, M. W .: 345.23)
HO
(104)
Mel
H3CK2CO;
(103)
A solution of 2-(2-bromobenzyl)-6-hydroxy-l,2,3,4-tetrahydro-l- 
naphthalenone (104) (0.7 g, 2.11 mmol) and K2CO3 (0.583 g, 4.22 mmol) in 
anhydrous acetone (30 mL) was refluxed for 2 h, Mel (0.2 mL, 2.47 mmol) was added 
and the resulting mixture stirred at reflux for a further 3 h. After cooling to room 
temperature, inorganic salts were filtered off. the filtrate was concentrated under 
reduced pressure to give 2-(2-bromobenzyl)-6-methoxy-1,2,3,4-tetrahydro-l- 
naphthaienone (103) as a colourless oil. Yield: 0.7 g (96%), t.l.c. system: petroleum 
ether -  EtOAc 3:1 v/v. Rp: 0.82, vanillin stain positive.
'H-NMR and 13C NMR as previously described (see page 183).
4.2.30. 6-Methoxy-2-[2-[(E)-2-phenyl-1 -ethenyl]benzyl]-1,2,3,4-tetrahydro- 
1-naphthaienone (105).
(Mol. Formula: C26H24O2 , M. W.: 368.47)
H .C
4"'
(103) (97)
3."
6" '
H3C.
(105)
2M aqueous Na2C0 3  (5 mL) was added to a solution of 2-(2-bromobenzyl)-6- 
methoxy-1 .2 ,3 .4-tetrahydro-1 -naphthaienone (103) (0.35 g, 1 mmol) in toluene (15 
mL). To the mixture Pd(PPh3) 4 (0.057 g. 0.05 mmol), and then trans-2 - 
phenylvinylboronic acid (97) (0.296 g, 2 mmol) in ethanol (5 mL) were added. The 
reaction mixture was refluxed at 90 °C for 5 h. After the reaction was complete, the
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residual borane was oxidized by the addition of H2O2 (30 %, 2.5 mL) at room 
temperature for 1 h. The crude product was extracted with CH2CI2 (50 mL) and H2O 
(3 x 50 mL). The organic layer was dried over MgSC>4 and reduced in vacuo to give 
an oily residue which was purified by flash column chromatography (petroleum ether 
-  EtOAc 100:0 v/v increasing to 70:30 v/v) to give 6-methoxy-2-[2-[(£)-2-phenyl-l- 
ethenyl]benzyl]-1,2,3,-4-tetrahydro-l -naphthaienone (105) as a thick colourless oil. 
Yield: 0.35 g (95%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, Rp: 0.82, vanillin 
stain positive.
HRMS (El): Calculated mass: 369.1849 [M+H]+, Measured mass: 369.1843 
[M +Hf.
'H-NMR fCDCht. 5: 1.80-1.87 (m, 1H, Ha), 2.07-2.12 (m, 1H, Hb), 2.65-2.75 
(m, 2H, He, He). 2.85-2.94 (m, 2H, Hd. Hf), 3.87 (s, 3H, O-CHj), 3.93 (dd, 1H, J = 3.2 
Hz. 13.6 Hz, CO-CH-CH2-Ar), 6.69 (d, 1H, J = 2.5 Hz, H-aromatic), 6.87 (dd, 1H, J =
2.6 Hz. 8 . 8  Hz. H-aromatic), 7.07 (d, 1H, J = 16.1 Hz, Hh), 7.24-7.32 (m, 5H, H- 
aromatic. H-g), 7.39 (t, 2H, J = 7.5 Hz, H-aromatic), 7.55 (t, 2H, J = 7.3 Hz, H- 
aromatic), 7.73 (d, 1H, J = 7.4 Hz, H-aromatic), 8.11 (d, 1H, J = 8 . 8  Hz, H-aromatic).
13C NMR (CDCLL 5: 27.95 (CH2, C-4), 29.17 (CH2, C-3), 33.45 (CH2, C-l'), 
48.77 (CH. C-2), 55.42 (CH3, C-2'), 112.46, 113.25, 125.91, 126.33, 126.76, 126.98, 
127.69, 128.41, 129.30, 130.05, 130.46, 130.92 (CH, aromatic and alkene), 125.98 (C, 
C-8 a). 136.40 (C, C-l'"), 137.51 (C, C-l"), 138.26 (C, C-2"), 146.57 (C, C-4a), 163.54 
(C, C-6 ). 197.91 (C, C-l).
4.2.31. 2-{2-[(E)-2-(3,5-Dimethoxyphenyl)-1 -ethenyl]benzyl}-6-methoxy-
1,2,3,4-tetrahydro-1-naphthaienone (106).
(Mol. Formula: C28H28O4 , M. W.: 428.52)
4 ...
TOP, Pd(OAC),
OCHj
+
H,C.
OCH3
(103) (68) (106)
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A solution of l,3-dimethoxy-5-vinylbenzene (6 8 ) (0.269 g, 1.64 mmol), 
Pd(OAc) 0 (0.015 g, 0.066 mmol), tri(o-tolyl)phosphine (ToP, 0.03 g, 0.098 mmol) and
2-(2-bromobenzyl)-6-methoxy-1,2,3,4-tetrahydro-l-naphthaienone (103) (0.51 g, 1.48 
mmol) in dry Et3N (25 mL) was stirred for 2 h at 60 °C under nitrogen. Then the
mixture was stirred for 3 day at 80 °C. After the reaction was complete, the solvent 
was evaporated. The crude product was dissolved in CH2 CI2 (50 mL) and washed 
with H2O (50 mL), dried (MgS04) and the solvent evaporated. The crude product was
purified by flash column chromatography (petroleum ether -  EtOAc 100:0 v/v 
increasing to 70:30 v/v) to give 2-{2-[(£)-2-(3,5-dimethoxyphenyl)-l- 
ethenyl]benzyl}-6 -methoxy - 1 ,2 ,3,4-tetrahydro-l-naphthaienone (106) as a colourless 
oil. Yield: 0.45 g (64%), t.l.c. system: petroleum ether -  EtOAc 3:1 v/v, RF: 0.57, 
vanillin stain positive.
HRMS (El): Calculated mass: 429.2060 [M+H]^, Measured mass: 429.2067 
[M+Hf.
'H-NMR (CDCIV). S: 1.81-1.85 (m, 1H, Ha), 2.08-2.12 (m, 1H, Hb), 2.65-2.75 
(m. 2H. He, He), 2.66-2.71 (m, 2H, Hd, Hf), 3.86 (s, 3H, O-CHj), 3.93 (dd, 1H, J = 3.2 
Hz. 13.6 Hz, CO-CH-CH2-Ar), 6.67 (d, 1H, J = 2.5 Hz, H-aromatic), 6.72 (d, 2H, J =
2.3 Hz, H-aromatic), 6.84 (dd. 1H, J = 6.4 Hz, 15.2 Hz, H-aromatic), 6.98 (d, 1H, J = 
16.1 Hz. Hh). 7.23-7.33 (m, 4H, H-aromatic, Hg), 7.51 (d, 1H, J = 16.1 Hz. H- 
aromatic). 7.69 (d, 2H, J = 8 . 6  Hz, H-aromatic), 8.07 (d, 1H, J = 8 . 8  Hz, H-aromatic).
13C NMR ICDCli). 6 : 27.99 (CH2, C-4), 29.17 (CH2, C-3), 33.49 (CH2, C -l’), 
48.94 (CH, C-2), 55.31 (CH3, C-2'), 55.42 (CH3, C-5', C-6 '), 100.23, 104.57, 112.43, 
113.25, 125.87, 126.54, 126.76, 127.65, 129.97, 130.29, 130.85 (CH, C-aromatic and 
alkene), 125.87 (C, C-8 a), 136.10 (C, C-l"), 138.49 (C, C-l"'), 139.55 (C, C-2"), 
146.57 (C, C-4a), 161.00 (C, C-3"’, C-5'"), 163.50 (C, C-6 ), 197.77 (C, C-l).
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4.3 .C YP26A 1
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4.3.1.Cell Based Assay:
These assays were performed using all-trans retinoic acid (ATRA) as substrate 
and using methods previously developed by our group.
4.3.1.1. Materials and equipment
Material/Chemical Source
ATRA Sigma Chemicals (Dorset, UK)
[JH-11.12] ATRA (9.25 MBq, 250 nCi) Perkin Elmer Life Science Ltd. 
(Massachussets, USA)
HPLC grade solvents (CHjCN, MeOH) Fisher Scientific (Leicestershire, UK)
Buffer (see preparation below) Aldrich Chemicals, UK
EtOAc, EtOH, CH3CI, ammonium acetate Sigma Chemicals, UK
OptiFlow Safe 1 liquid scintillation 
cocktail
Fisions Chemicals, UK
Borosilicate tubes (12 * 75 mm and 13 * 
1 0 0  mm)
Coming (New York, USA)
Equipment Source
Centrifuge MSE Harrier 18/80, Santo, Japan
Pump Milton-Roy
H2O bath with shaker Grant, UK
Rotating evaporator Christ Alpha RVC (Germany)
10 pm Ci8 pBondapak® 309 x 300 mm 
column
Waters, UK
Beta-RAM online scintillation detector LKB Wallace 1217 Rackbeta
Computer Compaq 1M
Laura data acquisition and analysis 
software
Lablogic Ltd.
Preparation o f  FHI ATRA stock solution
100 pL of 1.2 mM ATRA in EtOH was diluted with 900 pL of o f ‘PrOHiEtOH 
1:1 v/v. To this was added 10 pL of [3H] ATRA (9.25 MBq, 250 pCi).
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> 1 mL of the above stock solution contains 10/250 x 9.25 MBq = 0.37 
MBq.
> 10 jiL of the stock solution contains 0.01 pCi x 0.37 MBq/0.037 MBq 
= 0.10 pCi.
> Preparation o f  phosphate buffer (PBS) (50 mM, vH  7.4)
To prepare 1000 mL of phosphate buffer (50 mM, pH 7.4), 6 . 6 8  g of disodium 
hydrogen orthophosphate dodecahydrate was dissolved in 750 mL of H2O and 
1.95 g of monosodium dihydrogen orthophosphate dihydrate was dissolved in 
250 mL of H20 .
> Preparation o f mobile phase:
To prepare 1000 mL of the mobile phase, 2.5 g NH4OAC was dissolved in 250 
mL filtered distilled H20  and 1 mL formic acid was added, followed by 
completing the solution to 1000 mL using CH3CN.
> Preparation o f extraction phase:
To prepare 500 mL, 0.25g of butylated hydroxyanisole was dissolved in 500 
mL EtOAc.
4.3.1.2. Cell-line used
Retinoids have been known to have anti-proliferative effects on the growth of 
breast carcinoma cells (MCF-7, ZR-75.1) (239‘240). The cell line used in this assay is the 
oestrogen responsive MCF-7 human mammary-carcinoma cell line which is oestrogen 
receptor-positive. This cell line is also known as the wild-type MCF-7 cell line. This 
cell was routinely grown in RPMI medium, supplemented with 5 % (v/v) foetal calf 
serum (FCS), antibiotics (streptomycin and penicillin) and fungizone at the same 
concentration of 10 iU/mL. This is the basal medium for MCF-7. This cell line was 
chosen because it is available at the Welsh School of Pharmacy from the Tenovus 
group.
4.3.1.3. General method for the MCF-7 wild type ATRA assay
The method described below was based on a modification of the method of 
Jamo (l60) and Farhan et a l(24l\
1. The wild-type MCF-7 cell lines supplied by Tenovus were seeded at 3 x 106
cells per plate (12 wells) and left to settle for 24 h.
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After 24 h, the experimental medium of the wild-type MCF-7 cells were 
removed and then 1 mL of PBS was added to each well then removed and 
replaced by fresh experimental medium plus various treatments.
These treatments were prepared as follows: each treatment was performed in 
duplicate (one tube for 2  wells) therefore, 6  well dried and sterile glass tubes 
were prepared. To the first one was added 200 pL of EtOH as control and to 
the other five tubes was added separately 200 pL of five different 
concentrations of the inhibitor ranging from 50-1 prnol one concentration for 
each tube. 2 mL of the experimental media supplied by Tenovus was added to 
each tube (1 mL per well). 20 pL of [ H] ATRA was then added quickly to 
avoid exposure to air to each of the six tube (10 pL per well). The tubes were 
placed in the H2O bath and were shaken gently for 10-15 minutes.
The corresponding experimental media containing the substrate and inhibitor 
or control is transferred by the aid of micropipettes to the corresponding well 
(each glass tube into 2  wells).
Tissue culture plates were then wrapped in aluminium foil and incubated for 9 
hours.
The incubation with the respective substrate was stopped by the addition of 2 
% v/v AcOH (100 pL/well).
The medium and AcOH from each well was then removed and transferred to 
borosilicate glass tubes (13 x 100 mm) which contained 2 mL solution of 
EtOAc with 0.05 % (w/v) butylated-hydroxyanisole.
0.5 mL of distilled H2O was subsequently added to each well plate and the 
cells were scrapped off using the rubber end of a 1 mL syringe.
The cell suspension from each tube was transferred to the respective glass 
tubes.
Finally, each well was rinsed with 0.5 mL of distilled H2O and then transferred 
to the respective glass tubes.
The glass tubes were centrifuged (6000 rpm for 15 min at room temperature). 
The top organic layer containing the substrate and metabolites was transferred 
into respective borosilicate glass tubes (12 x 75 mm).
The tubes were placed in a rotating evaporator for 35 min.
The residues in each tube were redissolved in MeOH, then analysed using an 
on-line radioactive detector connected to a HPLC.
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The HPLC system was equipped with a high pressure pump (Milton-Roy 
pump), injector with a 50 pL loop connected to a beta-RAM radioactivity detector, 
connected to a Compaq™ computer running Laura® data acquisition and analysis 
software. This enabled on-line detection and quantification of radioactive peaks. A 10 
pm Ci8 pBondapak® 3.9 x 300 mm column (for ATRA assay) operating at ambient 
temperature was used to separate the metabolites which were eluted with mobile 
phase at a flow rate of 1.9 mL/min.
The experimental medium used was as follows: RPMI phenol red-free, 
supplemented with 5 % (v/v) stripped foetal calf serum (S-FCS), antibiotics 
(streptomycin and penicillin) and fungizone at the same concentration of 10 iU/mL 
and 2 % v/v L-glutamine (200 mM).
4.3.1.4. Experimental results
The HPLC and the Laura software were used to measure the I C 5 0  of our final 
compounds.
4.3.2. Biochemical Assay:
The inhibitory activity using microsomal preparations from MCF7 cells of the 
most promising compounds (14, 15, 19 and 20) versus CYP26A1 was performed by 
Dr Caroline Bridgens, Northern Institute for Cancer Research, Newcastle University, 
Newcastle, United Kingdom. Microsomes were prepared by differential centrifugation 
of homogenised cells.
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4 . 4 .  CYP24A1
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4.4.1. V79-CYP24 Assay:
The inhibitory activity of the novel compounds versus CYP24A1 was 
performed by Anna Robotham and Bart Makowski in the labs of Professor Glen 
Jones, Queen's University Kingston, Ontario, Canada. This involved an in vitro assay 
using recombinant cell lines expressing human CYP24 enzyme (V79-CYP24)(109,117, 
242). Chinese hamster lung fibroblasts (V79-4) stably expressing either CYP24A1 
(WT, L148F, M252L, V391L, or M416T) or CYP27A1 (WT) were maintained and 
grown using Dulbecco’s Modified Eagle Medium (DMEM) purchased from 
Invitrogen Life Technologies. The growth medium was supplemented with foetal calf 
serum (FCS) as well as antibiotics (1% v/v) and hygromycin (0.2% v/v) and glucose 
(lg/500mL). Cells were plated on standard 100mm cell culture dishes and were 
maintained in a humidified atmosphere of 5% CO2 in air.
Inhibitor Preparations
Milligram quantities were dissolved in 100% ethanol, while ketoconazole was 
dissolved in 0.05 M HC1. A 1 mg/mL stock solution was made up for each inhibitor to 
be tested. Serial 1/10 dilutions were then made to give stock solutions suitable for the 
low concentration incubations.
Incubations
Prior to incubation, cells were grown on P-150 plates until reaching -100% 
confluence. The cells were then subcultured onto 6 -well plates in the FCS- 
supplemented DMEM for 24 hours. The incubation medium for the experiments was 
bovine serum albumin (BSA) supplemented (1% w/v) DMEM containing the 
appropriate substrate; 105 CPM per well of [ip-3H]la,25-(OH)2D3 for the CYP24A1- 
containing cells and 10 pM of IG1-OH-D3 for the CYP27A1-containing cells. Each 
well also contained 1 pL of N,N-diphenyl-p-phenylene diamine (DPPD) (100 pM) to 
act as an anti-oxidant.
Each assay was conducted with a ‘no inhibitor’, ‘dead cell’ and ‘no cell’ 
control. The ‘dead cell’ control was prepared by microwaving the plate of cells for 30 
seconds prior to incubation. Each well contained ImL of incubation medium and 
each data point was performed in triplicate. Each inhibitor was tested at 4 different 
concentrations; lxlO*4 M, l x l 0 ‘5 M, lxlO' 6 M, and lxlO'7 M. The CYP24A1 assays 
were carried out at an optimised 6  hour time interval, while the CYP27A1 assay was 
carried out at a 24 h interval which had been previously optimised. The incubations
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were arrested by the addition of 2.5 mL of methanol to each well.
Extraction
The incubation medium was extracted using a modified Bligh and Dyer 
extraction (243). For samples destined for HPLC analysis (mainly samples taken from 
CYP27A1 assays). 2fig of 2 5 -OH-D3 was added to each sample as an internal 
recovery standard for subsequent normalisation of metabolite quantification.
Analysis
The samples from the CYP24A1 assays were analysed using scintillation 
counting of 0.5mL of the aqueous phase (from the Bligh and Dyer extraction). 
Beckman Coulter Ready Safe™ Liquid Scintillation Cocktail for Aqueous Samples 
(5mL) was added to the 0.5mL samples, and scintillation counting was performed 
using a Beckman Coulter L6500 Multipurpose Scintillation Counter.
To determine the amount of metabolite formed in the CYP27A1 incubations, 
HPLC paired with a photodiode array detector (Waters 996 PDA) or a RadioFlow 
Detector (LB509; EG&G Berthold, Bad Wilbad, Germany) was used.
4.4.2. VitD3 CLL Study:
The activity of the novel compounds versus these cells was performed by Dr
Chris Pepper, University of Wales College of Medicine, Cardiff, United Kingdom.
The assay has been done using the following procedure: freshly isolated
peripheral blood lymphocytes ( lx l0 6/mL) were cultured in Eagle medium
(Invitrogen, Paisley, United Kingdom) supplemented with penicillin, streptomycin,
and 10% foetal calf serum (FCS). The cultures were incubated at 37°C in a
12humidified 5% carbon dioxide atmosphere in the presence of tested compounds (10‘ 
to 10'5 M). In addition, control cultures were carried out to which no drug was added 
to cultured B-CLL cells. Cells were subsequently harvested by centrifugation and 
were analysed by flow cytometry. Experiments were performed in duplicate.
. C o n clu s io n
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5. Conclusion:
The main aim for this project was to develop agents which are capable of 
inhibiting the metabolism of two essential vitamins, A and D3 and their analogues. 
These vitamins are reported (43,109) to have the ability to restore the normal function of 
different types of cancer cells through cellular differentiation. The use of these 
vitamins and their analogues as anticancer drugs has been restricted due to the 
development of resistance to their action, and hence the need to increase their doses 
to reach the optimal plasma concentration and the subsequent development of the side 
effects. One of the main reasons for this development of resistance is due to the 
upregulation of the catabolic pathways of these vitamins through the endogenous 
CYPs. Blocking the effect of these CYPs; i.e. CYP26 inhibition in case of vitamin A 
and CYP24 inhibition in case of vitamin D3, could result in keeping the optimal 
plasma concentration level of these vitamins without the need for increasing the dose, 
and so they can proceed to perform their function in cellular differentiation of the 
cancer cells.
This project was divided into two main parts; development of potential 
inhibitors firstly for CYP26 and secondly for CYP24 that could be used in 
conjunction with vitamin A and vitamin D3 respectively or their analogues in 
differentiation therapy for different types of cancer, like prostate and breast cancer.
5.1. CYP26A1 inhibitors:
As for CYP26, the project involved first the construction of a pharmacophore 
model for CYP26A1 inhibitors that was used together with the homology model of 
CYP26A1 which was developed previously within our group (163) in the rational 
design of potential inhibitors. This was followed by chemical synthesis and biological 
evaluation of some of the promising compounds.
The pharmacophore model of CYP26A1 inhibitors was constructed using 
MOE software. A database of 71 CYP26A1 inhibitors with different conformations 
has been built and arranged according to activity. This resulted in a pharmacophore 
with 8 features, as shown in Figure 5.1.1.
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Figure 5.1.1. The suggested pharmacophore from the consensus.
After refining the query, CYP26A1 inhibitors pharmacophore has been found to 
have 8 features, of which only 5 features should be fulfilled to have an active inhibitor 
Those five features are FI, F2, F4, F5, F6.Therefore, a partial match could be allowed, 
so long as these 5 features are fulfilled from the 8 features identified.
The designed model was used first to investigate the ability of our lead compound 
to tolerate the changes in its structure, and also the model was used to build new 
inhibitors, which could have reasonable activity.
Investigation of the match of the lead compound with the CYP26A1 inhibitors 
pharmacophore shows that the lead compound has a very good hit with the essential 
pharmacophoric features, i.e. FI, F2, F4, F5, F6. As for the changes in the lead 
compound structure, some changes seems to be tolerated within the pharmacophore, 
such as replacement of the dimethyl groups with mono methyl or replacement of the 
naphthyl moiety with a phenyl one. Whereas, other changes in the lead compound, 
such as removing of the imidazole ring or replacing the imidazole moiety with 
imidazolyl carbonyloxy one do not seem to be tolerated within the pharmacophore as 
shown from decreased number of the pharmacophoric hits to the essential 
pharmacophoric features.
As for the search for new molecules which could have activity as inhibitors of
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C Y P26A 1. the new ly  designed com pounds w hich  resulted from  the search th rough  
the N CI database, show ed very good a lignm ent to the essential pharm acophoric 
features, i.e. F I .  F2, F4, F5. F6.
R egarding the synthesis o f  new  com pounds, tw o series were synthesised fo r 
CYP26A1 inhib ition . The first series w as designed to investigate the effect o f  
changing the structure o f  the lead com pound  on the inhibitory activity  against 
CY P26A1 and w as depending m ainly on p resence o f  im idazole m oiety, and the 
second series w as a result o f  the pharm acophore search and was m ainly oxad iazo le  
derivatives. These tw o series w ere b io log ically  evaluated using a M C F-7 b reast 
cancer cell assay previously  described by ou r group and also some o f  the com pounds 
were tested in the b iochem ical assay.
From  the b iological data; it seem s that the dim ethyl substitution (IC 50 = 2 .8  
nM ) at the a -carbon  is m uch m ore p referab le than the m ono-m ethyl substitution (IC 50 
= 26 nM ) as can be seen from  the huge decrease  in inhibitory activity by about 10 
fold. As the free acid seem s not to be the active form  o f  our com pounds, it m ay be the  
presence o f  the  d im ethyl group has a steric  effec t that restrains the attack o f  the 
esterase enzym e. O f  course, this steric effect decreases w ith the introduction o f  the 
m ono-m ethvl group resulting in m ore rapid  rem oval o f  the esters to give the free acid , 
this m ay exp lain  the loss in inhibitory activity . A lso  it appears that the d ifference in  
the d iastereo isom erism  does not affect the inh ib itory  activity.
The p resence o f  the im idazole is essential for the inhibitory activity, rem oval 
o f  the im idazole or replacem ent w ith the 1 ,3 ,4-oxadiazole ring, or in troducing o f  a 
link betw een the im idazole and the (3-carbon, dram atically  decreases the activ ity . 
In troduction  o f  a link betw een the im idazole and the p-carbon m ay m ake the  
com pound too big to enter the active site cavity  o f  the enzym e. As for the rep lacem ent 
o f  the im idazole  w ith the 1,3.4-oxadiazole part, a lthough these com pounds show ed 
good m atch to  the CYP26A1 pharm acophore m odel and dock very well in the  
CY P26A1 hom ology  m odel, the decrease in the flexibility  o f  the m olecules m ay  
explain  the decrease in the activity. The non-conform ity  betw een the biological resu lts 
and the m odelling  suggest a lim itation o f  the CYP26A1 pharm acophore and 
hom ology m odels.
The CY P26A 1 biochem ical assay o f  the m ost prom ising com pounds show ed 
that som e com pounds are good CYP26A1 inhibitors being about 70-100 tim es m ore
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active than  the w ell-know n CY P26A1 inh ib ito r liarazole (IC 5o= 6 pM ). H ow ever, they 
w ere still less active than R 1 15866. A lso, these com pounds are m uch less active than 
our lead com pound w hich show ed an I C 5 0  o f  2.8 nM .
5.2. CYT24A1 inhibitors:
A s for CYP24A1 inhibition, tw o series; the azoles and the tetralones, were 
syn thesised . M ost o f  these com pounds has been tested against CY P24A1 and 
C Y P 2 7 A 1 .
The results show ed that the inclusion  o f  a double bond at the position  o f  
a ttachm ent betw een the tetralone and benzyl ring appeared to reduce the inhibitor}7 
effect o f  the inhibitors. The double bond  will conjugate w ith the adjacent phenyl 
group resu lting  in decreased conform ational flex ib ility  o f  the structure. This loss o f  
flex ib ility  could  inhibit the entrance o f  the inh ib ito r through the access channel o f  
CY P24A 1 thus decreasing its access to the enzym e cavity  where it w ould exert its 
inh ib itory  effect. A lternatively, the loss o f  conform ational flexibility could prevent a 
favourab le  conform ation  that stabilises the inh ib itor inside the enzym e cavity.
The strong inhibitory capacity  o f  6-m ethoxy-2-[2-(trifluorom ethyl)benzyl]-
1.2.3.4 -te trahyd ro -l-naph thaienone  could reflect a trend  observed in inhibitor design; 
the add ition  o f  fluorine groups increases the  inh ib itory  capacity  o f  a com pound. It has 
been suggested  that th is increase is no t caused by a stronger enzym e-inhibitor 
com plex , but by increasing the cell-m em brane penetrating capacity and thus 
increasing  the b io-availability . H ow ever, m any o f  the com pounds appear to be 
hydrophob ic  and should have little p roblem  penetrating  cell m em branes. As such, the 
fluo rination  m ay have a stabilising effect on the inh ib ito r inside the enzym e resulting 
in m ore effective inhibition.
A s for the azoles, from the results, it seem s that the azoles w ould be m uch 
m ore active than the tetralone derivatives w ith A -[2 -( l//-l-Im id a z o ly l)-2 -  
pheny le thy l]-4 -[(£ )-2 -pheny l-l-e theny l]benzam ide  (IC 50 =  0.3 pM ) displaying greater 
inh ib ito ry  activ ity  than the standard ketoconazole (IC 50 = 0.52 pM ). This activity  m ay 
also  be a ttribu ted  to the resem blance betw een the structure o f  these azoles and 
calcitrio l.
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Also the activity of some of the novel compounds versus B-cell chronic 
lymphocytic leukemia (B-CLL) cells was performed. The results showed that the 
azole compounds have very good antiproliferative activity against B-CLL. 
Introduction of the dimethoxy groups did not greatly affect the activity, with only a 
fold increase in the activity which was the same case for the introduction of the 
fluorine group, as both compounds with or without the fluorine group showed 
comparable activity. Also, from the results, the tetralones seem to be much less active 
than the azoles. which suggest the low antiproliferative activity of these tetralones, 
this may reflect the difference in CYP24 inhibitory activity. These results encourages 
for further development and investigation of this type of azoles as CYP24A1 
inhibitors.
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